{"protocolSection": {"identificationModule": {"nctId": "NCT03268005", "orgStudyIdInfo": {"id": "NN1218-4113"}, "secondaryIdInfos": [{"id": "U1111-1180-0636", "type": "OTHER", "domain": "World Health Organization (WHO)"}, {"id": "2016-000878-38", "type": "REGISTRY", "domain": "European Medicines Agency (EudraCT)"}], "organization": {"fullName": "Novo Nordisk A/S", "class": "INDUSTRY"}, "briefTitle": "Research Study Comparing a New Medicine \"Fast-acting Insulin Aspart\" to Another Already Available Medicine \"NovoRapid\"/\"NovoLog\" in People With Type 2 Diabetes", "officialTitle": "Efficacy and Safety of Fast-acting Insulin Aspart Compared to NovoRapid\u00ae Both in Combination With Insulin Degludec With or Without Metformin in Adults With Type 2 Diabetes (Onset\u00ae 9)", "acronym": "onset 9"}, "statusModule": {"statusVerifiedDate": "2022-01", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2017-09-19", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2019-01-07", "type": "ACTUAL"}, "completionDateStruct": {"date": "2019-01-29", "type": "ACTUAL"}, "studyFirstSubmitDate": "2017-08-29", "studyFirstSubmitQcDate": "2017-08-29", "studyFirstPostDateStruct": {"date": "2017-08-31", "type": "ACTUAL"}, "resultsFirstSubmitDate": "2020-01-07", "resultsFirstSubmitQcDate": "2020-02-25", "resultsFirstPostDateStruct": {"date": "2020-03-12", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2022-01-06", "lastUpdatePostDateStruct": {"date": "2022-01-11", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Novo Nordisk A/S", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": false, "isFdaRegulatedDrug": true, "isFdaRegulatedDevice": false}, "descriptionModule": {"briefSummary": "The study compares 2 medicines for type 2 diabetes: fast-acting insulin aspart (a new medicine) and NovoRapid\u00ae/NovoLog\u00ae (a medicine doctors can already prescribe). Fast-acting insulin aspart will be tested to see how well it works and if it is safe. Participants will get either fast-acting insulin aspart or NovoRapid\u00ae/ NovoLog\u00ae - which treatment you get is decided by chance. Both medicines will be taken together with insulin degludec. Participants will need to take 1 injection 4 times every day (all insulins will be provided in pens). The study will last for about 8 months (34 weeks)."}, "conditionsModule": {"conditions": ["Diabetes", "Diabetes Mellitus, Type 2"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "QUADRUPLE", "maskingDescription": "Sponsor staff involved in the clinical trial is masked according to company standard procedures.", "whoMasked": ["PARTICIPANT", "CARE_PROVIDER", "INVESTIGATOR", "OUTCOMES_ASSESSOR"]}}, "enrollmentInfo": {"count": 1264, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Faster aspart + insulin degludec with or without metformin", "type": "EXPERIMENTAL", "interventionNames": ["Drug: Faster-acting insulin aspart", "Drug: Insulin degludec", "Drug: Metformin"]}, {"label": "NovoRapid/NovoLog + insulin degludec with or without metformin", "type": "ACTIVE_COMPARATOR", "interventionNames": ["Drug: Insulin aspart", "Drug: Insulin degludec", "Drug: Metformin"]}], "interventions": [{"type": "DRUG", "name": "Faster-acting insulin aspart", "description": "Faster aspart given subcutaneously (s.c., under the skin) once a day for 16 weeks. Dose individually adjusted.", "armGroupLabels": ["Faster aspart + insulin degludec with or without metformin"]}, {"type": "DRUG", "name": "Insulin aspart", "description": "Insulin aspart given subcutaneously (s.c., under the skin) once a day for 16 weeks. Dose individually adjusted.", "armGroupLabels": ["NovoRapid/NovoLog + insulin degludec with or without metformin"]}, {"type": "DRUG", "name": "Insulin degludec", "description": "Insulin degludec given subcutaneously (s.c., under the skin) once a day for 16 weeks. Dose individually adjusted.", "armGroupLabels": ["Faster aspart + insulin degludec with or without metformin", "NovoRapid/NovoLog + insulin degludec with or without metformin"]}, {"type": "DRUG", "name": "Metformin", "description": "Only participants who took metformin before the study should take metformin tablets, same dose as before the study", "armGroupLabels": ["Faster aspart + insulin degludec with or without metformin", "NovoRapid/NovoLog + insulin degludec with or without metformin"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Change in Glycosylated Haemoglobin (HbA1c)", "description": "Change from baseline (week 0) in glycosylated haemoglobin (HbA1c) was evaluated at week 16. The endpoint was evaluated based on data from the in-trial observation period. In-trial observation period was from date of randomisation and until last trial-related participant-site contact.", "timeFrame": "Week 0, week 16"}], "secondaryOutcomes": [{"measure": "Change From Baseline in 1-hour PPG Increment", "description": "Change from baseline (week 0) in 1-hour postprandial glucose (PPG) increment was evaluated after 16 weeks of randomisation. The results are based on the last in-trial value, which included the last available measurement in the in-trial period. In trial observation period was from date of randomisation and until last trial-related participant-site contact.", "timeFrame": "Week 0, week 16"}, {"measure": "Change From Baseline in 1,5-anhydroglucitol", "description": "Change from baseline (week 0) in 1,5-anhydroglucitol was evaluated after 16 weeks of randomisation. The results are based on the last in-trial value, which included the last available measurement in the in-trial period. In trial observation period was from date of randomisation and until last trial-related participant-site contact.", "timeFrame": "Week 0, week 16"}, {"measure": "Change From Baseline in Fasting Plasma Glucose (FPG)", "description": "Change from baseline (week 0) in fasting plasma glucose was evaluated after 16 weeks of randomisation. The results are based on the last in-trial value, which included the last available measurement in the in-trial period. In trial observation period was from date of randomisation and until last trial-related participant-site contact.", "timeFrame": "Week 0, week 16"}, {"measure": "Participants Who Achieved HbA1c <7.0% (53 mmol/L) (Yes/No)", "description": "Number of participants reaching HbA1c \\<7.0% (53 mmol/L) was evaluated after 16 weeks of randomisation. The results are based on the last in-trial value, which included the last available measurement in the in-trial period. In trial observation period was from date of randomisation and until last trial-related participant-site contact.", "timeFrame": "16 weeks after randomisation"}, {"measure": "Participants Who Achieved HbA1c <7.0% (53 mmol/L) Without Severe Hypoglycaemia Episodes (Yes/No)", "description": "Number of participants reaching HbA1c \\<7.0% (53 mmol/L) without severe hypoglycaemia episodes was evaluated after 16 weeks of randomisation. The results are based on the last in-trial value, which included the last available measurement in the in-trial period. In trial observation period was from date of randomisation and until last trial-related participant-site contact.", "timeFrame": "16 weeks after randomisation"}, {"measure": "Change From Baseline (Week 0) in 30-minute, 1-hour, 2-hour, 3-hour and 4-hour Postprandial Glucose (PPG [Meal Test])", "description": "Change from baseline (week 0) in 30-minute, 1-hour, 2-hour, 3-hour and 4-hour postprandial glucose (PPG \\[meal test\\]) was evaluated after 16 weeks of randomisation. The results are based on the last in-trial value, which included the last available measurement in the in-trial period. In trial observation period was from date of randomisation and until last trial-related participant-site contact. Meal test: The subjects were given a carbohydrate-rich standardised liquid meal immediately after bolus (faster aspart or NovoRapid) infusion in the morning of the meal test. The subjects were to consume the meal as quickly as possible (within 12 minutes) and blood samples were drawn after 30 minutes, 1, 2, 3 and 4 hours from the start of the meal.", "timeFrame": "Week 0, week 16"}, {"measure": "Change From Baseline (Week 0) in 30-minute, 1-hour, 2-hour, 3-hour and 4-hour PPG Increment (Meal Test)", "description": "Change from baseline (week 0) in 30-minute, 1-hour, 2-hour, 3-hour and 4-hour PPG increment (meal test) was evaluated after 16 weeks of randomisation. The results are based on the last in-trial value, which included the last available measurement in the in-trial period. In trial observation period was from date of randomisation and until last trial-related participant-site contact. Meal test: The subjects were given a carbohydrate-rich standardised liquid meal immediately after bolus (faster aspart or NovoRapid) infusion in the morning of the meal test. The subjects were to consume the meal as quickly as possible (within 12 minutes) and blood samples were drawn after 30 minutes, 1, 2, 3 and 4 hours from the start of the meal. PPG incremental value for each time point was derived as PPG value at that time point minus the preprandial glucose value.", "timeFrame": "Week 0, week 16"}, {"measure": "Change From Baseline in Mean of the 7-9-7 Point Self-measured Plasma Glucose (SMPG) Profile", "description": "Change from baseline (week 0) in mean of the 7-9-7 point SMPG profile was evaluated after 16 weeks of randomisation. The results are based on the last in-trial value, which included the last available measurement in the in-trial period. 7-9-7 point SMPG was measured at the following mentioned time points: 1) Before breakfast, 2) 60 mins after the start of Breakfast, 3) Before lunch, 4) 60 mins after the start of lunch, 5) Before main evening meal, 6) 60 mins after the start of main evening meal, 7) At bedtime, 8) At 4 AM, 9) Before breakfast.", "timeFrame": "Week 0, week 16"}, {"measure": "Change From Baseline of the 7-9-7 Point SMPG Profile: PPG (Mean, Breakfast, Lunch and Main Evening Meal)", "description": "Change from baseline (week 0) in PPG (breakfast, lunch, main evening meal and mean over all meals) of the 7-9-7 point SMPG profile was evaluated after 16 weeks of randomisation. The results are based on the last in-trial value, which included the last available measurement in the in-trial period. In trial observation period was from date of randomisation and until last trial-related participant-site contact.", "timeFrame": "Week 0, week 16"}, {"measure": "Change From Baseline of the 7-9-7 Point SMPG Profile: PPG Increment (Mean, Breakfast, Lunch and Main Evening Meal)", "description": "Change from baseline (week 0) in PPG increment (breakfast, lunch, main evening meal and mean over all meals) of the 7-9-7 point SMPG profile was evaluated after 16 weeks of randomisation. The results are based on the last in-trial value, which included the last available measurement in the in-trial period. PPG increment based on the 7-9-7-point profiles were derived separately for PG measurements made at 1 hour after main meals (breakfast, lunch and main evening meal). PPG incremental value for each time point was derived as PPG value at that time point minus the preprandial glucose value. In trial observation period was from date of randomisation and until last trial-related participant-site contact.", "timeFrame": "Week 0, week 16"}, {"measure": "Change From Baseline of the 7-9-7 Point SMPG Profile: Fluctuation in 7-9-7 Point Profile", "description": "Fluctuation in 7-point SMPG profile was the average absolute difference from the mean of the SMPG profile. Reported results are fluctuation in the 7-9-7 point SMPG profile from baseline (week 0) after 16 weeks of randomisation (i.e., week 16). The results are presented as ratio to baseline. The results are based on the last in-trial value, which included the last available measurement in the in-trial period. In trial observation period was from date of randomisation and until last trial-related participant-site contact.", "timeFrame": "Week 0, week 16"}, {"measure": "Change From Baseline of the 7-9-7 Point SMPG Profile: Nocturnal SMPG Measurements", "description": "Change from baseline (week 0) in nocturnal SMPG measurements was assessed by considering the differences between PG values available at bedtime, at 4 AM and the before breakfast value the following day: (4 AM PG value minus at bedtime PG value), (before breakfast PG value minus at bedtime PG value) and (before breakfast PG value minus 4 AM PG value). Change from baseline in nocturnal increments in SMPG measurements of the 7-9-7 point SMPG profile was evaluated after 16 weeks of randomisation and presented during three different time intervals as follows: 1) 04:00 to breakfast, 2) bedtime to 04:00, and 3) bedtime to breakfast. The results are based on the last in-trial value, which included the last available measurement in the in-trial period. In trial observation period was from date of randomisation and until last trial-related participant-site contact.", "timeFrame": "Week 0, week 16"}, {"measure": "Participants Who Achieved Overall PPG (1 Hour) <7.8 mmol/L (140 mg/dL) (Yes/No)", "description": "Participants reaching overall PPG (1 hour) \u22647.8 mmol/L \\[140 mg/dL\\] was evaluated after 16 weeks of randomisation. Participants without a postprandial glucose measurement at week 16 were considered not to have achieved HbA1c target at week 16. The results are based on the last in-trial value, which included the last available measurement in the in-trial period. In trial observation period was from date of randomisation and until last trial-related participant-site contact.", "timeFrame": "16 weeks after randomisation"}, {"measure": "Participants Who Achieved Overall PPG <7.8 mmol/L (140 mg/dL) Without Severe Hypoglycaemia Episodes (Yes/No)", "description": "Participants reaching overall PPG (1 hour) \u22647.8 mmol/L \\[140 mg/dL\\] without severe hypoglycaemia episodes was evaluated after 16 weeks of randomisation. Participants without a postprandial glucose measurement at week 16 were considered not to have achieved HbA1c target at week 16. The results are based on the last in-trial value, which included the last available measurement in the in-trial period. In trial observation period was from date of randomisation and until last trial-related participant-site contact.", "timeFrame": "16 weeks after randomisation"}, {"measure": "Total Bolus Insulin Dose: in Units/Day", "description": "Total bolus insulin dose (Units/day) was evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period. On-treatment period started from date of first dose of randomised NovoRapid/faster aspart and to 7 days after day of last dose or day before initiation of ancillary treatment.", "timeFrame": "16 weeks from randomisation"}, {"measure": "Total Bolus Insulin Dose: in Units/kg/Day", "description": "Total bolus insulin dose (Units/kg/day) was evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period. On-treatment period started from date of first dose of randomised NovoRapid/faster aspart and to 7 days after day of last dose or day before initiation of ancillary treatment.", "timeFrame": "16 weeks from randomisation"}, {"measure": "Total Basal Insulin Dose: in Units/Day", "description": "Total basal insulin dose (Units/day) was evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period. On-treatment period started from date of first dose of randomised NovoRapid/faster aspart and to 7 days after day of last dose or day before initiation of ancillary treatment.", "timeFrame": "16 weeks from randomisation"}, {"measure": "Total Basal Insulin Dose: in Units/kg/Day", "description": "Total basal insulin dose (Units/kg/day) was evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period. On-treatment period started from date of first dose of randomised NovoRapid/faster aspart and to 7 days after day of last dose or day before initiation of ancillary treatment.", "timeFrame": "16 weeks from randomisation"}, {"measure": "Individual Meal Insulin Dose: in Units", "description": "Individual meal time bolus insulin dose (Units) for breakast, lunch and main evening meal was evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period. On-treatment period started from date of first dose of randomised NovoRapid/faster aspart and to 7 days after day of last dose or day before initiation of ancillary treatment.", "timeFrame": "16 weeks from randomisation"}, {"measure": "Individual Meal Insulin Dose: in Units/kg", "description": "Individual meal time bolus insulin dose (Units/kg) for breakast, lunch and main evening meal was evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period. On-treatment period started from date of first dose of randomised NovoRapid/faster aspart and to 7 days after day of last dose or day before initiation of ancillary treatment.", "timeFrame": "16 weeks from randomisation"}, {"measure": "Change From Baseline in Lipids-lipoproteins Profile (Total Cholesterol, High Density Lipoproteins, Low Density Lipoproteins) - Ratio to Baseline", "description": "Reported results are lipids-lipoproteins (total cholesterol, high density lipoproteins, low density lipoproteins) values are given as ratio to baseline (week 0) after 16 weeks. The results are based on the last in-trial value, which included the last available measurement in the in-trial period. In trial observation period was from date of randomisation and until last trial-related participant-site contact.", "timeFrame": "Week 0, week 16"}, {"measure": "Number of Treatment Emergent Adverse Events", "description": "Number of treatment emergent adverse events were recorded from week 0 to week 16. The results are based on the on-treatment period. On-treatment period started from date of first dose of randomised NovoRapid/faster aspart and to 7 days after day of last dose or day before initiation of ancillary treatment.", "timeFrame": "Weeks 0-16"}, {"measure": "Number of Treatment Emergent Injection Site Reactions", "description": "Number of treatment emergent injection site reactions were recorded from week 0 to week 16. The results are based on the on-treatment period. On-treatment period started from date of first dose of randomised NovoRapid/faster aspart and to 7 days after day of last dose or day before initiation of ancillary treatment.", "timeFrame": "Weeks 0-16"}, {"measure": "Number of Treatment Emergent Hypoglycaemic Episodes (Hypos) According to the American Diabetes Association (ADA) and Novo Nordisk (NN) Definition: Overall", "description": "ADA classification of hypos:\n\n1. Severe: Requiring assistance of another person to actively administer carbohydrate/glucagon/take other corrective actions. PG levels may not be available during an event, but neurological recovery following return of PG to normal is considered sufficient evidence that event was induced by a low PG level.\n2. Documented symptomatic: PG \u22643.9 mmol/L with symptoms.\n3. Asymptomatic: PG \u22643.9 mmol/L without symptoms.\n4. Probable symptomatic: No measurement with symptoms.\n5. Pseudo: PG \\>3.9 mmol/L with symptoms.\n6. Unclassifiable.\n\nNN classification of hypos:\n\n1. BG confirmed: PG \\<3.1 mmol/L with/without symptoms.\n2. Severe or BG confirmed symptomatic: Severe as per ADA and BG confirmed by PG \\<3.1 mmol/L with symptoms.\n3. Severe or BG confirmed: Severe as per ADA and BG confirmed by PG \\<3.1 mmol/L with/without symptoms.\n4. Unclassifiable. Not able to self treat-unclassifiable: Not able to self treat but not classifiable as severe hypoglycaemia.", "timeFrame": "Weeks 0-16"}, {"measure": "Number of Treatment Emergent Hypoglycaemic Episodes According to the American Diabetes Association and Novo Nordisk Definition: Daytime Hypoglycaemic Episodes (06:00-00:00 - Inclusive)", "description": "Number of treatment emergent day time hypoglycaemic episodes according to the ADA and NN definitions were evaluated between 06:00 and 00:00 (both included). The results are based on the on-treatment period. On-treatment period started from date of first dose of randomised NovoRapid/faster aspart and to 7 days after day of last dose or day before initiation of ancillary treatment.", "timeFrame": "Weeks 0-16"}, {"measure": "Number of Treatment Emergent Hypoglycaemic Episodes According to the American Diabetes Association and Novo Nordisk Definition: Nocturnal Hypoglycaemic Episodes (00:01-05:59 - Inclusive)", "description": "Number of treatment emergent nocturnal hypoglycaemic episodes according to the ADA and NN definitions were evaluated between 00:01 and 05:59 (both included). The results are based on the on-treatment period. On-treatment period started from date of first dose of randomised NovoRapid/faster aspart and to 7 days after day of last dose or day before initiation of ancillary treatment.", "timeFrame": "Weeks 0-16"}, {"measure": "Number of Treatment Emergent Hypoglycaemic Episodes According to the American Diabetes Association and Novo Nordisk Definition: Hypoglycaemic Episodes During First 1 Hour After Start of the Meal", "description": "Number of treatment emergent hypoglycaemic episodes according to the ADA and NN definitions were evaluated during the first 1 hour after start of the meal. The results are based on the on-treatment period. On-treatment period started from date of first dose of randomised NovoRapid/faster aspart and to 7 days after day of last dose or day before initiation of ancillary treatment.", "timeFrame": "Weeks 0-16"}, {"measure": "Number of Treatment Emergent Hypoglycaemic Episodes According to the American Diabetes Association and Novo Nordisk Definition: Hypoglycaemic Episodes During First 2 Hours After Start of the Meal", "description": "Number of treatment emergent hypoglycaemic episodes according to the ADA and NN definitions were evaluated during the first 2 hours after start of the meal. The results are based on the on-treatment period. On-treatment period started from date of first dose of randomised NovoRapid/faster aspart and to 7 days after day of last dose or day before initiation of ancillary treatment.", "timeFrame": "Weeks 0-16"}, {"measure": "Number of Treatment Emergent Hypoglycaemic Episodes According to the American Diabetes Association and Novo Nordisk Definition: Hypoglycaemic Episodes During First 4 Hours After Start of the Meal", "description": "Number of treatment emergent hypoglycaemic episodes according to the ADA and NN definitions were evaluated during the first 4 hours after start of the meal. The results are based on the on-treatment period. On-treatment period started from date of first dose of randomised NovoRapid/faster aspart and to 7 days after day of last dose or day before initiation of ancillary treatment.", "timeFrame": "Weeks 0-16"}, {"measure": "Number of Treatment Emergent Hypoglycaemic Episodes According to the American Diabetes Association and NN Definition: Hypoglycaemic Episodes Occurring Between 2 to 4 Hours After Start of the Meal", "description": "Number of treatment emergent hypoglycaemic episodes according to the ADA and NN definitions were evaluated between 2 to 4 hours after start of the meal. The results are based on the on-treatment period. On-treatment period started from date of first dose of randomised NovoRapid/faster aspart and to 7 days after day of last dose or day before initiation of ancillary treatment.", "timeFrame": "Weeks 0-16"}, {"measure": "Change From Baseline in Physical Examination", "description": "Participants with physical examination findings, normal, abnormal NCS (non- clinically significant) and abnormal CS (clinically significant) at baseline (week 0) and week 16 presented. Results are based on the data from the on-treatment observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of rescue medication and/or premature discontinuation of trial product. Results are presented for the following examinations: 1) Cardiovascular system 2) Central \\& Peripheral nervous system 3) Gastrointestinal system incl. mouth 4) Head, ears, eyes, nose, throat and neck 5) Musculoskeletal system 6) Respiratory system 7) Skin", "timeFrame": "Week 0, week 16"}, {"measure": "Change From Baseline in Vital Signs: Systolic and Diastolic Blood Presure", "description": "Change in vital signs - systolic and diastolic blood pressure from baseline (week 0) was evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period. On-treatment period started from date of first dose of randomised NovoRapid/faster aspart and to 7 days after day of last dose or day before initiation of ancillary treatment.", "timeFrame": "Week 0, week 16"}, {"measure": "Change From Baseline in Vital Signs: Pulse", "description": "Change in vital signs - pulse from baseline (week 0) was evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period. On-treatment period started from date of first dose of randomised NovoRapid/faster aspart and to 7 days after day of last dose or day before initiation of ancillary treatment.", "timeFrame": "Week 0, week 16"}, {"measure": "Change From Baseline in Electrocardiogram (ECG)", "description": "Changes in electrocardiogram (ECG) from baseline (week 0) were evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period. On-treatment period started from date of first dose of randomised NovoRapid/faster aspart and to 7 days after day of last dose or day before initiation of ancillary treatment.", "timeFrame": "Week 0, week 16"}, {"measure": "Change From Baseline in Fundoscopy/Fundus Photography", "description": "Changes in fundoscopy/fundus photography from baseline (week 0) were evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period. On-treatment period started from date of first dose of randomised NovoRapid/faster aspart and to 7 days after day of last dose or day before initiation of ancillary treatment.", "timeFrame": "Week 0, week 16"}, {"measure": "Change From Baseline in Haematology - Haematocrit", "description": "Changes in haematology - haematocrit from baseline (week 0) were evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period. On-treatment period started from date of first dose of randomised NovoRapid/faster aspart and to 7 days after day of last dose or day before initiation of ancillary treatment.", "timeFrame": "Week 0, week 16"}, {"measure": "Change From Baseline in Haematology - Haemoglobin", "description": "Changes in haematology - haemoglobin from baseline (week 0) were evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period. On-treatment period started from date of first dose of randomised NovoRapid/faster aspart and to 7 days after day of last dose or day before initiation of ancillary treatment.", "timeFrame": "Week 0, week 16"}, {"measure": "Change From Baseline in Haematology - Leukocytes", "description": "Changes in haematology - leukocytes from baseline (week 0) were evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period. On-treatment period started from date of first dose of randomised NovoRapid/faster aspart and to 7 days after day of last dose or day before initiation of ancillary treatment.", "timeFrame": "Week 0, week 16"}, {"measure": "Change From Baseline in Haematology - Thrombocytes", "description": "Changes in haematology - thrombocytes from baseline (week 0) were evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period. On-treatment period started from date of first dose of randomised NovoRapid/faster aspart and to 7 days after day of last dose or day before initiation of ancillary treatment.", "timeFrame": "Week 0, week 16"}, {"measure": "Change From Baseline in Haematology - Erythrocytes", "description": "Changes in haematology - erythrocytes from baseline (week 0) were evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period. On-treatment period started from date of first dose of randomised NovoRapid/faster aspart and to 7 days after day of last dose or day before initiation of ancillary treatment.", "timeFrame": "Week 0, week 16"}, {"measure": "Change From Baseline in Biochemistry - Alanine Aminotransferase (ALT)", "description": "Changes in biochemistry - alanine aminotransferase from baseline (week 0) were evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period. On-treatment period started from date of first dose of randomised NovoRapid/faster aspart and to 7 days after day of last dose or day before initiation of ancillary treatment.", "timeFrame": "Week 0, week 16"}, {"measure": "Change From Baseline in Biochemistry - Alkaline Phosphatase", "description": "Changes in biochemistry - alkaline phosphatase from baseline (week 0) were evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period. On-treatment period started from date of first dose of randomised NovoRapid/faster aspart and to 7 days after day of last dose or day before initiation of ancillary treatment.", "timeFrame": "Week 0, week 16"}, {"measure": "Change From Baseline in Biochemistry - Aspartate Aminotransferase (AST)", "description": "Changes in biochemistry - aspratate aminotransferase from baseline (week 0) were evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period. On-treatment period started from date of first dose of randomised NovoRapid/faster aspart and to 7 days after day of last dose or day before initiation of ancillary treatment.", "timeFrame": "Week 0, week 16"}, {"measure": "Change From Baseline in Biochemistry - Albumin", "description": "Changes in biochemistry - albumin from baseline (week 0) were evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period. On-treatment period started from date of first dose of randomised NovoRapid/faster aspart and to 7 days after day of last dose or day before initiation of ancillary treatment.", "timeFrame": "Week 0, week 16"}, {"measure": "Change From Baseline in Biochemistry - Creatinine", "description": "Changes in biochemistry - creatinine from baseline (week 0) were evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period. On-treatment period started from date of first dose of randomised NovoRapid/faster aspart and to 7 days after day of last dose or day before initiation of ancillary treatment.", "timeFrame": "Week 0, week 16"}, {"measure": "Change From Baseline in Biochemistry - Potassium", "description": "Changes in biochemistry - potassium from baseline (week 0) were evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period. On-treatment period started from date of first dose of randomised NovoRapid/faster aspart and to 7 days after day of last dose or day before initiation of ancillary treatment.", "timeFrame": "Week 0, week 16"}, {"measure": "Change From Baseline in Biochemistry - Sodium", "description": "Changes in biochemistry - sodium from baseline (week 0) were evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period. On-treatment period started from date of first dose of randomised NovoRapid/faster aspart and to 7 days after day of last dose or day before initiation of ancillary treatment.", "timeFrame": "Week 0, week 16"}, {"measure": "Change From Baseline in Biochemistry - Total Bilirubin", "description": "Changes in biochemistry - total bilirubin from baseline (week 0) were evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period. On-treatment period started from date of first dose of randomised NovoRapid/faster aspart and to 7 days after day of last dose or day before initiation of ancillary treatment.", "timeFrame": "Week 0, week 16"}, {"measure": "Change From Baseline in Biochemistry - Total Protein", "description": "Changes in biochemistry - total protein from baseline (week 0) were evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period. On-treatment period started from date of first dose of randomised NovoRapid/faster aspart and to 7 days after day of last dose or day before initiation of ancillary treatment.", "timeFrame": "Week 0, week 16"}, {"measure": "Change From Baseline in Body Weight", "description": "Changes in body weight from baseline (week 0) were evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period. On-treatment period started from date of first dose of randomised NovoRapid/faster aspart and to 7 days after day of last dose or day before initiation of ancillary treatment.", "timeFrame": "Week 0, week 16"}, {"measure": "Change From Baseline in Body Mass Index (BMI)", "description": "Change in the body mass index (BMI) from baseline (week 0) were evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period. On-treatment period started from date of first dose of randomised NovoRapid/faster aspart and to 7 days after day of last dose or day before initiation of ancillary treatment.", "timeFrame": "Week 0, week 16"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria: - Male or female, age equal to or above 18 years at the time of signing informed consent. - Diagnosed with type 2 diabetes mellitus for 10 years or longer prior to screening (Visit 1). - Treated with a basal-bolus insulin regimen for 1 year or longer prior to the day of screening (Visit 1). A basal-bolus insulin regimen is defined as basal insulin once or twice daily and bolus insulin analogue taken with meals at least 3 times daily. Treatment with premixed insulin or soluble insulin combination is not considered a basal-bolus regimen. - Treated with or without oral antidiabetic drugs including extended release formulations. - HbA1c 7.0-10.0% (both inclusive) as assessed by central laboratory at screening (Visit 1). Exclusion Criteria: - Any of the following: myocardial infarction, stroke, hospitalization for unstable angina or transient ischaemic attack within the past 180 days prior to the day of screening (Visit 1). - Subjects presently classified as being in New York Heart Association (NYHA) Class IV. - Planned coronary, carotid or peripheral artery revascularisation known on the day of screening (Visit 1). - Treatment with injectable GLP-1 receptor agonists in a period of 90 days prior to screening (Visit 1). - Anticipated initiation or change in concomitant medications (for more than 14 consecutive days) known to affect weight or glucose metabolism (e.g. treatment with orlistat, thyroid hormones, or corticosteroids).", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"locations": [{"facility": "Novo Nordisk Investigational Site", "city": "Concord", "state": "California", "zip": "94520", "country": "United States", "geoPoint": {"lat": 37.97798, "lon": -122.03107}}, {"facility": "Novo Nordisk Investigational Site", "city": "Fresno", "state": "California", "zip": "93720", "country": "United States", "geoPoint": {"lat": 36.74773, "lon": -119.77237}}, {"facility": "Novo Nordisk Investigational Site", "city": "Fullerton", "state": "California", "zip": "92835", "country": "United States", "geoPoint": {"lat": 33.87029, "lon": -117.92534}}, {"facility": "Novo Nordisk Investigational Site", "city": "Lancaster", "state": "California", "zip": "93534", "country": "United States", "geoPoint": {"lat": 34.69804, "lon": -118.13674}}, {"facility": "Novo Nordisk Investigational Site", "city": "Norco", "state": "California", "zip": "92860", "country": "United States", "geoPoint": {"lat": 33.93113, "lon": -117.54866}}, {"facility": "Novo Nordisk Investigational Site", "city": "Sacramento", "state": "California", "zip": "95821", "country": "United States", "geoPoint": {"lat": 38.58157, "lon": -121.4944}}, {"facility": "Novo Nordisk Investigational Site", "city": "Ventura", "state": "California", "zip": "93003", "country": "United States", "geoPoint": {"lat": 34.27834, "lon": -119.29317}}, {"facility": "Novo Nordisk Investigational Site", "city": "Walnut Creek", "state": "California", "zip": "94598", "country": "United States", "geoPoint": {"lat": 37.90631, "lon": -122.06496}}, {"facility": "Novo Nordisk Investigational Site", "city": "Denver", "state": "Colorado", "zip": "80246", "country": "United States", "geoPoint": {"lat": 39.73915, "lon": -104.9847}}, {"facility": "Novo Nordisk Investigational Site", "city": "Golden", "state": "Colorado", "zip": "80401", "country": "United States", "geoPoint": {"lat": 39.75554, "lon": -105.2211}}, {"facility": "Novo Nordisk Investigational Site", "city": "Waterbury", "state": "Connecticut", "zip": "06708", "country": "United States", "geoPoint": {"lat": 41.55815, "lon": -73.0515}}, {"facility": "Novo Nordisk Investigational Site", "city": "Boynton Beach", "state": "Florida", "zip": "33472", "country": "United States", "geoPoint": {"lat": 26.52535, "lon": -80.06643}}, {"facility": "Novo Nordisk Investigational Site", "city": "Bradenton", "state": "Florida", "zip": "34201", "country": "United States", "geoPoint": {"lat": 27.49893, "lon": -82.57482}}, {"facility": "Novo Nordisk Investigational Site", "city": "Fort Lauderdale", "state": "Florida", "zip": "33312", "country": "United States", "geoPoint": {"lat": 26.12231, "lon": -80.14338}}, {"facility": "Novo Nordisk Investigational Site", "city": "Miami", "state": "Florida", "zip": "33174", "country": "United States", "geoPoint": {"lat": 25.77427, "lon": -80.19366}}, {"facility": "Novo Nordisk Investigational Site", "city": "Tampa", "state": "Florida", "zip": "33634", "country": "United States", "geoPoint": {"lat": 27.94752, "lon": -82.45843}}, {"facility": "Novo Nordisk Investigational Site", "city": "Alpharetta", "state": "Georgia", "zip": "30022", "country": "United States", "geoPoint": {"lat": 34.07538, "lon": -84.29409}}, {"facility": "Novo Nordisk Investigational Site", "city": "Lawrenceville", "state": "Georgia", "zip": "30046", "country": "United States", "geoPoint": {"lat": 33.95621, "lon": -83.98796}}, {"facility": "Novo Nordisk Investigational Site", "city": "Roswell", "state": "Georgia", "zip": "30076", "country": "United States", "geoPoint": {"lat": 34.02316, "lon": -84.36159}}, {"facility": "Novo Nordisk Investigational Site", "city": "Honolulu", "state": "Hawaii", "zip": "96814", "country": "United States", "geoPoint": {"lat": 21.30694, "lon": -157.85833}}, {"facility": "Novo Nordisk Investigational Site", "city": "Chicago", "state": "Illinois", "zip": "60611", "country": "United States", "geoPoint": {"lat": 41.85003, "lon": -87.65005}}, {"facility": "Novo Nordisk Investigational Site", "city": "Peoria", "state": "Illinois", "zip": "61603", "country": "United States", "geoPoint": {"lat": 40.69365, "lon": -89.58899}}, {"facility": "Novo Nordisk Investigational Site", "city": "Springfield", "state": "Illinois", "zip": "62711", "country": "United States", "geoPoint": {"lat": 39.80172, "lon": -89.64371}}, {"facility": "Novo Nordisk Investigational Site", "city": "Valparaiso", "state": "Indiana", "zip": "46383", "country": "United States", "geoPoint": {"lat": 41.47309, "lon": -87.06114}}, {"facility": "Novo Nordisk Investigational Site", "city": "West Des Moines", "state": "Iowa", "zip": "50266", "country": "United States", "geoPoint": {"lat": 41.57721, "lon": -93.71133}}, {"facility": "Novo Nordisk Investigational Site", "city": "Topeka", "state": "Kansas", "zip": "66606", "country": "United States", "geoPoint": {"lat": 39.04833, "lon": -95.67804}}, {"facility": "Novo Nordisk Investigational Site", "city": "Lexington", "state": "Kentucky", "zip": "40502", "country": "United States", "geoPoint": {"lat": 37.98869, "lon": -84.47772}}, {"facility": "Novo Nordisk Investigational Site", "city": "Lexington", "state": "Kentucky", "zip": "40503", "country": "United States", "geoPoint": {"lat": 37.98869, "lon": -84.47772}}, {"facility": "Novo Nordisk Investigational Site", "city": "Rockville", "state": "Maryland", "zip": "20852", "country": "United States", "geoPoint": {"lat": 39.084, "lon": -77.15276}}, {"facility": "Novo Nordisk Investigational Site", "city": "Waltham", "state": "Massachusetts", "zip": "02453", "country": "United States", "geoPoint": {"lat": 42.37649, "lon": -71.23561}}, {"facility": "Novo Nordisk Investigational Site", "city": "Worcester", "state": "Massachusetts", "zip": "01655", "country": "United States", "geoPoint": {"lat": 42.26259, "lon": -71.80229}}, {"facility": "Novo Nordisk Investigational Site", "city": "Henderson", "state": "Nevada", "zip": "89052-2649", "country": "United States", "geoPoint": {"lat": 36.0397, "lon": -114.98194}}, {"facility": "Novo Nordisk Investigational Site", "city": "Las Vegas", "state": "Nevada", "zip": "89148", "country": "United States", "geoPoint": {"lat": 36.17497, "lon": -115.13722}}, {"facility": "Novo Nordisk Investigational Site", "city": "Nashua", "state": "New Hampshire", "zip": "03063", "country": "United States", "geoPoint": {"lat": 42.76537, "lon": -71.46757}}, {"facility": "Novo Nordisk Investigational Site", "city": "Northport", "state": "New York", "zip": "11768", "country": "United States", "geoPoint": {"lat": 40.90093, "lon": -73.34317}}, {"facility": "Novo Nordisk Investigational Site", "city": "West Seneca", "state": "New York", "zip": "14224", "country": "United States", "geoPoint": {"lat": 42.85006, "lon": -78.79975}}, {"facility": "Novo Nordisk Investigational Site", "city": "Asheville", "state": "North Carolina", "zip": "28803", "country": "United States", "geoPoint": {"lat": 35.60095, "lon": -82.55402}}, {"facility": "Novo Nordisk Investigational Site", "city": "Chapel Hill", "state": "North Carolina", "zip": "27514", "country": "United States", "geoPoint": {"lat": 35.9132, "lon": -79.05584}}, {"facility": "Novo Nordisk Investigational Site", "city": "Mentor", "state": "Ohio", "zip": "44060", "country": "United States", "geoPoint": {"lat": 41.66616, "lon": -81.33955}}, {"facility": "Novo Nordisk Investigational Site", "city": "Oklahoma City", "state": "Oklahoma", "zip": "73104-5020", "country": "United States", "geoPoint": {"lat": 35.46756, "lon": -97.51643}}, {"facility": "Novo Nordisk Investigational Site", "city": "Philadelphia", "state": "Pennsylvania", "zip": "19140", "country": "United States", "geoPoint": {"lat": 39.95233, "lon": -75.16379}}, {"facility": "Novo Nordisk Investigational Site", "city": "Greenville", "state": "South Carolina", "zip": "29605-4254", "country": "United States", "geoPoint": {"lat": 34.85262, "lon": -82.39401}}, {"facility": "Novo Nordisk Investigational Site", "city": "Chattanooga", "state": "Tennessee", "zip": "37404", "country": "United States", "geoPoint": {"lat": 35.04563, "lon": -85.30968}}, {"facility": "Novo Nordisk Investigational Site", "city": "Chattanooga", "state": "Tennessee", "zip": "37411", "country": "United States", "geoPoint": {"lat": 35.04563, "lon": -85.30968}}, {"facility": "Novo Nordisk Investigational Site", "city": "Nashville", "state": "Tennessee", "zip": "37212", "country": "United States", "geoPoint": {"lat": 36.16589, "lon": -86.78444}}, {"facility": "Novo Nordisk Investigational Site", "city": "Amarillo", "state": "Texas", "zip": "79106", "country": "United States", "geoPoint": {"lat": 35.222, "lon": -101.8313}}, {"facility": "Novo Nordisk Investigational Site", "city": "Austin", "state": "Texas", "zip": "78731", "country": "United States", "geoPoint": {"lat": 30.26715, "lon": -97.74306}}, {"facility": "Novo Nordisk Investigational Site", "city": "Austin", "state": "Texas", "zip": "78749", "country": "United States", "geoPoint": {"lat": 30.26715, "lon": -97.74306}}, {"facility": "Novo Nordisk Investigational Site", "city": "Beaumont", "state": "Texas", "zip": "77701", "country": "United States", "geoPoint": {"lat": 30.08605, "lon": -94.10185}}, {"facility": "Novo Nordisk Investigational Site", "city": "Dallas", "state": "Texas", "zip": "75226", "country": "United States", "geoPoint": {"lat": 32.78306, "lon": -96.80667}}, {"facility": "Novo Nordisk Investigational Site", "city": "Dallas", "state": "Texas", "zip": "75230", "country": "United States", "geoPoint": {"lat": 32.78306, "lon": -96.80667}}, {"facility": "Novo Nordisk Investigational Site", "city": "Dallas", "state": "Texas", "zip": "75231", "country": "United States", "geoPoint": {"lat": 32.78306, "lon": -96.80667}}, {"facility": "Novo Nordisk Investigational Site", "city": "Longview", "state": "Texas", "zip": "75605", "country": "United States", "geoPoint": {"lat": 32.5007, "lon": -94.74049}}, {"facility": "Novo Nordisk Investigational Site", "city": "Pearland", "state": "Texas", "zip": "77584", "country": "United States", "geoPoint": {"lat": 29.56357, "lon": -95.28605}}, {"facility": "Novo Nordisk Investigational Site", "city": "Round Rock", "state": "Texas", "zip": "78681", "country": "United States", "geoPoint": {"lat": 30.50826, "lon": -97.6789}}, {"facility": "Novo Nordisk Investigational Site", "city": "Ogden", "state": "Utah", "zip": "84405", "country": "United States", "geoPoint": {"lat": 41.223, "lon": -111.97383}}, {"facility": "Novo Nordisk Investigational Site", "city": "Bennington", "state": "Vermont", "zip": "05201", "country": "United States", "geoPoint": {"lat": 42.87813, "lon": -73.19677}}, {"facility": "Novo Nordisk Investigational Site", "city": "South Burlington", "state": "Vermont", "zip": "05403", "country": "United States", "geoPoint": {"lat": 44.46699, "lon": -73.17096}}, {"facility": "Novo Nordisk Investigational Site", "city": "Chesapeake", "state": "Virginia", "zip": "23321", "country": "United States", "geoPoint": {"lat": 36.81904, "lon": -76.27494}}, {"facility": "Novo Nordisk Investigational Site", "city": "Winchester", "state": "Virginia", "zip": "22601-3834", "country": "United States", "geoPoint": {"lat": 39.18566, "lon": -78.16333}}, {"facility": "Novo Nordisk Investigational Site", "city": "Olympia", "state": "Washington", "zip": "98502", "country": "United States", "geoPoint": {"lat": 47.03787, "lon": -122.9007}}, {"facility": "Novo Nordisk Investigational Site", "city": "Seattle", "state": "Washington", "zip": "98105", "country": "United States", "geoPoint": {"lat": 47.60621, "lon": -122.33207}}, {"facility": "Novo Nordisk Investigational Site", "city": "Spokane", "state": "Washington", "zip": "99201", "country": "United States", "geoPoint": {"lat": 47.65966, "lon": -117.42908}}, {"facility": "Novo Nordisk Investigational Site", "city": "Green Bay", "state": "Wisconsin", "zip": "54303", "country": "United States", "geoPoint": {"lat": 44.51916, "lon": -88.01983}}, {"facility": "Novo Nordisk Investigational Site", "city": "Caba", "zip": "C1060ABA", "country": "Argentina", "geoPoint": {"lat": -34.61315, "lon": -58.37723}}, {"facility": "Novo Nordisk Investigational Site", "city": "Caba", "zip": "C1440AAD", "country": "Argentina", "geoPoint": {"lat": -34.61315, "lon": -58.37723}}, {"facility": "Novo Nordisk Investigational Site", "city": "Cordoba", "zip": "5000", "country": "Argentina", "geoPoint": {"lat": -31.4135, "lon": -64.18105}}, {"facility": "Novo Nordisk Investigational Site", "city": "C\u00f3rdoba", "zip": "5008", "country": "Argentina", "geoPoint": {"lat": -31.4135, "lon": -64.18105}}, {"facility": "Novo Nordisk Investigational Site", "city": "Kozloduy", "zip": "3320", "country": "Bulgaria", "geoPoint": {"lat": 43.77867, "lon": 23.72067}}, {"facility": "Novo Nordisk Investigational Site", "city": "Razgrad", "zip": "7200", "country": "Bulgaria", "geoPoint": {"lat": 43.53333, "lon": 26.51667}}, {"facility": "Novo Nordisk Investigational Site", "city": "Sofia", "zip": "1233", "country": "Bulgaria", "geoPoint": {"lat": 42.69751, "lon": 23.32415}}, {"facility": "Novo Nordisk Investigational Site", "city": "Sofia", "zip": "1618", "country": "Bulgaria", "geoPoint": {"lat": 42.69751, "lon": 23.32415}}, {"facility": "Novo Nordisk Investigational Site", "city": "Edmonton", "state": "Alberta", "zip": "T6G 2E1", "country": "Canada", "geoPoint": {"lat": 53.55014, "lon": -113.46871}}, {"facility": "Novo Nordisk Investigational Site", "city": "Victoria", "state": "British Columbia", "zip": "V8V 4A1", "country": "Canada", "geoPoint": {"lat": 48.43294, "lon": -123.3693}}, {"facility": "Novo Nordisk Investigational Site", "city": "Halifax", "state": "Nova Scotia", "zip": "B3H 2Y9", "country": "Canada", "geoPoint": {"lat": 44.64533, "lon": -63.57239}}, {"facility": "Novo Nordisk Investigational Site", "city": "Barrie", "state": "Ontario", "zip": "L4N 7L3", "country": "Canada", "geoPoint": {"lat": 44.40011, "lon": -79.66634}}, {"facility": "Novo Nordisk Investigational Site", "city": "Concord", "state": "Ontario", "zip": "L4K 4M2", "country": "Canada", "geoPoint": {"lat": 43.80011, "lon": -79.48291}}, {"facility": "Novo Nordisk Investigational Site", "city": "Etobicoke", "state": "Ontario", "zip": "M9R 4E1", "country": "Canada", "geoPoint": {"lat": 43.65421, "lon": -79.56711}}, {"facility": "Novo Nordisk Investigational Site", "city": "Hamilton", "state": "Ontario", "zip": "L8M 1K7", "country": "Canada", "geoPoint": {"lat": 43.25011, "lon": -79.84963}}, {"facility": "Novo Nordisk Investigational Site", "city": "Newmarket", "state": "Ontario", "zip": "L3Y 5G8", "country": "Canada", "geoPoint": {"lat": 44.05011, "lon": -79.46631}}, {"facility": "Novo Nordisk Investigational Site", "city": "Thunder Bay", "state": "Ontario", "zip": "P7A 4V7", "country": "Canada", "geoPoint": {"lat": 48.38202, "lon": -89.25018}}, {"facility": "Novo Nordisk Investigational Site", "city": "Toronto", "state": "Ontario", "zip": "M4G 3E8", "country": "Canada", "geoPoint": {"lat": 43.70011, "lon": -79.4163}}, {"facility": "Novo Nordisk Investigational Site", "city": "Montreal", "state": "Quebec", "zip": "H4T 1Z9", "country": "Canada", "geoPoint": {"lat": 45.50884, "lon": -73.58781}}, {"facility": "Novo Nordisk Investigational Site", "city": "Karlovac", "zip": "47000", "country": "Croatia", "geoPoint": {"lat": 45.48941, "lon": 15.54887}}, {"facility": "Novo Nordisk Investigational Site", "city": "Osijek", "zip": "31 000", "country": "Croatia", "geoPoint": {"lat": 45.55111, "lon": 18.69389}}, {"facility": "Novo Nordisk Investigational Site", "city": "Varazdin", "zip": "42 000", "country": "Croatia", "geoPoint": {"lat": 46.30444, "lon": 16.33778}}, {"facility": "Novo Nordisk Investigational Site", "city": "Zagreb", "zip": "10 000", "country": "Croatia", "geoPoint": {"lat": 45.81444, "lon": 15.97798}}, {"facility": "Novo Nordisk Investigational Site", "city": "Hradec Kralove", "zip": "500 05", "country": "Czechia", "geoPoint": {"lat": 50.20923, "lon": 15.83277}}, {"facility": "Novo Nordisk Investigational Site", "city": "Plzen", "zip": "30100", "country": "Czechia", "geoPoint": {"lat": 49.74747, "lon": 13.37759}}, {"facility": "Novo Nordisk Investigational Site", "city": "Plzen", "zip": "32600", "country": "Czechia", "geoPoint": {"lat": 49.74747, "lon": 13.37759}}, {"facility": "Novo Nordisk Investigational Site", "city": "Trutnov", "zip": "541 01", "country": "Czechia", "geoPoint": {"lat": 50.56101, "lon": 15.9127}}, {"facility": "Novo Nordisk Investigational Site", "city": "Dresden", "zip": "01219", "country": "Germany", "geoPoint": {"lat": 51.05089, "lon": 13.73832}}, {"facility": "Novo Nordisk Investigational Site", "city": "Essen", "zip": "45136", "country": "Germany", "geoPoint": {"lat": 51.45657, "lon": 7.01228}}, {"facility": "Novo Nordisk Investigational Site", "city": "Falkensee", "zip": "14612", "country": "Germany", "geoPoint": {"lat": 52.56014, "lon": 13.0927}}, {"facility": "Novo Nordisk Investigational Site", "city": "Lingen", "zip": "49808", "country": "Germany", "geoPoint": {"lat": 52.52143, "lon": 7.31845}}, {"facility": "Novo Nordisk Investigational Site", "city": "M\u00fcnster", "zip": "48145", "country": "Germany", "geoPoint": {"lat": 51.96236, "lon": 7.62571}}, {"facility": "Novo Nordisk Investigational Site", "city": "Saint Ingbert-Oberw\u00fcrzbach", "zip": "66386", "country": "Germany"}, {"facility": "Novo Nordisk Investigational Site", "city": "Schweinfurt", "zip": "97421", "country": "Germany", "geoPoint": {"lat": 50.04937, "lon": 10.22175}}, {"facility": "Novo Nordisk Investigational Site", "city": "Athens", "zip": "115 25", "country": "Greece", "geoPoint": {"lat": 37.97945, "lon": 23.71622}}, {"facility": "Novo Nordisk Investigational Site", "city": "Athens", "zip": "GR-11527", "country": "Greece", "geoPoint": {"lat": 37.97945, "lon": 23.71622}}, {"facility": "Novo Nordisk Investigational Site", "city": "Ioannina", "zip": "45500", "country": "Greece", "geoPoint": {"lat": 39.66486, "lon": 20.85189}}, {"facility": "Novo Nordisk Investigational Site", "city": "Larissa", "zip": "GR-41110", "country": "Greece", "geoPoint": {"lat": 39.63689, "lon": 22.41761}}, {"facility": "Novo Nordisk Investigational Site", "city": "Thessaloniki", "zip": "GR-54636", "country": "Greece", "geoPoint": {"lat": 40.64361, "lon": 22.93086}}, {"facility": "Novo Nordisk Investigational Site", "city": "Thessaloniki", "zip": "GR-54642", "country": "Greece", "geoPoint": {"lat": 40.64361, "lon": 22.93086}}, {"facility": "Novo Nordisk Investigational Site", "city": "Thessaloniki", "zip": "GR-54643", "country": "Greece", "geoPoint": {"lat": 40.64361, "lon": 22.93086}}, {"facility": "Novo Nordisk Investigational Site", "city": "Thessaloniki", "zip": "GR-57001", "country": "Greece", "geoPoint": {"lat": 40.64361, "lon": 22.93086}}, {"facility": "Novo Nordisk Investigational Site", "city": "Catanzaro", "zip": "88100", "country": "Italy", "geoPoint": {"lat": 38.88247, "lon": 16.60086}}, {"facility": "Novo Nordisk Investigational Site", "city": "Chieti", "zip": "66100", "country": "Italy", "geoPoint": {"lat": 42.34827, "lon": 14.16494}}, {"facility": "Novo Nordisk Investigational Site", "city": "Cittadella (PD)", "zip": "35013", "country": "Italy"}, {"facility": "Novo Nordisk Investigational Site", "city": "Milano (MI)", "zip": "20132", "country": "Italy"}, {"facility": "Novo Nordisk Investigational Site", "city": "Olbia", "zip": "07026", "country": "Italy", "geoPoint": {"lat": 40.92337, "lon": 9.49802}}, {"facility": "Novo Nordisk Investigational Site", "city": "Palermo", "zip": "90129", "country": "Italy", "geoPoint": {"lat": 38.13205, "lon": 13.33561}}, {"facility": "Novo Nordisk Investigational Site", "city": "Bucheon", "zip": "14647", "country": "Korea, Republic of", "geoPoint": {"lat": 37.49889, "lon": 126.78306}}, {"facility": "Novo Nordisk Investigational Site", "city": "Daegu", "zip": "42472", "country": "Korea, Republic of", "geoPoint": {"lat": 35.87028, "lon": 128.59111}}, {"facility": "Novo Nordisk Investigational Site", "city": "Seongnam-si", "zip": "463-707", "country": "Korea, Republic of", "geoPoint": {"lat": 37.43861, "lon": 127.13778}}, {"facility": "Novo Nordisk Investigational Site", "city": "Seoul", "zip": "02447", "country": "Korea, Republic of", "geoPoint": {"lat": 37.566, "lon": 126.9784}}, {"facility": "Novo Nordisk Investigational Site", "city": "Seoul", "zip": "03080", "country": "Korea, Republic of", "geoPoint": {"lat": 37.566, "lon": 126.9784}}, {"facility": "Novo Nordisk Investigational Site", "city": "Seoul", "zip": "04516", "country": "Korea, Republic of", "geoPoint": {"lat": 37.566, "lon": 126.9784}}, {"facility": "Novo Nordisk Investigational Site", "city": "Seoul", "zip": "06351", "country": "Korea, Republic of", "geoPoint": {"lat": 37.566, "lon": 126.9784}}, {"facility": "Novo Nordisk Investigational Site", "city": "Seoul", "zip": "08308", "country": "Korea, Republic of", "geoPoint": {"lat": 37.566, "lon": 126.9784}}, {"facility": "Novo Nordisk Investigational Site", "city": "Seoul", "zip": "137-701", "country": "Korea, Republic of", "geoPoint": {"lat": 37.566, "lon": 126.9784}}, {"facility": "Novo Nordisk Investigational Site", "city": "Wonju", "zip": "26426", "country": "Korea, Republic of", "geoPoint": {"lat": 37.35139, "lon": 127.94528}}, {"facility": "Novo Nordisk Investigational Site", "city": "Bialystok", "zip": "15-435", "country": "Poland", "geoPoint": {"lat": 53.13333, "lon": 23.16433}}, {"facility": "Novo Nordisk Investigational Site", "city": "Skorzewo", "zip": "60-185", "country": "Poland"}, {"facility": "Novo Nordisk Investigational Site", "city": "Warsaw", "zip": "00-465", "country": "Poland", "geoPoint": {"lat": 52.22977, "lon": 21.01178}}, {"facility": "Novo Nordisk Investigational Site", "city": "Warsaw", "zip": "02-793", "country": "Poland", "geoPoint": {"lat": 52.22977, "lon": 21.01178}}, {"facility": "Novo Nordisk Investigational Site", "city": "Warszawa", "zip": "02-507", "country": "Poland", "geoPoint": {"lat": 52.22977, "lon": 21.01178}}, {"facility": "Novo Nordisk Investigational Site", "city": "Wroclaw", "zip": "50-381", "country": "Poland", "geoPoint": {"lat": 51.1, "lon": 17.03333}}, {"facility": "Novo Nordisk Investigational Site", "city": "Ponce", "zip": "00716", "country": "Puerto Rico", "geoPoint": {"lat": 18.01108, "lon": -66.61406}}, {"facility": "Novo Nordisk Investigational Site", "city": "Baia Mare", "state": "Maramures", "zip": "430222", "country": "Romania", "geoPoint": {"lat": 47.65529, "lon": 23.57381}}, {"facility": "Novo Nordisk Investigational Site", "city": "Tirgu Mures", "state": "Mures", "zip": "540142", "country": "Romania"}, {"facility": "Novo Nordisk Investigational Site", "city": "Timisoara", "state": "Timis", "zip": "300125", "country": "Romania", "geoPoint": {"lat": 45.75372, "lon": 21.22571}}, {"facility": "Novo Nordisk Investigational Site", "city": "Brasov", "zip": "500101", "country": "Romania", "geoPoint": {"lat": 45.64861, "lon": 25.60613}}, {"facility": "Novo Nordisk Investigational Site", "city": "Brasov", "zip": "500283", "country": "Romania", "geoPoint": {"lat": 45.64861, "lon": 25.60613}}, {"facility": "Novo Nordisk Investigational Site", "city": "Bucharest", "zip": "13682", "country": "Romania", "geoPoint": {"lat": 44.43225, "lon": 26.10626}}, {"facility": "Novo Nordisk Investigational Site", "city": "Arkhangelsk", "zip": "163045", "country": "Russian Federation", "geoPoint": {"lat": 64.5401, "lon": 40.5433}}, {"facility": "Novo Nordisk Investigational Site", "city": "Kazan", "zip": "420073", "country": "Russian Federation", "geoPoint": {"lat": 55.78874, "lon": 49.12214}}, {"facility": "Novo Nordisk Investigational Site", "city": "Moscow", "zip": "123448", "country": "Russian Federation", "geoPoint": {"lat": 55.75222, "lon": 37.61556}}, {"facility": "Novo Nordisk Investigational Site", "city": "Penza", "zip": "440026", "country": "Russian Federation", "geoPoint": {"lat": 53.20066, "lon": 45.00464}}, {"facility": "Novo Nordisk Investigational Site", "city": "Saint Petersburg", "zip": "194291", "country": "Russian Federation", "geoPoint": {"lat": 59.93863, "lon": 30.31413}}, {"facility": "Novo Nordisk Investigational Site", "city": "Saint-Petersburg", "zip": "194356", "country": "Russian Federation", "geoPoint": {"lat": 59.93863, "lon": 30.31413}}, {"facility": "Novo Nordisk Investigational Site", "city": "Tumen", "zip": "625023", "country": "Russian Federation"}, {"facility": "Novo Nordisk Investigational Site", "city": "Voronezh", "zip": "394018", "country": "Russian Federation", "geoPoint": {"lat": 51.67204, "lon": 39.1843}}, {"facility": "Novo Nordisk Investigational Site", "city": "Belgrade", "zip": "11000", "country": "Serbia", "geoPoint": {"lat": 44.80401, "lon": 20.46513}}, {"facility": "Novo Nordisk Investigational Site", "city": "Kragujevac", "zip": "34000", "country": "Serbia", "geoPoint": {"lat": 44.01667, "lon": 20.91667}}, {"facility": "Novo Nordisk Investigational Site", "city": "Nis", "zip": "18000", "country": "Serbia", "geoPoint": {"lat": 43.32472, "lon": 21.90333}}, {"facility": "Novo Nordisk Investigational Site", "city": "Novi Sad", "zip": "21000", "country": "Serbia", "geoPoint": {"lat": 45.25167, "lon": 19.83694}}, {"facility": "Novo Nordisk Investigational Site", "city": "Zajecar", "zip": "19000", "country": "Serbia", "geoPoint": {"lat": 43.90358, "lon": 22.26405}}, {"facility": "Novo Nordisk Investigational Site", "city": "Kosice", "zip": "040 01", "country": "Slovakia", "geoPoint": {"lat": 48.71395, "lon": 21.25808}}, {"facility": "Novo Nordisk Investigational Site", "city": "Kysucke Nove Mesto", "zip": "024 01", "country": "Slovakia", "geoPoint": {"lat": 49.3, "lon": 18.78333}}, {"facility": "Novo Nordisk Investigational Site", "city": "Lubochna", "zip": "03491", "country": "Slovakia", "geoPoint": {"lat": 49.12011, "lon": 19.16891}}, {"facility": "Novo Nordisk Investigational Site", "city": "Lucenec", "zip": "984 01", "country": "Slovakia", "geoPoint": {"lat": 48.33249, "lon": 19.66708}}, {"facility": "Novo Nordisk Investigational Site", "city": "Zilina", "zip": "01001", "country": "Slovakia", "geoPoint": {"lat": 49.22315, "lon": 18.73941}}, {"facility": "Novo Nordisk Investigational Site", "city": "Alcobendas", "zip": "28100", "country": "Spain", "geoPoint": {"lat": 40.54746, "lon": -3.64197}}, {"facility": "Novo Nordisk Investigational Site", "city": "Almer\u00eda", "zip": "04001", "country": "Spain", "geoPoint": {"lat": 36.83814, "lon": -2.45974}}, {"facility": "Novo Nordisk Investigational Site", "city": "Girona", "zip": "17007", "country": "Spain", "geoPoint": {"lat": 41.98311, "lon": 2.82493}}, {"facility": "Novo Nordisk Investigational Site", "city": "La Coru\u00f1a", "zip": "15006", "country": "Spain", "geoPoint": {"lat": 43.37135, "lon": -8.396}}, {"facility": "Novo Nordisk Investigational Site", "city": "Pozuelo de Alarcon", "zip": "28223", "country": "Spain", "geoPoint": {"lat": 40.43293, "lon": -3.81338}}, {"facility": "Novo Nordisk Investigational Site", "city": "Sabadell", "zip": "08208", "country": "Spain", "geoPoint": {"lat": 41.54329, "lon": 2.10942}}, {"facility": "Novo Nordisk Investigational Site", "city": "Sevilla", "zip": "41003", "country": "Spain", "geoPoint": {"lat": 37.38283, "lon": -5.97317}}, {"facility": "Novo Nordisk Investigational Site", "city": "Sevilla", "zip": "41010", "country": "Spain", "geoPoint": {"lat": 37.38283, "lon": -5.97317}}, {"facility": "Novo Nordisk Investigational Site", "city": "Dnipro", "zip": "49038", "country": "Ukraine", "geoPoint": {"lat": 48.4593, "lon": 35.03864}}, {"facility": "Novo Nordisk Investigational Site", "city": "Kharkiv", "zip": "61000", "country": "Ukraine", "geoPoint": {"lat": 49.98081, "lon": 36.25272}}, {"facility": "Novo Nordisk Investigational Site", "city": "Kyiv", "zip": "03049", "country": "Ukraine", "geoPoint": {"lat": 50.45466, "lon": 30.5238}}, {"facility": "Novo Nordisk Investigational Site", "city": "Lviv", "zip": "79010", "country": "Ukraine", "geoPoint": {"lat": 49.83826, "lon": 24.02324}}, {"facility": "Novo Nordisk Investigational Site", "city": "Ternopil", "zip": "46002", "country": "Ukraine", "geoPoint": {"lat": 49.55589, "lon": 25.60556}}, {"facility": "Novo Nordisk Investigational Site", "city": "Vinnytsia", "zip": "21010", "country": "Ukraine", "geoPoint": {"lat": 49.23278, "lon": 28.48097}}]}, "referencesModule": {"references": [{"pmid": "32209647", "type": "RESULT", "citation": "Lane WS, Favaro E, Rathor N, Jang HC, Kjaersgaard MIS, Oviedo A, Rose L, Senior P, Sesti G, Soto Gonzalez A, Franek E. A Randomized Trial Evaluating the Efficacy and Safety of Fast-Acting Insulin Aspart Compared With Insulin Aspart, Both in Combination With Insulin Degludec With or Without Metformin, in Adults With Type 2 Diabetes (ONSET 9). Diabetes Care. 2020 Aug;43(8):1710-1716. doi: 10.2337/dc19-2232. Epub 2020 Mar 24."}, {"pmid": "35290624", "type": "DERIVED", "citation": "Lane W, Favaro E, Jodar E, Kelkar P, Oviedo A, Sivarathinasami R, Senior PA, Sesti G, Franek E. Effective Overall Glycaemic Control with Fast-Acting Insulin Aspart Across Patients with Different Baseline Characteristics: A Post Hoc Analysis of the Onset 9 Trial. Diabetes Ther. 2022 Apr;13(4):761-774. doi: 10.1007/s13300-022-01213-3. Epub 2022 Mar 15."}]}, "ipdSharingStatementModule": {"ipdSharing": "YES", "description": "According to the Novo Nordisk disclosure commitment on novonordisk-trials.com"}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "There was a 12-week run-in period primarily for optimisation of the basal insulin and reinforcement of subject training in trial procedures, diabetes education and dietary training. Out of the 1264 participants enrolled in the study, 173 were run-in failures and 1091 were randomised.", "recruitmentDetails": "The trial was conducted at 165 sites in 17 countries as follows: Argentina-3, Bulgaria-4, Canada-10, Croatia-4, Czech Republic-4, Germany-6, Greece-8, Italy-4, Poland-10, Republic of Korea-6, Romania-6, Russia-8, Serbia-9, Slovakia-5, Spain-8, Ukraine-6 and United States (US)-62. Two sites in the US screened but didn't randomise any subject.", "groups": [{"id": "FG000", "title": "Faster Aspart", "description": "Participants received Faster aspart along with insulin degludec (basal-bolus regimen) with or without metformin for 16 weeks. Before the treatment period was a 12-week run-in period in which the investigator optimised basal insulin dose. Insulin degludec dose was adjusted weekly by the investigator in the run-in period based on the mean of three pre-breakfast SMPG values measured on the last two days prior to and on the day of contact. If one of the SMPG values were below target (\\< 4.0 mmol/L or 71 mg/dL) then the insulin degludec dose was adjusted according to the titration guideline specified in the protocol. Faster aspart was titrated from randomisation (week 0) and onwards, twice weekly to reach the glycaemic target of pre-prandial and bedtime PG between 4.0-6.0 mmol/L (71 - 108 mg/dL) in a treat-to-target fashion."}, {"id": "FG001", "title": "NovoRapid", "description": "Participants received insulin aspart (NovoRapid\u00ae/NovoLog\u00ae: basal-bolus regimen) with or without metformin for 16 weeks. Before the treatment period was a 12-week run-in period in which the investigator optimised basal insulin dose. Insulin degludec dose was adjusted weekly by the investigator in the run-in period based on the mean of three pre-breakfast SMPG values measured on the last two days prior to and on the day of contact. If one of the SMPG values were below target (\\< 4.0 mmol/L or 71 mg/dL) then the insulin degludec dose was adjusted according to the titration guideline specified in the protocol. NovoRapid was titrated from randomisation (week 0) and onwards, twice weekly to reach the glycaemic target of pre-prandial and bedtime PG between 4.0-6.0 mmol/L (71 - 108 mg/dL) in a treat-to-target fashion."}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "546"}, {"groupId": "FG001", "numSubjects": "545"}]}, {"type": "Full Analysis Set", "achievements": [{"groupId": "FG000", "numSubjects": "546"}, {"groupId": "FG001", "numSubjects": "545"}]}, {"type": "Safety Analysis Set", "achievements": [{"groupId": "FG000", "numSubjects": "544"}, {"groupId": "FG001", "numSubjects": "544"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "531"}, {"groupId": "FG001", "numSubjects": "531"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "15"}, {"groupId": "FG001", "numSubjects": "14"}]}], "dropWithdraws": [{"type": "Death", "reasons": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "1"}]}, {"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "2"}]}, {"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "11"}, {"groupId": "FG001", "numSubjects": "11"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Faster Aspart", "description": "Participants received Faster aspart along with insulin degludec (basal-bolus regimen) with or without metformin for 16 weeks. Before the treatment period was a 12-week run-in period in which the investigator optimised basal insulin dose. Insulin degludec dose was adjusted weekly by the investigator in the run-in period based on the mean of three pre-breakfast SMPG values measured on the last two days prior to and on the day of contact. If one of the SMPG values were below target (\\< 4.0 mmol/L or 71 mg/dL) then the insulin degludec dose was adjusted according to the titration guideline specified in the protocol. Faster aspart was titrated from randomisation (week 0) and onwards, twice weekly to reach the glycaemic target of pre-prandial and bedtime PG between 4.0-6.0 mmol/L (71 - 108 mg/dL) in a treat-to-target fashion."}, {"id": "BG001", "title": "NovoRapid", "description": "Participants received insulin aspart (NovoRapid\u00ae/NovoLog\u00ae: basal-bolus regimen) with or without metformin for 16 weeks. Before the treatment period was a 12-week run-in period in which the investigator optimised basal insulin dose. Insulin degludec dose was adjusted weekly by the investigator in the run-in period based on the mean of three pre-breakfast SMPG values measured on the last two days prior to and on the day of contact. If one of the SMPG values were below target (\\< 4.0 mmol/L or 71 mg/dL) then the insulin degludec dose was adjusted according to the titration guideline specified in the protocol. NovoRapid was titrated from randomisation (week 0) and onwards, twice weekly to reach the glycaemic target of pre-prandial and bedtime PG between 4.0-6.0 mmol/L (71 - 108 mg/dL) in a treat-to-target fashion."}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "546"}, {"groupId": "BG001", "value": "545"}, {"groupId": "BG002", "value": "1091"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "Years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "62.6", "spread": "8.6"}, {"groupId": "BG001", "value": "62.1", "spread": "8.8"}, {"groupId": "BG002", "value": "62.3", "spread": "8.7"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "281"}, {"groupId": "BG001", "value": "256"}, {"groupId": "BG002", "value": "537"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "265"}, {"groupId": "BG001", "value": "289"}, {"groupId": "BG002", "value": "554"}]}]}]}, {"title": "Race/Ethnicity, Customized", "description": "Race", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "White", "measurements": [{"groupId": "BG000", "value": "487"}, {"groupId": "BG001", "value": "487"}, {"groupId": "BG002", "value": "974"}]}, {"title": "Asian", "measurements": [{"groupId": "BG000", "value": "43"}, {"groupId": "BG001", "value": "31"}, {"groupId": "BG002", "value": "74"}]}, {"title": "Black or African American", "measurements": [{"groupId": "BG000", "value": "14"}, {"groupId": "BG001", "value": "19"}, {"groupId": "BG002", "value": "33"}]}, {"title": "Native Hawaiian or Other Pacific Islander", "measurements": [{"groupId": "BG000", "value": "2"}, {"groupId": "BG001", "value": "5"}, {"groupId": "BG002", "value": "7"}]}, {"title": "Other", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "3"}, {"groupId": "BG002", "value": "3"}]}]}]}, {"title": "Race/Ethnicity, Customized", "description": "Ethnicity", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Not Hispanic or Latino", "measurements": [{"groupId": "BG000", "value": "485"}, {"groupId": "BG001", "value": "488"}, {"groupId": "BG002", "value": "973"}]}, {"title": "Hispanic Latino", "measurements": [{"groupId": "BG000", "value": "61"}, {"groupId": "BG001", "value": "57"}, {"groupId": "BG002", "value": "118"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Change in Glycosylated Haemoglobin (HbA1c)", "description": "Change from baseline (week 0) in glycosylated haemoglobin (HbA1c) was evaluated at week 16. The endpoint was evaluated based on data from the in-trial observation period. In-trial observation period was from date of randomisation and until last trial-related participant-site contact.", "populationDescription": "Overall number of participants analyzed = number of participants with available data.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Percentage of HbA1c", "timeFrame": "Week 0, week 16", "groups": [{"id": "OG000", "title": "Faster Aspart", "description": "Participants received Faster aspart along with insulin degludec (basal-bolus regimen) with or without metformin for 16 weeks. Before the treatment period was a 12-week run-in period in which the investigator optimised basal insulin dose. Insulin degludec dose was adjusted weekly by the investigator in the run-in period based on the mean of three pre-breakfast SMPG values measured on the last two days prior to and on the day of contact. If one of the SMPG values were below target (\\< 4.0 mmol/L or 71 mg/dL) then the insulin degludec dose was adjusted according to the titration guideline specified in the protocol. Faster aspart was titrated from randomisation (week 0) and onwards, twice weekly to reach the glycaemic target of pre-prandial and bedtime PG between 4.0-6.0 mmol/L (71 - 108 mg/dL) in a treat-to-target fashion."}, {"id": "OG001", "title": "NovoRapid", "description": "Participants received Insulin aspart (NovoRapid\u00ae/NovoLog\u00ae: basal-bolus regimen) along with insulin degludec (basal-bolus regimen) with or without metformin for 16 weeks. Before the treatment period was a 12-week run-in period in which the investigator optimised basal insulin dose. Insulin degludec dose was adjusted weekly by the investigator in the run-in period based on the mean of three pre-breakfast SMPG values measured on the last two days prior to and on the day of contact. If one of the SMPG values were below target (\\< 4.0 mmol/L or 71 mg/dL) then the insulin degludec dose was adjusted according to the titration guideline specified in the protocol. NovoRapid was titrated from randomisation (week 0) and onwards, twice weekly to reach the glycaemic target of pre-prandial and bedtime PG between 4.0-6.0 mmol/L (71 - 108 mg/dL) in a treat-to-target fashion."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "544"}, {"groupId": "OG001", "value": "539"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.15", "spread": "0.62"}, {"groupId": "OG001", "value": "-0.09", "spread": "0.60"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Change from baseline in HbA1c was analysed using an analysis of variance model after multiple imputation assuming treatment according to randomisation. The model included treatment, region and metformin use at baseline (Yes/No) as factors, and baseline HbA1c as a covariate.", "nonInferiorityType": "NON_INFERIORITY", "nonInferiorityComment": "The upper limit of the 95% confidence interval for the difference between faster aspart and NovoRapid was compared to a non-inferiority margin of 0.4%. If it was below or equal to 0.4% non-inferiority was considered established and effect demonstrated.", "pValue": "0.310", "statisticalMethod": "ANOVA", "paramType": "Treatment difference", "paramValue": "-0.04", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.11", "ciUpperLimit": "0.03", "estimateComment": "Faster aspart-NovoRapid"}]}, {"type": "SECONDARY", "title": "Change From Baseline in 1-hour PPG Increment", "description": "Change from baseline (week 0) in 1-hour postprandial glucose (PPG) increment was evaluated after 16 weeks of randomisation. The results are based on the last in-trial value, which included the last available measurement in the in-trial period. In trial observation period was from date of randomisation and until last trial-related participant-site contact.", "populationDescription": "Overall number of participants analyzed = number of participants with available data.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mmol/L", "timeFrame": "Week 0, week 16", "groups": [{"id": "OG000", "title": "Faster Aspart", "description": "Participants received Faster aspart along with insulin degludec (basal-bolus regimen) with or without metformin for 16 weeks. Before the treatment period was a 12-week run-in period in which the investigator optimised basal insulin dose. Insulin degludec dose was adjusted weekly by the investigator in the run-in period based on the mean of three pre-breakfast SMPG values measured on the last two days prior to and on the day of contact. If one of the SMPG values were below target (\\< 4.0 mmol/L or 71 mg/dL) then the insulin degludec dose was adjusted according to the titration guideline specified in the protocol. Faster aspart was titrated from randomisation (week 0) and onwards, twice weekly to reach the glycaemic target of pre-prandial and bedtime PG between 4.0-6.0 mmol/L (71 - 108 mg/dL) in a treat-to-target fashion."}, {"id": "OG001", "title": "NovoRapid", "description": "Participants received Insulin aspart (NovoRapid\u00ae/NovoLog\u00ae: basal-bolus regimen) along with insulin degludec (basal-bolus regimen) with or without metformin for 16 weeks. Before the treatment period was a 12-week run-in period in which the investigator optimised basal insulin dose. Insulin degludec dose was adjusted weekly by the investigator in the run-in period based on the mean of three pre-breakfast SMPG values measured on the last two days prior to and on the day of contact. If one of the SMPG values were below target (\\< 4.0 mmol/L or 71 mg/dL) then the insulin degludec dose was adjusted according to the titration guideline specified in the protocol. NovoRapid was titrated from randomisation (week 0) and onwards, twice weekly to reach the glycaemic target of pre-prandial and bedtime PG between 4.0-6.0 mmol/L (71 - 108 mg/dL) in a treat-to-target fashion."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "519"}, {"groupId": "OG001", "value": "523"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.43", "spread": "2.45"}, {"groupId": "OG001", "value": "0.08", "spread": "2.65"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in 1,5-anhydroglucitol", "description": "Change from baseline (week 0) in 1,5-anhydroglucitol was evaluated after 16 weeks of randomisation. The results are based on the last in-trial value, which included the last available measurement in the in-trial period. In trial observation period was from date of randomisation and until last trial-related participant-site contact.", "populationDescription": "Overall number of participants analyzed = number of participants with available data.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mmol/L", "timeFrame": "Week 0, week 16", "groups": [{"id": "OG000", "title": "Faster Aspart", "description": "Participants received Faster aspart along with insulin degludec (basal-bolus regimen) with or without metformin for 16 weeks. Before the treatment period was a 12-week run-in period in which the investigator optimised basal insulin dose. Insulin degludec dose was adjusted weekly by the investigator in the run-in period based on the mean of three pre-breakfast SMPG values measured on the last two days prior to and on the day of contact. If one of the SMPG values were below target (\\< 4.0 mmol/L or 71 mg/dL) then the insulin degludec dose was adjusted according to the titration guideline specified in the protocol. Faster aspart was titrated from randomisation (week 0) and onwards, twice weekly to reach the glycaemic target of pre-prandial and bedtime PG between 4.0-6.0 mmol/L (71 - 108 mg/dL) in a treat-to-target fashion."}, {"id": "OG001", "title": "NovoRapid", "description": "Participants received Insulin aspart (NovoRapid\u00ae/NovoLog\u00ae: basal-bolus regimen) along with insulin degludec (basal-bolus regimen) with or without metformin for 16 weeks. Before the treatment period was a 12-week run-in period in which the investigator optimised basal insulin dose. Insulin degludec dose was adjusted weekly by the investigator in the run-in period based on the mean of three pre-breakfast SMPG values measured on the last two days prior to and on the day of contact. If one of the SMPG values were below target (\\< 4.0 mmol/L or 71 mg/dL) then the insulin degludec dose was adjusted according to the titration guideline specified in the protocol. NovoRapid was titrated from randomisation (week 0) and onwards, twice weekly to reach the glycaemic target of pre-prandial and bedtime PG between 4.0-6.0 mmol/L (71 - 108 mg/dL) in a treat-to-target fashion."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "534"}, {"groupId": "OG001", "value": "531"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "1.38", "spread": "3.10"}, {"groupId": "OG001", "value": "0.89", "spread": "3.31"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Fasting Plasma Glucose (FPG)", "description": "Change from baseline (week 0) in fasting plasma glucose was evaluated after 16 weeks of randomisation. The results are based on the last in-trial value, which included the last available measurement in the in-trial period. In trial observation period was from date of randomisation and until last trial-related participant-site contact.", "populationDescription": "Overall number of participants analyzed = number of participants with available data.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mmol/L", "timeFrame": "Week 0, week 16", "groups": [{"id": "OG000", "title": "Faster Aspart", "description": "Participants received Faster aspart along with insulin degludec (basal-bolus regimen) with or without metformin for 16 weeks. Before the treatment period was a 12-week run-in period in which the investigator optimised basal insulin dose. Insulin degludec dose was adjusted weekly by the investigator in the run-in period based on the mean of three pre-breakfast SMPG values measured on the last two days prior to and on the day of contact. If one of the SMPG values were below target (\\< 4.0 mmol/L or 71 mg/dL) then the insulin degludec dose was adjusted according to the titration guideline specified in the protocol. Faster aspart was titrated from randomisation (week 0) and onwards, twice weekly to reach the glycaemic target of pre-prandial and bedtime PG between 4.0-6.0 mmol/L (71 - 108 mg/dL) in a treat-to-target fashion."}, {"id": "OG001", "title": "NovoRapid", "description": "Participants received Insulin aspart (NovoRapid\u00ae/NovoLog\u00ae: basal-bolus regimen) along with insulin degludec (basal-bolus regimen) with or without metformin for 16 weeks. Before the treatment period was a 12-week run-in period in which the investigator optimised basal insulin dose. Insulin degludec dose was adjusted weekly by the investigator in the run-in period based on the mean of three pre-breakfast SMPG values measured on the last two days prior to and on the day of contact. If one of the SMPG values were below target (\\< 4.0 mmol/L or 71 mg/dL) then the insulin degludec dose was adjusted according to the titration guideline specified in the protocol. NovoRapid was titrated from randomisation (week 0) and onwards, twice weekly to reach the glycaemic target of pre-prandial and bedtime PG between 4.0-6.0 mmol/L (71 - 108 mg/dL) in a treat-to-target fashion."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "533"}, {"groupId": "OG001", "value": "530"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.56", "spread": "2.38"}, {"groupId": "OG001", "value": "0.68", "spread": "2.40"}]}]}]}, {"type": "SECONDARY", "title": "Participants Who Achieved HbA1c <7.0% (53 mmol/L) (Yes/No)", "description": "Number of participants reaching HbA1c \\<7.0% (53 mmol/L) was evaluated after 16 weeks of randomisation. The results are based on the last in-trial value, which included the last available measurement in the in-trial period. In trial observation period was from date of randomisation and until last trial-related participant-site contact.", "populationDescription": "Overall number of participants analyzed = full analysis set (FAS) which comprised all randomised participants. Number Analyzed = number of participants with available data.", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "timeFrame": "16 weeks after randomisation", "groups": [{"id": "OG000", "title": "Faster Aspart", "description": "Participants received Faster aspart along with insulin degludec (basal-bolus regimen) with or without metformin for 16 weeks. Before the treatment period was a 12-week run-in period in which the investigator optimised basal insulin dose. Insulin degludec dose was adjusted weekly by the investigator in the run-in period based on the mean of three pre-breakfast SMPG values measured on the last two days prior to and on the day of contact. If one of the SMPG values were below target (\\< 4.0 mmol/L or 71 mg/dL) then the insulin degludec dose was adjusted according to the titration guideline specified in the protocol. Faster aspart was titrated from randomisation (week 0) and onwards, twice weekly to reach the glycaemic target of pre-prandial and bedtime PG between 4.0-6.0 mmol/L (71 - 108 mg/dL) in a treat-to-target fashion."}, {"id": "OG001", "title": "NovoRapid", "description": "Participants received Insulin aspart (NovoRapid\u00ae/NovoLog\u00ae: basal-bolus regimen) along with insulin degludec (basal-bolus regimen) with or without metformin for 16 weeks. Before the treatment period was a 12-week run-in period in which the investigator optimised basal insulin dose. Insulin degludec dose was adjusted weekly by the investigator in the run-in period based on the mean of three pre-breakfast SMPG values measured on the last two days prior to and on the day of contact. If one of the SMPG values were below target (\\< 4.0 mmol/L or 71 mg/dL) then the insulin degludec dose was adjusted according to the titration guideline specified in the protocol. NovoRapid was titrated from randomisation (week 0) and onwards, twice weekly to reach the glycaemic target of pre-prandial and bedtime PG between 4.0-6.0 mmol/L (71 - 108 mg/dL) in a treat-to-target fashion."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "546"}, {"groupId": "OG001", "value": "545"}]}], "classes": [{"categories": [{"title": "Yes", "measurements": [{"groupId": "OG000", "value": "271"}, {"groupId": "OG001", "value": "282"}]}, {"title": "No", "measurements": [{"groupId": "OG000", "value": "275"}, {"groupId": "OG001", "value": "263"}]}]}]}, {"type": "SECONDARY", "title": "Participants Who Achieved HbA1c <7.0% (53 mmol/L) Without Severe Hypoglycaemia Episodes (Yes/No)", "description": "Number of participants reaching HbA1c \\<7.0% (53 mmol/L) without severe hypoglycaemia episodes was evaluated after 16 weeks of randomisation. The results are based on the last in-trial value, which included the last available measurement in the in-trial period. In trial observation period was from date of randomisation and until last trial-related participant-site contact.", "populationDescription": "Overall number of participants analyzed = full analysis set (FAS) which comprised all randomised participants. Number Analyzed = number of participants with available data.", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "timeFrame": "16 weeks after randomisation", "groups": [{"id": "OG000", "title": "Faster Aspart", "description": "Participants received Faster aspart along with insulin degludec (basal-bolus regimen) with or without metformin for 16 weeks. Before the treatment period was a 12-week run-in period in which the investigator optimised basal insulin dose. Insulin degludec dose was adjusted weekly by the investigator in the run-in period based on the mean of three pre-breakfast SMPG values measured on the last two days prior to and on the day of contact. If one of the SMPG values were below target (\\< 4.0 mmol/L or 71 mg/dL) then the insulin degludec dose was adjusted according to the titration guideline specified in the protocol. Faster aspart was titrated from randomisation (week 0) and onwards, twice weekly to reach the glycaemic target of pre-prandial and bedtime PG between 4.0-6.0 mmol/L (71 - 108 mg/dL) in a treat-to-target fashion."}, {"id": "OG001", "title": "NovoRapid", "description": "Participants received Insulin aspart (NovoRapid\u00ae/NovoLog\u00ae: basal-bolus regimen) along with insulin degludec (basal-bolus regimen) with or without metformin for 16 weeks. Before the treatment period was a 12-week run-in period in which the investigator optimised basal insulin dose. Insulin degludec dose was adjusted weekly by the investigator in the run-in period based on the mean of three pre-breakfast SMPG values measured on the last two days prior to and on the day of contact. If one of the SMPG values were below target (\\< 4.0 mmol/L or 71 mg/dL) then the insulin degludec dose was adjusted according to the titration guideline specified in the protocol. NovoRapid was titrated from randomisation (week 0) and onwards, twice weekly to reach the glycaemic target of pre-prandial and bedtime PG between 4.0-6.0 mmol/L (71 - 108 mg/dL) in a treat-to-target fashion."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "546"}, {"groupId": "OG001", "value": "545"}]}], "classes": [{"categories": [{"title": "Yes", "measurements": [{"groupId": "OG000", "value": "265"}, {"groupId": "OG001", "value": "278"}]}, {"title": "No", "measurements": [{"groupId": "OG000", "value": "281"}, {"groupId": "OG001", "value": "267"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline (Week 0) in 30-minute, 1-hour, 2-hour, 3-hour and 4-hour Postprandial Glucose (PPG [Meal Test])", "description": "Change from baseline (week 0) in 30-minute, 1-hour, 2-hour, 3-hour and 4-hour postprandial glucose (PPG \\[meal test\\]) was evaluated after 16 weeks of randomisation. The results are based on the last in-trial value, which included the last available measurement in the in-trial period. In trial observation period was from date of randomisation and until last trial-related participant-site contact. Meal test: The subjects were given a carbohydrate-rich standardised liquid meal immediately after bolus (faster aspart or NovoRapid) infusion in the morning of the meal test. The subjects were to consume the meal as quickly as possible (within 12 minutes) and blood samples were drawn after 30 minutes, 1, 2, 3 and 4 hours from the start of the meal.", "populationDescription": "Overall number of participants analyzed = full analysis set (FAS) which comprised all randomised participants. Number Analyzed = number of participants with available data.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mmol/L", "timeFrame": "Week 0, week 16", "groups": [{"id": "OG000", "title": "Faster Aspart", "description": "Participants received Faster aspart along with insulin degludec (basal-bolus regimen) with or without metformin for 16 weeks. Before the treatment period was a 12-week run-in period in which the investigator optimised basal insulin dose. Insulin degludec dose was adjusted weekly by the investigator in the run-in period based on the mean of three pre-breakfast SMPG values measured on the last two days prior to and on the day of contact. If one of the SMPG values were below target (\\< 4.0 mmol/L or 71 mg/dL) then the insulin degludec dose was adjusted according to the titration guideline specified in the protocol. Faster aspart was titrated from randomisation (week 0) and onwards, twice weekly to reach the glycaemic target of pre-prandial and bedtime PG between 4.0-6.0 mmol/L (71 - 108 mg/dL) in a treat-to-target fashion."}, {"id": "OG001", "title": "NovoRapid", "description": "Participants received Insulin aspart (NovoRapid\u00ae/NovoLog\u00ae: basal-bolus regimen) along with insulin degludec (basal-bolus regimen) with or without metformin for 16 weeks. Before the treatment period was a 12-week run-in period in which the investigator optimised basal insulin dose. Insulin degludec dose was adjusted weekly by the investigator in the run-in period based on the mean of three pre-breakfast SMPG values measured on the last two days prior to and on the day of contact. If one of the SMPG values were below target (\\< 4.0 mmol/L or 71 mg/dL) then the insulin degludec dose was adjusted according to the titration guideline specified in the protocol. NovoRapid was titrated from randomisation (week 0) and onwards, twice weekly to reach the glycaemic target of pre-prandial and bedtime PG between 4.0-6.0 mmol/L (71 - 108 mg/dL) in a treat-to-target fashion."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "546"}, {"groupId": "OG001", "value": "545"}]}], "classes": [{"title": "30-min", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "519"}, {"groupId": "OG001", "value": "522"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.31", "spread": "2.90"}, {"groupId": "OG001", "value": "0.55", "spread": "2.80"}]}]}, {"title": "1-hour", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "521"}, {"groupId": "OG001", "value": "526"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.03", "spread": "3.30"}, {"groupId": "OG001", "value": "0.68", "spread": "3.23"}]}]}, {"title": "2-hour", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "519"}, {"groupId": "OG001", "value": "524"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.08", "spread": "3.96"}, {"groupId": "OG001", "value": "0.61", "spread": "3.48"}]}]}, {"title": "3-hour", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "518"}, {"groupId": "OG001", "value": "519"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.30", "spread": "3.85"}, {"groupId": "OG001", "value": "0.89", "spread": "3.72"}]}]}, {"title": "4-hour", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "514"}, {"groupId": "OG001", "value": "519"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.51", "spread": "3.47"}, {"groupId": "OG001", "value": "0.75", "spread": "3.51"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline (Week 0) in 30-minute, 1-hour, 2-hour, 3-hour and 4-hour PPG Increment (Meal Test)", "description": "Change from baseline (week 0) in 30-minute, 1-hour, 2-hour, 3-hour and 4-hour PPG increment (meal test) was evaluated after 16 weeks of randomisation. The results are based on the last in-trial value, which included the last available measurement in the in-trial period. In trial observation period was from date of randomisation and until last trial-related participant-site contact. Meal test: The subjects were given a carbohydrate-rich standardised liquid meal immediately after bolus (faster aspart or NovoRapid) infusion in the morning of the meal test. The subjects were to consume the meal as quickly as possible (within 12 minutes) and blood samples were drawn after 30 minutes, 1, 2, 3 and 4 hours from the start of the meal. PPG incremental value for each time point was derived as PPG value at that time point minus the preprandial glucose value.", "populationDescription": "Overall number of participants analyzed = full analysis set (FAS) which comprised all randomised participants. Number Analyzed = number of participants with available data.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mmol/L", "timeFrame": "Week 0, week 16", "groups": [{"id": "OG000", "title": "Faster Aspart", "description": "Participants received Faster aspart along with insulin degludec (basal-bolus regimen) with or without metformin for 16 weeks. Before the treatment period was a 12-week run-in period in which the investigator optimised basal insulin dose. Insulin degludec dose was adjusted weekly by the investigator in the run-in period based on the mean of three pre-breakfast SMPG values measured on the last two days prior to and on the day of contact. If one of the SMPG values were below target (\\< 4.0 mmol/L or 71 mg/dL) then the insulin degludec dose was adjusted according to the titration guideline specified in the protocol. Faster aspart was titrated from randomisation (week 0) and onwards, twice weekly to reach the glycaemic target of pre-prandial and bedtime PG between 4.0-6.0 mmol/L (71 - 108 mg/dL) in a treat-to-target fashion."}, {"id": "OG001", "title": "NovoRapid", "description": "Participants received Insulin aspart (NovoRapid\u00ae/NovoLog\u00ae: basal-bolus regimen) along with insulin degludec (basal-bolus regimen) with or without metformin for 16 weeks. Before the treatment period was a 12-week run-in period in which the investigator optimised basal insulin dose. Insulin degludec dose was adjusted weekly by the investigator in the run-in period based on the mean of three pre-breakfast SMPG values measured on the last two days prior to and on the day of contact. If one of the SMPG values were below target (\\< 4.0 mmol/L or 71 mg/dL) then the insulin degludec dose was adjusted according to the titration guideline specified in the protocol. NovoRapid was titrated from randomisation (week 0) and onwards, twice weekly to reach the glycaemic target of pre-prandial and bedtime PG between 4.0-6.0 mmol/L (71 - 108 mg/dL) in a treat-to-target fashion."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "546"}, {"groupId": "OG001", "value": "545"}]}], "classes": [{"title": "30-min", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "518"}, {"groupId": "OG001", "value": "519"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.13", "spread": "1.85"}, {"groupId": "OG001", "value": "-0.05", "spread": "1.95"}]}]}, {"title": "1-hour", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "519"}, {"groupId": "OG001", "value": "523"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.43", "spread": "2.45"}, {"groupId": "OG001", "value": "0.08", "spread": "2.65"}]}]}, {"title": "2-hour", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "517"}, {"groupId": "OG001", "value": "521"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.37", "spread": "3.25"}, {"groupId": "OG001", "value": "0.001", "spread": "3.13"}]}]}, {"title": "3-hour", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "516"}, {"groupId": "OG001", "value": "516"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.15", "spread": "3.23"}, {"groupId": "OG001", "value": "0.28", "spread": "3.54"}]}]}, {"title": "4-hour", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "513"}, {"groupId": "OG001", "value": "516"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.04", "spread": "3.00"}, {"groupId": "OG001", "value": "0.15", "spread": "3.45"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Mean of the 7-9-7 Point Self-measured Plasma Glucose (SMPG) Profile", "description": "Change from baseline (week 0) in mean of the 7-9-7 point SMPG profile was evaluated after 16 weeks of randomisation. The results are based on the last in-trial value, which included the last available measurement in the in-trial period. 7-9-7 point SMPG was measured at the following mentioned time points: 1) Before breakfast, 2) 60 mins after the start of Breakfast, 3) Before lunch, 4) 60 mins after the start of lunch, 5) Before main evening meal, 6) 60 mins after the start of main evening meal, 7) At bedtime, 8) At 4 AM, 9) Before breakfast.", "populationDescription": "Overall number of participants analyzed = number of participants with available data.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mmol/L", "timeFrame": "Week 0, week 16", "groups": [{"id": "OG000", "title": "Faster Aspart", "description": "Participants received Faster aspart along with insulin degludec (basal-bolus regimen) with or without metformin for 16 weeks. Before the treatment period was a 12-week run-in period in which the investigator optimised basal insulin dose. Insulin degludec dose was adjusted weekly by the investigator in the run-in period based on the mean of three pre-breakfast SMPG values measured on the last two days prior to and on the day of contact. If one of the SMPG values were below target (\\< 4.0 mmol/L or 71 mg/dL) then the insulin degludec dose was adjusted according to the titration guideline specified in the protocol. Faster aspart was titrated from randomisation (week 0) and onwards, twice weekly to reach the glycaemic target of pre-prandial and bedtime PG between 4.0-6.0 mmol/L (71 - 108 mg/dL) in a treat-to-target fashion."}, {"id": "OG001", "title": "NovoRapid", "description": "Participants received Insulin aspart (NovoRapid\u00ae/NovoLog\u00ae: basal-bolus regimen) along with insulin degludec (basal-bolus regimen) with or without metformin for 16 weeks. Before the treatment period was a 12-week run-in period in which the investigator optimised basal insulin dose. Insulin degludec dose was adjusted weekly by the investigator in the run-in period based on the mean of three pre-breakfast SMPG values measured on the last two days prior to and on the day of contact. If one of the SMPG values were below target (\\< 4.0 mmol/L or 71 mg/dL) then the insulin degludec dose was adjusted according to the titration guideline specified in the protocol. NovoRapid was titrated from randomisation (week 0) and onwards, twice weekly to reach the glycaemic target of pre-prandial and bedtime PG between 4.0-6.0 mmol/L (71 - 108 mg/dL) in a treat-to-target fashion."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "454"}, {"groupId": "OG001", "value": "464"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.56", "spread": "1.66"}, {"groupId": "OG001", "value": "-0.50", "spread": "1.61"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline of the 7-9-7 Point SMPG Profile: PPG (Mean, Breakfast, Lunch and Main Evening Meal)", "description": "Change from baseline (week 0) in PPG (breakfast, lunch, main evening meal and mean over all meals) of the 7-9-7 point SMPG profile was evaluated after 16 weeks of randomisation. The results are based on the last in-trial value, which included the last available measurement in the in-trial period. In trial observation period was from date of randomisation and until last trial-related participant-site contact.", "populationDescription": "Overall number of participants analyzed = full analysis set (FAS) which comprised all randomised participants. Number Analyzed = number of participants with available data.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mmol/L", "timeFrame": "Week 0, week 16", "groups": [{"id": "OG000", "title": "Faster Aspart", "description": "Participants received Faster aspart along with insulin degludec (basal-bolus regimen) with or without metformin for 16 weeks. Before the treatment period was a 12-week run-in period in which the investigator optimised basal insulin dose. Insulin degludec dose was adjusted weekly by the investigator in the run-in period based on the mean of three pre-breakfast SMPG values measured on the last two days prior to and on the day of contact. If one of the SMPG values were below target (\\< 4.0 mmol/L or 71 mg/dL) then the insulin degludec dose was adjusted according to the titration guideline specified in the protocol. Faster aspart was titrated from randomisation (week 0) and onwards, twice weekly to reach the glycaemic target of pre-prandial and bedtime PG between 4.0-6.0 mmol/L (71 - 108 mg/dL) in a treat-to-target fashion."}, {"id": "OG001", "title": "NovoRapid", "description": "Participants received Insulin aspart (NovoRapid\u00ae/NovoLog\u00ae: basal-bolus regimen) along with insulin degludec (basal-bolus regimen) with or without metformin for 16 weeks. Before the treatment period was a 12-week run-in period in which the investigator optimised basal insulin dose. Insulin degludec dose was adjusted weekly by the investigator in the run-in period based on the mean of three pre-breakfast SMPG values measured on the last two days prior to and on the day of contact. If one of the SMPG values were below target (\\< 4.0 mmol/L or 71 mg/dL) then the insulin degludec dose was adjusted according to the titration guideline specified in the protocol. NovoRapid was titrated from randomisation (week 0) and onwards, twice weekly to reach the glycaemic target of pre-prandial and bedtime PG between 4.0-6.0 mmol/L (71 - 108 mg/dL) in a treat-to-target fashion."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "546"}, {"groupId": "OG001", "value": "545"}]}], "classes": [{"title": "Breakfast", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "447"}, {"groupId": "OG001", "value": "462"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.38", "spread": "2.53"}, {"groupId": "OG001", "value": "-0.28", "spread": "2.44"}]}]}, {"title": "Lunch", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "453"}, {"groupId": "OG001", "value": "462"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.78", "spread": "2.48"}, {"groupId": "OG001", "value": "-0.58", "spread": "2.68"}]}]}, {"title": "Main evening meal", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "447"}, {"groupId": "OG001", "value": "459"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-1.04", "spread": "2.67"}, {"groupId": "OG001", "value": "-0.71", "spread": "2.50"}]}]}, {"title": "All meals", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "440"}, {"groupId": "OG001", "value": "457"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.75", "spread": "1.89"}, {"groupId": "OG001", "value": "-0.52", "spread": "1.91"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline of the 7-9-7 Point SMPG Profile: PPG Increment (Mean, Breakfast, Lunch and Main Evening Meal)", "description": "Change from baseline (week 0) in PPG increment (breakfast, lunch, main evening meal and mean over all meals) of the 7-9-7 point SMPG profile was evaluated after 16 weeks of randomisation. The results are based on the last in-trial value, which included the last available measurement in the in-trial period. PPG increment based on the 7-9-7-point profiles were derived separately for PG measurements made at 1 hour after main meals (breakfast, lunch and main evening meal). PPG incremental value for each time point was derived as PPG value at that time point minus the preprandial glucose value. In trial observation period was from date of randomisation and until last trial-related participant-site contact.", "populationDescription": "Overall number of participants analyzed = full analysis set (FAS) which comprised all randomised participants. Number Analyzed = number of participants with available data.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mmol/L", "timeFrame": "Week 0, week 16", "groups": [{"id": "OG000", "title": "Faster Aspart", "description": "Participants received Faster aspart along with insulin degludec (basal-bolus regimen) with or without metformin for 16 weeks. Before the treatment period was a 12-week run-in period in which the investigator optimised basal insulin dose. Insulin degludec dose was adjusted weekly by the investigator in the run-in period based on the mean of three pre-breakfast SMPG values measured on the last two days prior to and on the day of contact. If one of the SMPG values were below target (\\< 4.0 mmol/L or 71 mg/dL) then the insulin degludec dose was adjusted according to the titration guideline specified in the protocol. Faster aspart was titrated from randomisation (week 0) and onwards, twice weekly to reach the glycaemic target of pre-prandial and bedtime PG between 4.0-6.0 mmol/L (71 - 108 mg/dL) in a treat-to-target fashion."}, {"id": "OG001", "title": "NovoRapid", "description": "Participants received Insulin aspart (NovoRapid\u00ae/NovoLog\u00ae: basal-bolus regimen) along with insulin degludec (basal-bolus regimen) with or without metformin for 16 weeks. Before the treatment period was a 12-week run-in period in which the investigator optimised basal insulin dose. Insulin degludec dose was adjusted weekly by the investigator in the run-in period based on the mean of three pre-breakfast SMPG values measured on the last two days prior to and on the day of contact. If one of the SMPG values were below target (\\< 4.0 mmol/L or 71 mg/dL) then the insulin degludec dose was adjusted according to the titration guideline specified in the protocol. NovoRapid was titrated from randomisation (week 0) and onwards, twice weekly to reach the glycaemic target of pre-prandial and bedtime PG between 4.0-6.0 mmol/L (71 - 108 mg/dL) in a treat-to-target fashion."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "546"}, {"groupId": "OG001", "value": "545"}]}], "classes": [{"title": "Breakfast", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "447"}, {"groupId": "OG001", "value": "461"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.56", "spread": "2.23"}, {"groupId": "OG001", "value": "-0.42", "spread": "2.17"}]}]}, {"title": "Lunch", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "453"}, {"groupId": "OG001", "value": "460"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.38", "spread": "2.69"}, {"groupId": "OG001", "value": "-0.23", "spread": "2.46"}]}]}, {"title": "Main evening meal", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "444"}, {"groupId": "OG001", "value": "459"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.44", "spread": "2.61"}, {"groupId": "OG001", "value": "-0.10", "spread": "2.28"}]}]}, {"title": "All meals", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "438"}, {"groupId": "OG001", "value": "455"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.48", "spread": "1.55"}, {"groupId": "OG001", "value": "-0.23", "spread": "1.42"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline of the 7-9-7 Point SMPG Profile: Fluctuation in 7-9-7 Point Profile", "description": "Fluctuation in 7-point SMPG profile was the average absolute difference from the mean of the SMPG profile. Reported results are fluctuation in the 7-9-7 point SMPG profile from baseline (week 0) after 16 weeks of randomisation (i.e., week 16). The results are presented as ratio to baseline. The results are based on the last in-trial value, which included the last available measurement in the in-trial period. In trial observation period was from date of randomisation and until last trial-related participant-site contact.", "populationDescription": "Overall number of participants analyzed = number of participants with available data.", "reportingStatus": "POSTED", "paramType": "GEOMETRIC_MEAN", "dispersionType": "Geometric Coefficient of Variation", "unitOfMeasure": "Ratio", "timeFrame": "Week 0, week 16", "groups": [{"id": "OG000", "title": "Faster Aspart", "description": "Participants received Faster aspart along with insulin degludec (basal-bolus regimen) with or without metformin for 16 weeks. Before the treatment period was a 12-week run-in period in which the investigator optimised basal insulin dose. Insulin degludec dose was adjusted weekly by the investigator in the run-in period based on the mean of three pre-breakfast SMPG values measured on the last two days prior to and on the day of contact. If one of the SMPG values were below target (\\< 4.0 mmol/L or 71 mg/dL) then the insulin degludec dose was adjusted according to the titration guideline specified in the protocol. Faster aspart was titrated from randomisation (week 0) and onwards, twice weekly to reach the glycaemic target of pre-prandial and bedtime PG between 4.0-6.0 mmol/L (71 - 108 mg/dL) in a treat-to-target fashion."}, {"id": "OG001", "title": "NovoRapid", "description": "Participants received Insulin aspart (NovoRapid\u00ae/NovoLog\u00ae: basal-bolus regimen) along with insulin degludec (basal-bolus regimen) with or without metformin for 16 weeks. Before the treatment period was a 12-week run-in period in which the investigator optimised basal insulin dose. Insulin degludec dose was adjusted weekly by the investigator in the run-in period based on the mean of three pre-breakfast SMPG values measured on the last two days prior to and on the day of contact. If one of the SMPG values were below target (\\< 4.0 mmol/L or 71 mg/dL) then the insulin degludec dose was adjusted according to the titration guideline specified in the protocol. NovoRapid was titrated from randomisation (week 0) and onwards, twice weekly to reach the glycaemic target of pre-prandial and bedtime PG between 4.0-6.0 mmol/L (71 - 108 mg/dL) in a treat-to-target fashion."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "454"}, {"groupId": "OG001", "value": "464"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.82", "spread": "48.32"}, {"groupId": "OG001", "value": "0.85", "spread": "55.06"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline of the 7-9-7 Point SMPG Profile: Nocturnal SMPG Measurements", "description": "Change from baseline (week 0) in nocturnal SMPG measurements was assessed by considering the differences between PG values available at bedtime, at 4 AM and the before breakfast value the following day: (4 AM PG value minus at bedtime PG value), (before breakfast PG value minus at bedtime PG value) and (before breakfast PG value minus 4 AM PG value). Change from baseline in nocturnal increments in SMPG measurements of the 7-9-7 point SMPG profile was evaluated after 16 weeks of randomisation and presented during three different time intervals as follows: 1) 04:00 to breakfast, 2) bedtime to 04:00, and 3) bedtime to breakfast. The results are based on the last in-trial value, which included the last available measurement in the in-trial period. In trial observation period was from date of randomisation and until last trial-related participant-site contact.", "populationDescription": "Overall number of participants analyzed = full analysis set (FAS) which comprised all randomised participants. Number Analyzed = number of participants with available data.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mmol/L", "timeFrame": "Week 0, week 16", "groups": [{"id": "OG000", "title": "Faster Aspart", "description": "Participants received Faster aspart along with insulin degludec (basal-bolus regimen) with or without metformin for 16 weeks. Before the treatment period was a 12-week run-in period in which the investigator optimised basal insulin dose. Insulin degludec dose was adjusted weekly by the investigator in the run-in period based on the mean of three pre-breakfast SMPG values measured on the last two days prior to and on the day of contact. If one of the SMPG values were below target (\\< 4.0 mmol/L or 71 mg/dL) then the insulin degludec dose was adjusted according to the titration guideline specified in the protocol. Faster aspart was titrated from randomisation (week 0) and onwards, twice weekly to reach the glycaemic target of pre-prandial and bedtime PG between 4.0-6.0 mmol/L (71 - 108 mg/dL) in a treat-to-target fashion."}, {"id": "OG001", "title": "NovoRapid", "description": "Participants received Insulin aspart (NovoRapid\u00ae/NovoLog\u00ae: basal-bolus regimen) along with insulin degludec (basal-bolus regimen) with or without metformin for 16 weeks. Before the treatment period was a 12-week run-in period in which the investigator optimised basal insulin dose. Insulin degludec dose was adjusted weekly by the investigator in the run-in period based on the mean of three pre-breakfast SMPG values measured on the last two days prior to and on the day of contact. If one of the SMPG values were below target (\\< 4.0 mmol/L or 71 mg/dL) then the insulin degludec dose was adjusted according to the titration guideline specified in the protocol. NovoRapid was titrated from randomisation (week 0) and onwards, twice weekly to reach the glycaemic target of pre-prandial and bedtime PG between 4.0-6.0 mmol/L (71 - 108 mg/dL) in a treat-to-target fashion."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "546"}, {"groupId": "OG001", "value": "545"}]}], "classes": [{"title": "Bedtime to 04:00", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "343"}, {"groupId": "OG001", "value": "347"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.70", "spread": "4.09"}, {"groupId": "OG001", "value": "0.29", "spread": "4.09"}]}]}, {"title": "Bedtime to breakfast", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "419"}, {"groupId": "OG001", "value": "438"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "1.30", "spread": "4.25"}, {"groupId": "OG001", "value": "0.90", "spread": "3.99"}]}]}, {"title": "04:00 to breakfast", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "351"}, {"groupId": "OG001", "value": "355"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.66", "spread": "2.76"}, {"groupId": "OG001", "value": "0.75", "spread": "2.87"}]}]}]}, {"type": "SECONDARY", "title": "Participants Who Achieved Overall PPG (1 Hour) <7.8 mmol/L (140 mg/dL) (Yes/No)", "description": "Participants reaching overall PPG (1 hour) \u22647.8 mmol/L \\[140 mg/dL\\] was evaluated after 16 weeks of randomisation. Participants without a postprandial glucose measurement at week 16 were considered not to have achieved HbA1c target at week 16. The results are based on the last in-trial value, which included the last available measurement in the in-trial period. In trial observation period was from date of randomisation and until last trial-related participant-site contact.", "populationDescription": "Overall number of participants analyzed = full analysis set (FAS) which comprised all randomised participants. Number Analyzed = number of participants with available data.", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "timeFrame": "16 weeks after randomisation", "groups": [{"id": "OG000", "title": "Faster Aspart", "description": "Participants received Faster aspart along with insulin degludec (basal-bolus regimen) with or without metformin for 16 weeks. Before the treatment period was a 12-week run-in period in which the investigator optimised basal insulin dose. Insulin degludec dose was adjusted weekly by the investigator in the run-in period based on the mean of three pre-breakfast SMPG values measured on the last two days prior to and on the day of contact. If one of the SMPG values were below target (\\< 4.0 mmol/L or 71 mg/dL) then the insulin degludec dose was adjusted according to the titration guideline specified in the protocol. Faster aspart was titrated from randomisation (week 0) and onwards, twice weekly to reach the glycaemic target of pre-prandial and bedtime PG between 4.0-6.0 mmol/L (71 - 108 mg/dL) in a treat-to-target fashion."}, {"id": "OG001", "title": "NovoRapid", "description": "Participants received Insulin aspart (NovoRapid\u00ae/NovoLog\u00ae: basal-bolus regimen) along with insulin degludec (basal-bolus regimen) with or without metformin for 16 weeks. Before the treatment period was a 12-week run-in period in which the investigator optimised basal insulin dose. Insulin degludec dose was adjusted weekly by the investigator in the run-in period based on the mean of three pre-breakfast SMPG values measured on the last two days prior to and on the day of contact. If one of the SMPG values were below target (\\< 4.0 mmol/L or 71 mg/dL) then the insulin degludec dose was adjusted according to the titration guideline specified in the protocol. NovoRapid was titrated from randomisation (week 0) and onwards, twice weekly to reach the glycaemic target of pre-prandial and bedtime PG between 4.0-6.0 mmol/L (71 - 108 mg/dL) in a treat-to-target fashion."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "546"}, {"groupId": "OG001", "value": "545"}]}], "classes": [{"categories": [{"title": "Yes", "measurements": [{"groupId": "OG000", "value": "186"}, {"groupId": "OG001", "value": "192"}]}, {"title": "No", "measurements": [{"groupId": "OG000", "value": "360"}, {"groupId": "OG001", "value": "353"}]}]}]}, {"type": "SECONDARY", "title": "Participants Who Achieved Overall PPG <7.8 mmol/L (140 mg/dL) Without Severe Hypoglycaemia Episodes (Yes/No)", "description": "Participants reaching overall PPG (1 hour) \u22647.8 mmol/L \\[140 mg/dL\\] without severe hypoglycaemia episodes was evaluated after 16 weeks of randomisation. Participants without a postprandial glucose measurement at week 16 were considered not to have achieved HbA1c target at week 16. The results are based on the last in-trial value, which included the last available measurement in the in-trial period. In trial observation period was from date of randomisation and until last trial-related participant-site contact.", "populationDescription": "Overall number of participants analyzed = full analysis set (FAS) which comprised all randomised participants. Number Analyzed = number of participants with available data.", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "timeFrame": "16 weeks after randomisation", "groups": [{"id": "OG000", "title": "Faster Aspart", "description": "Participants received Faster aspart along with insulin degludec (basal-bolus regimen) with or without metformin for 16 weeks. Before the treatment period was a 12-week run-in period in which the investigator optimised basal insulin dose. Insulin degludec dose was adjusted weekly by the investigator in the run-in period based on the mean of three pre-breakfast SMPG values measured on the last two days prior to and on the day of contact. If one of the SMPG values were below target (\\< 4.0 mmol/L or 71 mg/dL) then the insulin degludec dose was adjusted according to the titration guideline specified in the protocol. Faster aspart was titrated from randomisation (week 0) and onwards, twice weekly to reach the glycaemic target of pre-prandial and bedtime PG between 4.0-6.0 mmol/L (71 - 108 mg/dL) in a treat-to-target fashion."}, {"id": "OG001", "title": "NovoRapid", "description": "Participants received Insulin aspart (NovoRapid\u00ae/NovoLog\u00ae: basal-bolus regimen) along with insulin degludec (basal-bolus regimen) with or without metformin for 16 weeks. Before the treatment period was a 12-week run-in period in which the investigator optimised basal insulin dose. Insulin degludec dose was adjusted weekly by the investigator in the run-in period based on the mean of three pre-breakfast SMPG values measured on the last two days prior to and on the day of contact. If one of the SMPG values were below target (\\< 4.0 mmol/L or 71 mg/dL) then the insulin degludec dose was adjusted according to the titration guideline specified in the protocol. NovoRapid was titrated from randomisation (week 0) and onwards, twice weekly to reach the glycaemic target of pre-prandial and bedtime PG between 4.0-6.0 mmol/L (71 - 108 mg/dL) in a treat-to-target fashion."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "546"}, {"groupId": "OG001", "value": "545"}]}], "classes": [{"categories": [{"title": "Yes", "measurements": [{"groupId": "OG000", "value": "182"}, {"groupId": "OG001", "value": "190"}]}, {"title": "No", "measurements": [{"groupId": "OG000", "value": "364"}, {"groupId": "OG001", "value": "355"}]}]}]}, {"type": "SECONDARY", "title": "Total Bolus Insulin Dose: in Units/Day", "description": "Total bolus insulin dose (Units/day) was evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period. On-treatment period started from date of first dose of randomised NovoRapid/faster aspart and to 7 days after day of last dose or day before initiation of ancillary treatment.", "populationDescription": "Overall number of participants analyzed = number of participants with available data.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Units/day", "timeFrame": "16 weeks from randomisation", "groups": [{"id": "OG000", "title": "Faster Aspart", "description": "Participants received Faster aspart along with insulin degludec (basal-bolus regimen) with or without metformin for 16 weeks. Before the treatment period was a 12-week run-in period in which the investigator optimised basal insulin dose. Insulin degludec dose was adjusted weekly by the investigator in the run-in period based on the mean of three pre-breakfast SMPG values measured on the last two days prior to and on the day of contact. If one of the SMPG values were below target (\\< 4.0 mmol/L or 71 mg/dL) then the insulin degludec dose was adjusted according to the titration guideline specified in the protocol. Faster aspart was titrated from randomisation (week 0) and onwards, twice weekly to reach the glycaemic target of pre-prandial and bedtime PG between 4.0-6.0 mmol/L (71 - 108 mg/dL) in a treat-to-target fashion."}, {"id": "OG001", "title": "NovoRapid", "description": "Participants received Insulin aspart (NovoRapid\u00ae/NovoLog\u00ae: basal-bolus regimen) along with insulin degludec (basal-bolus regimen) with or without metformin for 16 weeks. Before the treatment period was a 12-week run-in period in which the investigator optimised basal insulin dose. Insulin degludec dose was adjusted weekly by the investigator in the run-in period based on the mean of three pre-breakfast SMPG values measured on the last two days prior to and on the day of contact. If one of the SMPG values were below target (\\< 4.0 mmol/L or 71 mg/dL) then the insulin degludec dose was adjusted according to the titration guideline specified in the protocol. NovoRapid was titrated from randomisation (week 0) and onwards, twice weekly to reach the glycaemic target of pre-prandial and bedtime PG between 4.0-6.0 mmol/L (71 - 108 mg/dL) in a treat-to-target fashion."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "544"}, {"groupId": "OG001", "value": "542"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "54.72", "spread": "35.82"}, {"groupId": "OG001", "value": "53.38", "spread": "35.35"}]}]}]}, {"type": "SECONDARY", "title": "Total Bolus Insulin Dose: in Units/kg/Day", "description": "Total bolus insulin dose (Units/kg/day) was evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period. On-treatment period started from date of first dose of randomised NovoRapid/faster aspart and to 7 days after day of last dose or day before initiation of ancillary treatment.", "populationDescription": "Overall number of participants analyzed = number of participants with available data.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Units/kg/day", "timeFrame": "16 weeks from randomisation", "groups": [{"id": "OG000", "title": "Faster Aspart", "description": "Participants received Faster aspart along with insulin degludec (basal-bolus regimen) with or without metformin for 16 weeks. Before the treatment period was a 12-week run-in period in which the investigator optimised basal insulin dose. Insulin degludec dose was adjusted weekly by the investigator in the run-in period based on the mean of three pre-breakfast SMPG values measured on the last two days prior to and on the day of contact. If one of the SMPG values were below target (\\< 4.0 mmol/L or 71 mg/dL) then the insulin degludec dose was adjusted according to the titration guideline specified in the protocol. Faster aspart was titrated from randomisation (week 0) and onwards, twice weekly to reach the glycaemic target of pre-prandial and bedtime PG between 4.0-6.0 mmol/L (71 - 108 mg/dL) in a treat-to-target fashion."}, {"id": "OG001", "title": "NovoRapid", "description": "Participants received Insulin aspart (NovoRapid\u00ae/NovoLog\u00ae: basal-bolus regimen) along with insulin degludec (basal-bolus regimen) with or without metformin for 16 weeks. Before the treatment period was a 12-week run-in period in which the investigator optimised basal insulin dose. Insulin degludec dose was adjusted weekly by the investigator in the run-in period based on the mean of three pre-breakfast SMPG values measured on the last two days prior to and on the day of contact. If one of the SMPG values were below target (\\< 4.0 mmol/L or 71 mg/dL) then the insulin degludec dose was adjusted according to the titration guideline specified in the protocol. NovoRapid was titrated from randomisation (week 0) and onwards, twice weekly to reach the glycaemic target of pre-prandial and bedtime PG between 4.0-6.0 mmol/L (71 - 108 mg/dL) in a treat-to-target fashion."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "544"}, {"groupId": "OG001", "value": "542"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.57", "spread": "0.33"}, {"groupId": "OG001", "value": "0.55", "spread": "0.34"}]}]}]}, {"type": "SECONDARY", "title": "Total Basal Insulin Dose: in Units/Day", "description": "Total basal insulin dose (Units/day) was evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period. On-treatment period started from date of first dose of randomised NovoRapid/faster aspart and to 7 days after day of last dose or day before initiation of ancillary treatment.", "populationDescription": "Overall number of participants analyzed = number of participants with available data.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Units/day", "timeFrame": "16 weeks from randomisation", "groups": [{"id": "OG000", "title": "Faster Aspart", "description": "Participants received Faster aspart along with insulin degludec (basal-bolus regimen) with or without metformin for 16 weeks. Before the treatment period was a 12-week run-in period in which the investigator optimised basal insulin dose. Insulin degludec dose was adjusted weekly by the investigator in the run-in period based on the mean of three pre-breakfast SMPG values measured on the last two days prior to and on the day of contact. If one of the SMPG values were below target (\\< 4.0 mmol/L or 71 mg/dL) then the insulin degludec dose was adjusted according to the titration guideline specified in the protocol. Faster aspart was titrated from randomisation (week 0) and onwards, twice weekly to reach the glycaemic target of pre-prandial and bedtime PG between 4.0-6.0 mmol/L (71 - 108 mg/dL) in a treat-to-target fashion."}, {"id": "OG001", "title": "NovoRapid", "description": "Participants received Insulin aspart (NovoRapid\u00ae/NovoLog\u00ae: basal-bolus regimen) along with insulin degludec (basal-bolus regimen) with or without metformin for 16 weeks. Before the treatment period was a 12-week run-in period in which the investigator optimised basal insulin dose. Insulin degludec dose was adjusted weekly by the investigator in the run-in period based on the mean of three pre-breakfast SMPG values measured on the last two days prior to and on the day of contact. If one of the SMPG values were below target (\\< 4.0 mmol/L or 71 mg/dL) then the insulin degludec dose was adjusted according to the titration guideline specified in the protocol. NovoRapid was titrated from randomisation (week 0) and onwards, twice weekly to reach the glycaemic target of pre-prandial and bedtime PG between 4.0-6.0 mmol/L (71 - 108 mg/dL) in a treat-to-target fashion."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "544"}, {"groupId": "OG001", "value": "542"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "63.76", "spread": "35.21"}, {"groupId": "OG001", "value": "62.25", "spread": "36.03"}]}]}]}, {"type": "SECONDARY", "title": "Total Basal Insulin Dose: in Units/kg/Day", "description": "Total basal insulin dose (Units/kg/day) was evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period. On-treatment period started from date of first dose of randomised NovoRapid/faster aspart and to 7 days after day of last dose or day before initiation of ancillary treatment.", "populationDescription": "Overall number of participants analyzed = number of participants with available data.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Units/kg/day", "timeFrame": "16 weeks from randomisation", "groups": [{"id": "OG000", "title": "Faster Aspart", "description": "Participants received Faster aspart along with insulin degludec (basal-bolus regimen) with or without metformin for 16 weeks. Before the treatment period was a 12-week run-in period in which the investigator optimised basal insulin dose. Insulin degludec dose was adjusted weekly by the investigator in the run-in period based on the mean of three pre-breakfast SMPG values measured on the last two days prior to and on the day of contact. If one of the SMPG values were below target (\\< 4.0 mmol/L or 71 mg/dL) then the insulin degludec dose was adjusted according to the titration guideline specified in the protocol. Faster aspart was titrated from randomisation (week 0) and onwards, twice weekly to reach the glycaemic target of pre-prandial and bedtime PG between 4.0-6.0 mmol/L (71 - 108 mg/dL) in a treat-to-target fashion."}, {"id": "OG001", "title": "NovoRapid", "description": "Participants received Insulin aspart (NovoRapid\u00ae/NovoLog\u00ae: basal-bolus regimen) along with insulin degludec (basal-bolus regimen) with or without metformin for 16 weeks. Before the treatment period was a 12-week run-in period in which the investigator optimised basal insulin dose. Insulin degludec dose was adjusted weekly by the investigator in the run-in period based on the mean of three pre-breakfast SMPG values measured on the last two days prior to and on the day of contact. If one of the SMPG values were below target (\\< 4.0 mmol/L or 71 mg/dL) then the insulin degludec dose was adjusted according to the titration guideline specified in the protocol. NovoRapid was titrated from randomisation (week 0) and onwards, twice weekly to reach the glycaemic target of pre-prandial and bedtime PG between 4.0-6.0 mmol/L (71 - 108 mg/dL) in a treat-to-target fashion."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "544"}, {"groupId": "OG001", "value": "542"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.66", "spread": "0.32"}, {"groupId": "OG001", "value": "0.64", "spread": "0.32"}]}]}]}, {"type": "SECONDARY", "title": "Individual Meal Insulin Dose: in Units", "description": "Individual meal time bolus insulin dose (Units) for breakast, lunch and main evening meal was evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period. On-treatment period started from date of first dose of randomised NovoRapid/faster aspart and to 7 days after day of last dose or day before initiation of ancillary treatment.", "populationDescription": "Overall number of participants analyzed = safety analysis set (SAS) which comprised all randomised participants. Number Analyzed = number of participants with available data.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Units", "timeFrame": "16 weeks from randomisation", "groups": [{"id": "OG000", "title": "Faster Aspart", "description": "Participants received Faster aspart along with insulin degludec (basal-bolus regimen) with or without metformin for 16 weeks. Before the treatment period was a 12-week run-in period in which the investigator optimised basal insulin dose. Insulin degludec dose was adjusted weekly by the investigator in the run-in period based on the mean of three pre-breakfast SMPG values measured on the last two days prior to and on the day of contact. If one of the SMPG values were below target (\\< 4.0 mmol/L or 71 mg/dL) then the insulin degludec dose was adjusted according to the titration guideline specified in the protocol. Faster aspart was titrated from randomisation (week 0) and onwards, twice weekly to reach the glycaemic target of pre-prandial and bedtime PG between 4.0-6.0 mmol/L (71 - 108 mg/dL) in a treat-to-target fashion."}, {"id": "OG001", "title": "NovoRapid", "description": "Participants received Insulin aspart (NovoRapid\u00ae/NovoLog\u00ae: basal-bolus regimen) along with insulin degludec (basal-bolus regimen) with or without metformin for 16 weeks. Before the treatment period was a 12-week run-in period in which the investigator optimised basal insulin dose. Insulin degludec dose was adjusted weekly by the investigator in the run-in period based on the mean of three pre-breakfast SMPG values measured on the last two days prior to and on the day of contact. If one of the SMPG values were below target (\\< 4.0 mmol/L or 71 mg/dL) then the insulin degludec dose was adjusted according to the titration guideline specified in the protocol. NovoRapid was titrated from randomisation (week 0) and onwards, twice weekly to reach the glycaemic target of pre-prandial and bedtime PG between 4.0-6.0 mmol/L (71 - 108 mg/dL) in a treat-to-target fashion."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "544"}, {"groupId": "OG001", "value": "544"}]}], "classes": [{"title": "Breakfast", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "544"}, {"groupId": "OG001", "value": "543"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "16.27", "spread": "12.04"}, {"groupId": "OG001", "value": "15.52", "spread": "11.38"}]}]}, {"title": "Lunch", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "544"}, {"groupId": "OG001", "value": "543"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "18.51", "spread": "12.09"}, {"groupId": "OG001", "value": "17.96", "spread": "11.73"}]}]}, {"title": "Daily main evening meal", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "544"}, {"groupId": "OG001", "value": "542"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "19.88", "spread": "13.46"}, {"groupId": "OG001", "value": "19.85", "spread": "14.47"}]}]}]}, {"type": "SECONDARY", "title": "Individual Meal Insulin Dose: in Units/kg", "description": "Individual meal time bolus insulin dose (Units/kg) for breakast, lunch and main evening meal was evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period. On-treatment period started from date of first dose of randomised NovoRapid/faster aspart and to 7 days after day of last dose or day before initiation of ancillary treatment.", "populationDescription": "Overall number of participants analyzed = safety analysis set (SAS) which comprised all randomised participants. Number Analyzed = number of participants with available data.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Units/kg", "timeFrame": "16 weeks from randomisation", "groups": [{"id": "OG000", "title": "Faster Aspart", "description": "Participants received Faster aspart along with insulin degludec (basal-bolus regimen) with or without metformin for 16 weeks. Before the treatment period was a 12-week run-in period in which the investigator optimised basal insulin dose. Insulin degludec dose was adjusted weekly by the investigator in the run-in period based on the mean of three pre-breakfast SMPG values measured on the last two days prior to and on the day of contact. If one of the SMPG values were below target (\\< 4.0 mmol/L or 71 mg/dL) then the insulin degludec dose was adjusted according to the titration guideline specified in the protocol. Faster aspart was titrated from randomisation (week 0) and onwards, twice weekly to reach the glycaemic target of pre-prandial and bedtime PG between 4.0-6.0 mmol/L (71 - 108 mg/dL) in a treat-to-target fashion."}, {"id": "OG001", "title": "NovoRapid", "description": "Participants received Insulin aspart (NovoRapid\u00ae/NovoLog\u00ae: basal-bolus regimen) along with insulin degludec (basal-bolus regimen) with or without metformin for 16 weeks. Before the treatment period was a 12-week run-in period in which the investigator optimised basal insulin dose. Insulin degludec dose was adjusted weekly by the investigator in the run-in period based on the mean of three pre-breakfast SMPG values measured on the last two days prior to and on the day of contact. If one of the SMPG values were below target (\\< 4.0 mmol/L or 71 mg/dL) then the insulin degludec dose was adjusted according to the titration guideline specified in the protocol. NovoRapid was titrated from randomisation (week 0) and onwards, twice weekly to reach the glycaemic target of pre-prandial and bedtime PG between 4.0-6.0 mmol/L (71 - 108 mg/dL) in a treat-to-target fashion."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "544"}, {"groupId": "OG001", "value": "544"}]}], "classes": [{"title": "Breakfast", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "544"}, {"groupId": "OG001", "value": "543"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.17", "spread": "0.12"}, {"groupId": "OG001", "value": "0.16", "spread": "0.11"}]}]}, {"title": "Lunch", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "544"}, {"groupId": "OG001", "value": "543"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.19", "spread": "0.11"}, {"groupId": "OG001", "value": "0.19", "spread": "0.12"}]}]}, {"title": "Daily main evening meal", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "544"}, {"groupId": "OG001", "value": "542"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.21", "spread": "0.13"}, {"groupId": "OG001", "value": "0.20", "spread": "0.14"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Lipids-lipoproteins Profile (Total Cholesterol, High Density Lipoproteins, Low Density Lipoproteins) - Ratio to Baseline", "description": "Reported results are lipids-lipoproteins (total cholesterol, high density lipoproteins, low density lipoproteins) values are given as ratio to baseline (week 0) after 16 weeks. The results are based on the last in-trial value, which included the last available measurement in the in-trial period. In trial observation period was from date of randomisation and until last trial-related participant-site contact.", "populationDescription": "Overall number of participants analyzed = full analysis set (FAS) which comprised all randomised participants. Number Analyzed = number of participants with available data.", "reportingStatus": "POSTED", "paramType": "GEOMETRIC_MEAN", "dispersionType": "Geometric Coefficient of Variation", "unitOfMeasure": "Ratio", "timeFrame": "Week 0, week 16", "groups": [{"id": "OG000", "title": "Faster Aspart", "description": "Participants received Faster aspart along with insulin degludec (basal-bolus regimen) with or without metformin for 16 weeks. Before the treatment period was a 12-week run-in period in which the investigator optimised basal insulin dose. Insulin degludec dose was adjusted weekly by the investigator in the run-in period based on the mean of three pre-breakfast SMPG values measured on the last two days prior to and on the day of contact. If one of the SMPG values were below target (\\< 4.0 mmol/L or 71 mg/dL) then the insulin degludec dose was adjusted according to the titration guideline specified in the protocol. Faster aspart was titrated from randomisation (week 0) and onwards, twice weekly to reach the glycaemic target of pre-prandial and bedtime PG between 4.0-6.0 mmol/L (71 - 108 mg/dL) in a treat-to-target fashion."}, {"id": "OG001", "title": "NovoRapid", "description": "Participants received Insulin aspart (NovoRapid\u00ae/NovoLog\u00ae: basal-bolus regimen) along with insulin degludec (basal-bolus regimen) with or without metformin for 16 weeks. Before the treatment period was a 12-week run-in period in which the investigator optimised basal insulin dose. Insulin degludec dose was adjusted weekly by the investigator in the run-in period based on the mean of three pre-breakfast SMPG values measured on the last two days prior to and on the day of contact. If one of the SMPG values were below target (\\< 4.0 mmol/L or 71 mg/dL) then the insulin degludec dose was adjusted according to the titration guideline specified in the protocol. NovoRapid was titrated from randomisation (week 0) and onwards, twice weekly to reach the glycaemic target of pre-prandial and bedtime PG between 4.0-6.0 mmol/L (71 - 108 mg/dL) in a treat-to-target fashion."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "546"}, {"groupId": "OG001", "value": "545"}]}], "classes": [{"title": "Total cholesterol", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "542"}, {"groupId": "OG001", "value": "537"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "1.01", "spread": "15.98"}, {"groupId": "OG001", "value": "1.00", "spread": "17.09"}]}]}, {"title": "High density lipoproteins", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "542"}, {"groupId": "OG001", "value": "537"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.97", "spread": "14.47"}, {"groupId": "OG001", "value": "0.98", "spread": "17.57"}]}]}, {"title": "Low density lipoproteins", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "542"}, {"groupId": "OG001", "value": "537"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.99", "spread": "25.36"}, {"groupId": "OG001", "value": "0.99", "spread": "40.51"}]}]}]}, {"type": "SECONDARY", "title": "Number of Treatment Emergent Adverse Events", "description": "Number of treatment emergent adverse events were recorded from week 0 to week 16. The results are based on the on-treatment period. On-treatment period started from date of first dose of randomised NovoRapid/faster aspart and to 7 days after day of last dose or day before initiation of ancillary treatment.", "populationDescription": "Overall number of participants analyzed = number of participants with available data.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Events", "timeFrame": "Weeks 0-16", "groups": [{"id": "OG000", "title": "Faster Aspart", "description": "Participants received Faster aspart along with insulin degludec (basal-bolus regimen) with or without metformin for 16 weeks. Before the treatment period was a 12-week run-in period in which the investigator optimised basal insulin dose. Insulin degludec dose was adjusted weekly by the investigator in the run-in period based on the mean of three pre-breakfast SMPG values measured on the last two days prior to and on the day of contact. If one of the SMPG values were below target (\\< 4.0 mmol/L or 71 mg/dL) then the insulin degludec dose was adjusted according to the titration guideline specified in the protocol. Faster aspart was titrated from randomisation (week 0) and onwards, twice weekly to reach the glycaemic target of pre-prandial and bedtime PG between 4.0-6.0 mmol/L (71 - 108 mg/dL) in a treat-to-target fashion."}, {"id": "OG001", "title": "NovoRapid", "description": "Participants received Insulin aspart (NovoRapid\u00ae/NovoLog\u00ae: basal-bolus regimen) along with insulin degludec (basal-bolus regimen) with or without metformin for 16 weeks. Before the treatment period was a 12-week run-in period in which the investigator optimised basal insulin dose. Insulin degludec dose was adjusted weekly by the investigator in the run-in period based on the mean of three pre-breakfast SMPG values measured on the last two days prior to and on the day of contact. If one of the SMPG values were below target (\\< 4.0 mmol/L or 71 mg/dL) then the insulin degludec dose was adjusted according to the titration guideline specified in the protocol. NovoRapid was titrated from randomisation (week 0) and onwards, twice weekly to reach the glycaemic target of pre-prandial and bedtime PG between 4.0-6.0 mmol/L (71 - 108 mg/dL) in a treat-to-target fashion."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "544"}, {"groupId": "OG001", "value": "544"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "667"}, {"groupId": "OG001", "value": "643"}]}]}]}, {"type": "SECONDARY", "title": "Number of Treatment Emergent Injection Site Reactions", "description": "Number of treatment emergent injection site reactions were recorded from week 0 to week 16. The results are based on the on-treatment period. On-treatment period started from date of first dose of randomised NovoRapid/faster aspart and to 7 days after day of last dose or day before initiation of ancillary treatment.", "populationDescription": "Overall number of participants analyzed = number of participants with available data.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Number of injection site reactions", "timeFrame": "Weeks 0-16", "groups": [{"id": "OG000", "title": "Faster Aspart", "description": "Participants received Faster aspart along with insulin degludec (basal-bolus regimen) with or without metformin for 16 weeks. Before the treatment period was a 12-week run-in period in which the investigator optimised basal insulin dose. Insulin degludec dose was adjusted weekly by the investigator in the run-in period based on the mean of three pre-breakfast SMPG values measured on the last two days prior to and on the day of contact. If one of the SMPG values were below target (\\< 4.0 mmol/L or 71 mg/dL) then the insulin degludec dose was adjusted according to the titration guideline specified in the protocol. Faster aspart was titrated from randomisation (week 0) and onwards, twice weekly to reach the glycaemic target of pre-prandial and bedtime PG between 4.0-6.0 mmol/L (71 - 108 mg/dL) in a treat-to-target fashion."}, {"id": "OG001", "title": "NovoRapid", "description": "Participants received Insulin aspart (NovoRapid\u00ae/NovoLog\u00ae: basal-bolus regimen) along with insulin degludec (basal-bolus regimen) with or without metformin for 16 weeks. Before the treatment period was a 12-week run-in period in which the investigator optimised basal insulin dose. Insulin degludec dose was adjusted weekly by the investigator in the run-in period based on the mean of three pre-breakfast SMPG values measured on the last two days prior to and on the day of contact. If one of the SMPG values were below target (\\< 4.0 mmol/L or 71 mg/dL) then the insulin degludec dose was adjusted according to the titration guideline specified in the protocol. NovoRapid was titrated from randomisation (week 0) and onwards, twice weekly to reach the glycaemic target of pre-prandial and bedtime PG between 4.0-6.0 mmol/L (71 - 108 mg/dL) in a treat-to-target fashion."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "544"}, {"groupId": "OG001", "value": "544"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "3"}, {"groupId": "OG001", "value": "1"}]}]}]}, {"type": "SECONDARY", "title": "Number of Treatment Emergent Hypoglycaemic Episodes (Hypos) According to the American Diabetes Association (ADA) and Novo Nordisk (NN) Definition: Overall", "description": "ADA classification of hypos:\n\n1. Severe: Requiring assistance of another person to actively administer carbohydrate/glucagon/take other corrective actions. PG levels may not be available during an event, but neurological recovery following return of PG to normal is considered sufficient evidence that event was induced by a low PG level.\n2. Documented symptomatic: PG \u22643.9 mmol/L with symptoms.\n3. Asymptomatic: PG \u22643.9 mmol/L without symptoms.\n4. Probable symptomatic: No measurement with symptoms.\n5. Pseudo: PG \\>3.9 mmol/L with symptoms.\n6. Unclassifiable.\n\nNN classification of hypos:\n\n1. BG confirmed: PG \\<3.1 mmol/L with/without symptoms.\n2. Severe or BG confirmed symptomatic: Severe as per ADA and BG confirmed by PG \\<3.1 mmol/L with symptoms.\n3. Severe or BG confirmed: Severe as per ADA and BG confirmed by PG \\<3.1 mmol/L with/without symptoms.\n4. Unclassifiable. Not able to self treat-unclassifiable: Not able to self treat but not classifiable as severe hypoglycaemia.", "populationDescription": "Overall number of participants analyzed = safety analysis set (SAS) which comprised all randomised participants. Number Analyzed = number of participants with available data.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Number of hypoglycaemic episodes", "timeFrame": "Weeks 0-16", "groups": [{"id": "OG000", "title": "Faster Aspart", "description": "Participants received Faster aspart along with insulin degludec (basal-bolus regimen) with or without metformin for 16 weeks. Before the treatment period was a 12-week run-in period in which the investigator optimised basal insulin dose. Insulin degludec dose was adjusted weekly by the investigator in the run-in period based on the mean of three pre-breakfast SMPG values measured on the last two days prior to and on the day of contact. If one of the SMPG values were below target (\\< 4.0 mmol/L or 71 mg/dL) then the insulin degludec dose was adjusted according to the titration guideline specified in the protocol. Faster aspart was titrated from randomisation (week 0) and onwards, twice weekly to reach the glycaemic target of pre-prandial and bedtime PG between 4.0-6.0 mmol/L (71 - 108 mg/dL) in a treat-to-target fashion."}, {"id": "OG001", "title": "NovoRapid", "description": "Participants received Insulin aspart (NovoRapid\u00ae/NovoLog\u00ae: basal-bolus regimen) along with insulin degludec (basal-bolus regimen) with or without metformin for 16 weeks. Before the treatment period was a 12-week run-in period in which the investigator optimised basal insulin dose. Insulin degludec dose was adjusted weekly by the investigator in the run-in period based on the mean of three pre-breakfast SMPG values measured on the last two days prior to and on the day of contact. If one of the SMPG values were below target (\\< 4.0 mmol/L or 71 mg/dL) then the insulin degludec dose was adjusted according to the titration guideline specified in the protocol. NovoRapid was titrated from randomisation (week 0) and onwards, twice weekly to reach the glycaemic target of pre-prandial and bedtime PG between 4.0-6.0 mmol/L (71 - 108 mg/dL) in a treat-to-target fashion."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "544"}, {"groupId": "OG001", "value": "544"}]}], "classes": [{"title": "ADA: Severe", "categories": [{"measurements": [{"groupId": "OG000", "value": "18"}, {"groupId": "OG001", "value": "14"}]}]}, {"title": "ADA: Documented symptomatic", "categories": [{"measurements": [{"groupId": "OG000", "value": "5038"}, {"groupId": "OG001", "value": "6165"}]}]}, {"title": "ADA: Asymptomatic", "categories": [{"measurements": [{"groupId": "OG000", "value": "3761"}, {"groupId": "OG001", "value": "3681"}]}]}, {"title": "ADA: Probable symptomatic", "categories": [{"measurements": [{"groupId": "OG000", "value": "68"}, {"groupId": "OG001", "value": "68"}]}]}, {"title": "ADA: Pseudo", "categories": [{"measurements": [{"groupId": "OG000", "value": "145"}, {"groupId": "OG001", "value": "75"}]}]}, {"title": "ADA: Unclassifiable", "categories": [{"measurements": [{"groupId": "OG000", "value": "3"}, {"groupId": "OG001", "value": "3"}]}]}, {"title": "NN: BG confirmed", "categories": [{"measurements": [{"groupId": "OG000", "value": "2209"}, {"groupId": "OG001", "value": "2735"}]}]}, {"title": "NN: Severe or BG confirmed symptomatic", "categories": [{"measurements": [{"groupId": "OG000", "value": "1490"}, {"groupId": "OG001", "value": "2055"}]}]}, {"title": "NN: Severe or BG confirmed", "categories": [{"measurements": [{"groupId": "OG000", "value": "2227"}, {"groupId": "OG001", "value": "2749"}]}]}, {"title": "NN: Unclassifiable", "categories": [{"measurements": [{"groupId": "OG000", "value": "6806"}, {"groupId": "OG001", "value": "7257"}]}]}, {"title": "Not able to selftreat - unclassifiable", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}]}, {"type": "SECONDARY", "title": "Number of Treatment Emergent Hypoglycaemic Episodes According to the American Diabetes Association and Novo Nordisk Definition: Daytime Hypoglycaemic Episodes (06:00-00:00 - Inclusive)", "description": "Number of treatment emergent day time hypoglycaemic episodes according to the ADA and NN definitions were evaluated between 06:00 and 00:00 (both included). The results are based on the on-treatment period. On-treatment period started from date of first dose of randomised NovoRapid/faster aspart and to 7 days after day of last dose or day before initiation of ancillary treatment.", "populationDescription": "Overall number of participants analyzed = safety analysis set (SAS) which comprised all randomised participants. Number Analyzed = number of participants with available data.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Number of hypoglycaemic episodes", "timeFrame": "Weeks 0-16", "groups": [{"id": "OG000", "title": "Faster Aspart", "description": "Participants received Faster aspart along with insulin degludec (basal-bolus regimen) with or without metformin for 16 weeks. Before the treatment period was a 12-week run-in period in which the investigator optimised basal insulin dose. Insulin degludec dose was adjusted weekly by the investigator in the run-in period based on the mean of three pre-breakfast SMPG values measured on the last two days prior to and on the day of contact. If one of the SMPG values were below target (\\< 4.0 mmol/L or 71 mg/dL) then the insulin degludec dose was adjusted according to the titration guideline specified in the protocol. Faster aspart was titrated from randomisation (week 0) and onwards, twice weekly to reach the glycaemic target of pre-prandial and bedtime PG between 4.0-6.0 mmol/L (71 - 108 mg/dL) in a treat-to-target fashion."}, {"id": "OG001", "title": "NovoRapid", "description": "Participants received Insulin aspart (NovoRapid\u00ae/NovoLog\u00ae: basal-bolus regimen) along with insulin degludec (basal-bolus regimen) with or without metformin for 16 weeks. Before the treatment period was a 12-week run-in period in which the investigator optimised basal insulin dose. Insulin degludec dose was adjusted weekly by the investigator in the run-in period based on the mean of three pre-breakfast SMPG values measured on the last two days prior to and on the day of contact. If one of the SMPG values were below target (\\< 4.0 mmol/L or 71 mg/dL) then the insulin degludec dose was adjusted according to the titration guideline specified in the protocol. NovoRapid was titrated from randomisation (week 0) and onwards, twice weekly to reach the glycaemic target of pre-prandial and bedtime PG between 4.0-6.0 mmol/L (71 - 108 mg/dL) in a treat-to-target fashion."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "544"}, {"groupId": "OG001", "value": "544"}]}], "classes": [{"title": "ADA: Severe", "categories": [{"measurements": [{"groupId": "OG000", "value": "16"}, {"groupId": "OG001", "value": "12"}]}]}, {"title": "ADA: Documented symptomatic", "categories": [{"measurements": [{"groupId": "OG000", "value": "4703"}, {"groupId": "OG001", "value": "5700"}]}]}, {"title": "ADA: Asymptomatic", "categories": [{"measurements": [{"groupId": "OG000", "value": "3617"}, {"groupId": "OG001", "value": "3484"}]}]}, {"title": "ADA: Probable symptomatic", "categories": [{"measurements": [{"groupId": "OG000", "value": "62"}, {"groupId": "OG001", "value": "64"}]}]}, {"title": "ADA: Pseudo", "categories": [{"measurements": [{"groupId": "OG000", "value": "141"}, {"groupId": "OG001", "value": "66"}]}]}, {"title": "ADA: Unclassifiable", "categories": [{"measurements": [{"groupId": "OG000", "value": "3"}, {"groupId": "OG001", "value": "3"}]}]}, {"title": "NN: BG confirmed", "categories": [{"measurements": [{"groupId": "OG000", "value": "2016"}, {"groupId": "OG001", "value": "2442"}]}]}, {"title": "NN: Severe or BG confirmed symptomatic", "categories": [{"measurements": [{"groupId": "OG000", "value": "1333"}, {"groupId": "OG001", "value": "1814"}]}]}, {"title": "NN: Severe or BG confirmed", "categories": [{"measurements": [{"groupId": "OG000", "value": "2032"}, {"groupId": "OG001", "value": "2454"}]}]}, {"title": "NN: Unclassifiable", "categories": [{"measurements": [{"groupId": "OG000", "value": "6510"}, {"groupId": "OG001", "value": "6875"}]}]}, {"title": "Not able to selftreat - unclassifiable", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}]}, {"type": "SECONDARY", "title": "Number of Treatment Emergent Hypoglycaemic Episodes According to the American Diabetes Association and Novo Nordisk Definition: Nocturnal Hypoglycaemic Episodes (00:01-05:59 - Inclusive)", "description": "Number of treatment emergent nocturnal hypoglycaemic episodes according to the ADA and NN definitions were evaluated between 00:01 and 05:59 (both included). The results are based on the on-treatment period. On-treatment period started from date of first dose of randomised NovoRapid/faster aspart and to 7 days after day of last dose or day before initiation of ancillary treatment.", "populationDescription": "Overall number of participants analyzed = safety analysis set (SAS) which comprised all randomised participants. Number Analyzed = number of participants with available data.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Number of hypoglycaemic episodes", "timeFrame": "Weeks 0-16", "groups": [{"id": "OG000", "title": "Faster Aspart", "description": "Participants received Faster aspart along with insulin degludec (basal-bolus regimen) with or without metformin for 16 weeks. Before the treatment period was a 12-week run-in period in which the investigator optimised basal insulin dose. Insulin degludec dose was adjusted weekly by the investigator in the run-in period based on the mean of three pre-breakfast SMPG values measured on the last two days prior to and on the day of contact. If one of the SMPG values were below target (\\< 4.0 mmol/L or 71 mg/dL) then the insulin degludec dose was adjusted according to the titration guideline specified in the protocol. Faster aspart was titrated from randomisation (week 0) and onwards, twice weekly to reach the glycaemic target of pre-prandial and bedtime PG between 4.0-6.0 mmol/L (71 - 108 mg/dL) in a treat-to-target fashion."}, {"id": "OG001", "title": "NovoRapid", "description": "Participants received Insulin aspart (NovoRapid\u00ae/NovoLog\u00ae: basal-bolus regimen) along with insulin degludec (basal-bolus regimen) with or without metformin for 16 weeks. Before the treatment period was a 12-week run-in period in which the investigator optimised basal insulin dose. Insulin degludec dose was adjusted weekly by the investigator in the run-in period based on the mean of three pre-breakfast SMPG values measured on the last two days prior to and on the day of contact. If one of the SMPG values were below target (\\< 4.0 mmol/L or 71 mg/dL) then the insulin degludec dose was adjusted according to the titration guideline specified in the protocol. NovoRapid was titrated from randomisation (week 0) and onwards, twice weekly to reach the glycaemic target of pre-prandial and bedtime PG between 4.0-6.0 mmol/L (71 - 108 mg/dL) in a treat-to-target fashion."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "544"}, {"groupId": "OG001", "value": "544"}]}], "classes": [{"title": "ADA: Severe", "categories": [{"measurements": [{"groupId": "OG000", "value": "2"}, {"groupId": "OG001", "value": "2"}]}]}, {"title": "ADA: Documented symptomatic", "categories": [{"measurements": [{"groupId": "OG000", "value": "335"}, {"groupId": "OG001", "value": "465"}]}]}, {"title": "ADA: Asymptomatic", "categories": [{"measurements": [{"groupId": "OG000", "value": "144"}, {"groupId": "OG001", "value": "197"}]}]}, {"title": "ADA: Probable symptomatic", "categories": [{"measurements": [{"groupId": "OG000", "value": "6"}, {"groupId": "OG001", "value": "4"}]}]}, {"title": "ADA: Pseudo", "categories": [{"measurements": [{"groupId": "OG000", "value": "4"}, {"groupId": "OG001", "value": "9"}]}]}, {"title": "ADA: Unclassifiable", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "NN: BG confirmed", "categories": [{"measurements": [{"groupId": "OG000", "value": "193"}, {"groupId": "OG001", "value": "293"}]}]}, {"title": "NN: Severe or BG confirmed symptomatic", "categories": [{"measurements": [{"groupId": "OG000", "value": "157"}, {"groupId": "OG001", "value": "241"}]}]}, {"title": "NN: Severe or BG confirmed", "categories": [{"measurements": [{"groupId": "OG000", "value": "195"}, {"groupId": "OG001", "value": "295"}]}]}, {"title": "NN: Unclassifiable", "categories": [{"measurements": [{"groupId": "OG000", "value": "296"}, {"groupId": "OG001", "value": "382"}]}]}, {"title": "Not able to selftreat - unclassifiable", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}]}, {"type": "SECONDARY", "title": "Number of Treatment Emergent Hypoglycaemic Episodes According to the American Diabetes Association and Novo Nordisk Definition: Hypoglycaemic Episodes During First 1 Hour After Start of the Meal", "description": "Number of treatment emergent hypoglycaemic episodes according to the ADA and NN definitions were evaluated during the first 1 hour after start of the meal. The results are based on the on-treatment period. On-treatment period started from date of first dose of randomised NovoRapid/faster aspart and to 7 days after day of last dose or day before initiation of ancillary treatment.", "populationDescription": "Overall number of participants analyzed = safety analysis set (SAS) which comprised all randomised participants. Number Analyzed = number of participants with available data.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Number of hypoglycaemic episodes", "timeFrame": "Weeks 0-16", "groups": [{"id": "OG000", "title": "Faster Aspart", "description": "Participants received Faster aspart along with insulin degludec (basal-bolus regimen) with or without metformin for 16 weeks. Before the treatment period was a 12-week run-in period in which the investigator optimised basal insulin dose. Insulin degludec dose was adjusted weekly by the investigator in the run-in period based on the mean of three pre-breakfast SMPG values measured on the last two days prior to and on the day of contact. If one of the SMPG values were below target (\\< 4.0 mmol/L or 71 mg/dL) then the insulin degludec dose was adjusted according to the titration guideline specified in the protocol. Faster aspart was titrated from randomisation (week 0) and onwards, twice weekly to reach the glycaemic target of pre-prandial and bedtime PG between 4.0-6.0 mmol/L (71 - 108 mg/dL) in a treat-to-target fashion."}, {"id": "OG001", "title": "NovoRapid", "description": "Participants received Insulin aspart (NovoRapid\u00ae/NovoLog\u00ae: basal-bolus regimen) along with insulin degludec (basal-bolus regimen) with or without metformin for 16 weeks. Before the treatment period was a 12-week run-in period in which the investigator optimised basal insulin dose. Insulin degludec dose was adjusted weekly by the investigator in the run-in period based on the mean of three pre-breakfast SMPG values measured on the last two days prior to and on the day of contact. If one of the SMPG values were below target (\\< 4.0 mmol/L or 71 mg/dL) then the insulin degludec dose was adjusted according to the titration guideline specified in the protocol. NovoRapid was titrated from randomisation (week 0) and onwards, twice weekly to reach the glycaemic target of pre-prandial and bedtime PG between 4.0-6.0 mmol/L (71 - 108 mg/dL) in a treat-to-target fashion."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "544"}, {"groupId": "OG001", "value": "544"}]}], "classes": [{"title": "ADA: Severe", "categories": [{"measurements": [{"groupId": "OG000", "value": "2"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "ADA: Documented symptomatic", "categories": [{"measurements": [{"groupId": "OG000", "value": "149"}, {"groupId": "OG001", "value": "148"}]}]}, {"title": "ADA: Asymptomatic", "categories": [{"measurements": [{"groupId": "OG000", "value": "87"}, {"groupId": "OG001", "value": "80"}]}]}, {"title": "ADA: Probable symptomatic", "categories": [{"measurements": [{"groupId": "OG000", "value": "11"}, {"groupId": "OG001", "value": "8"}]}]}, {"title": "ADA: Pseudo", "categories": [{"measurements": [{"groupId": "OG000", "value": "2"}, {"groupId": "OG001", "value": "4"}]}]}, {"title": "ADA: Unclassifiable", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "NN: BG confirmed", "categories": [{"measurements": [{"groupId": "OG000", "value": "72"}, {"groupId": "OG001", "value": "65"}]}]}, {"title": "NN: Severe or BG confirmed symptomatic", "categories": [{"measurements": [{"groupId": "OG000", "value": "48"}, {"groupId": "OG001", "value": "50"}]}]}, {"title": "NN: Severe or BG confirmed", "categories": [{"measurements": [{"groupId": "OG000", "value": "74"}, {"groupId": "OG001", "value": "65"}]}]}, {"title": "NN: Unclassifiable", "categories": [{"measurements": [{"groupId": "OG000", "value": "177"}, {"groupId": "OG001", "value": "175"}]}]}, {"title": "Not able to selftreat - unclassifiable", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}]}, {"type": "SECONDARY", "title": "Number of Treatment Emergent Hypoglycaemic Episodes According to the American Diabetes Association and Novo Nordisk Definition: Hypoglycaemic Episodes During First 2 Hours After Start of the Meal", "description": "Number of treatment emergent hypoglycaemic episodes according to the ADA and NN definitions were evaluated during the first 2 hours after start of the meal. The results are based on the on-treatment period. On-treatment period started from date of first dose of randomised NovoRapid/faster aspart and to 7 days after day of last dose or day before initiation of ancillary treatment.", "populationDescription": "Overall number of participants analyzed = safety analysis set (SAS) which comprised all randomised participants. Number Analyzed = number of participants with available data.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Number of hypoglycaemic episodes", "timeFrame": "Weeks 0-16", "groups": [{"id": "OG000", "title": "Faster Aspart", "description": "Participants received Faster aspart along with insulin degludec (basal-bolus regimen) with or without metformin for 16 weeks. Before the treatment period was a 12-week run-in period in which the investigator optimised basal insulin dose. Insulin degludec dose was adjusted weekly by the investigator in the run-in period based on the mean of three pre-breakfast SMPG values measured on the last two days prior to and on the day of contact. If one of the SMPG values were below target (\\< 4.0 mmol/L or 71 mg/dL) then the insulin degludec dose was adjusted according to the titration guideline specified in the protocol. Faster aspart was titrated from randomisation (week 0) and onwards, twice weekly to reach the glycaemic target of pre-prandial and bedtime PG between 4.0-6.0 mmol/L (71 - 108 mg/dL) in a treat-to-target fashion."}, {"id": "OG001", "title": "NovoRapid", "description": "Participants received Insulin aspart (NovoRapid\u00ae/NovoLog\u00ae: basal-bolus regimen) along with insulin degludec (basal-bolus regimen) with or without metformin for 16 weeks. Before the treatment period was a 12-week run-in period in which the investigator optimised basal insulin dose. Insulin degludec dose was adjusted weekly by the investigator in the run-in period based on the mean of three pre-breakfast SMPG values measured on the last two days prior to and on the day of contact. If one of the SMPG values were below target (\\< 4.0 mmol/L or 71 mg/dL) then the insulin degludec dose was adjusted according to the titration guideline specified in the protocol. NovoRapid was titrated from randomisation (week 0) and onwards, twice weekly to reach the glycaemic target of pre-prandial and bedtime PG between 4.0-6.0 mmol/L (71 - 108 mg/dL) in a treat-to-target fashion."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "544"}, {"groupId": "OG001", "value": "544"}]}], "classes": [{"title": "ADA: Severe", "categories": [{"measurements": [{"groupId": "OG000", "value": "2"}, {"groupId": "OG001", "value": "1"}]}]}, {"title": "ADA: Documented symptomatic", "categories": [{"measurements": [{"groupId": "OG000", "value": "465"}, {"groupId": "OG001", "value": "446"}]}]}, {"title": "ADA: Asymptomatic", "categories": [{"measurements": [{"groupId": "OG000", "value": "201"}, {"groupId": "OG001", "value": "159"}]}]}, {"title": "ADA: Probable symptomatic", "categories": [{"measurements": [{"groupId": "OG000", "value": "16"}, {"groupId": "OG001", "value": "11"}]}]}, {"title": "ADA: Pseudo", "categories": [{"measurements": [{"groupId": "OG000", "value": "10"}, {"groupId": "OG001", "value": "7"}]}]}, {"title": "ADA: Unclassifiable", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "NN: BG confirmed", "categories": [{"measurements": [{"groupId": "OG000", "value": "233"}, {"groupId": "OG001", "value": "246"}]}]}, {"title": "NN: Severe or BG confirmed symptomatic", "categories": [{"measurements": [{"groupId": "OG000", "value": "181"}, {"groupId": "OG001", "value": "212"}]}]}, {"title": "NN: Severe or BG confirmed", "categories": [{"measurements": [{"groupId": "OG000", "value": "235"}, {"groupId": "OG001", "value": "247"}]}]}, {"title": "NN: Unclassifiable", "categories": [{"measurements": [{"groupId": "OG000", "value": "459"}, {"groupId": "OG001", "value": "377"}]}]}, {"title": "Not able to selftreat - unclassifiable", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}]}, {"type": "SECONDARY", "title": "Number of Treatment Emergent Hypoglycaemic Episodes According to the American Diabetes Association and Novo Nordisk Definition: Hypoglycaemic Episodes During First 4 Hours After Start of the Meal", "description": "Number of treatment emergent hypoglycaemic episodes according to the ADA and NN definitions were evaluated during the first 4 hours after start of the meal. The results are based on the on-treatment period. On-treatment period started from date of first dose of randomised NovoRapid/faster aspart and to 7 days after day of last dose or day before initiation of ancillary treatment.", "populationDescription": "Overall number of participants analyzed = safety analysis set (SAS) which comprised all randomised participants. Number Analyzed = number of participants with available data.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Number of hypoglycaemic episodes", "timeFrame": "Weeks 0-16", "groups": [{"id": "OG000", "title": "Faster Aspart", "description": "Participants received Faster aspart along with insulin degludec (basal-bolus regimen) with or without metformin for 16 weeks. Before the treatment period was a 12-week run-in period in which the investigator optimised basal insulin dose. Insulin degludec dose was adjusted weekly by the investigator in the run-in period based on the mean of three pre-breakfast SMPG values measured on the last two days prior to and on the day of contact. If one of the SMPG values were below target (\\< 4.0 mmol/L or 71 mg/dL) then the insulin degludec dose was adjusted according to the titration guideline specified in the protocol. Faster aspart was titrated from randomisation (week 0) and onwards, twice weekly to reach the glycaemic target of pre-prandial and bedtime PG between 4.0-6.0 mmol/L (71 - 108 mg/dL) in a treat-to-target fashion."}, {"id": "OG001", "title": "NovoRapid", "description": "Participants received Insulin aspart (NovoRapid\u00ae/NovoLog\u00ae: basal-bolus regimen) along with insulin degludec (basal-bolus regimen) with or without metformin for 16 weeks. Before the treatment period was a 12-week run-in period in which the investigator optimised basal insulin dose. Insulin degludec dose was adjusted weekly by the investigator in the run-in period based on the mean of three pre-breakfast SMPG values measured on the last two days prior to and on the day of contact. If one of the SMPG values were below target (\\< 4.0 mmol/L or 71 mg/dL) then the insulin degludec dose was adjusted according to the titration guideline specified in the protocol. NovoRapid was titrated from randomisation (week 0) and onwards, twice weekly to reach the glycaemic target of pre-prandial and bedtime PG between 4.0-6.0 mmol/L (71 - 108 mg/dL) in a treat-to-target fashion."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "544"}, {"groupId": "OG001", "value": "544"}]}], "classes": [{"title": "ADA: Severe", "categories": [{"measurements": [{"groupId": "OG000", "value": "6"}, {"groupId": "OG001", "value": "9"}]}]}, {"title": "ADA: Documented symptomatic", "categories": [{"measurements": [{"groupId": "OG000", "value": "1627"}, {"groupId": "OG001", "value": "1882"}]}]}, {"title": "ADA: Asymptomatic", "categories": [{"measurements": [{"groupId": "OG000", "value": "852"}, {"groupId": "OG001", "value": "744"}]}]}, {"title": "ADA: Probable symptomatic", "categories": [{"measurements": [{"groupId": "OG000", "value": "37"}, {"groupId": "OG001", "value": "27"}]}]}, {"title": "ADA: Pseudo", "categories": [{"measurements": [{"groupId": "OG000", "value": "55"}, {"groupId": "OG001", "value": "26"}]}]}, {"title": "ADA: Unclassifiable", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "NN: BG confirmed", "categories": [{"measurements": [{"groupId": "OG000", "value": "762"}, {"groupId": "OG001", "value": "965"}]}]}, {"title": "NN: Severe or BG confirmed symptomatic", "categories": [{"measurements": [{"groupId": "OG000", "value": "557"}, {"groupId": "OG001", "value": "820"}]}]}, {"title": "NN: Severe or BG confirmed", "categories": [{"measurements": [{"groupId": "OG000", "value": "768"}, {"groupId": "OG001", "value": "974"}]}]}, {"title": "NN: Unclassifiable", "categories": [{"measurements": [{"groupId": "OG000", "value": "1809"}, {"groupId": "OG001", "value": "1714"}]}]}, {"title": "Not able to selftreat - unclassifiable", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}]}, {"type": "SECONDARY", "title": "Number of Treatment Emergent Hypoglycaemic Episodes According to the American Diabetes Association and NN Definition: Hypoglycaemic Episodes Occurring Between 2 to 4 Hours After Start of the Meal", "description": "Number of treatment emergent hypoglycaemic episodes according to the ADA and NN definitions were evaluated between 2 to 4 hours after start of the meal. The results are based on the on-treatment period. On-treatment period started from date of first dose of randomised NovoRapid/faster aspart and to 7 days after day of last dose or day before initiation of ancillary treatment.", "populationDescription": "Overall number of participants analyzed = safety analysis set (SAS) which comprised all randomised participants. Number Analyzed = number of participants with available data.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Number of hypoglycaemic episodes", "timeFrame": "Weeks 0-16", "groups": [{"id": "OG000", "title": "Faster Aspart", "description": "Participants received Faster aspart along with insulin degludec (basal-bolus regimen) with or without metformin for 16 weeks. Before the treatment period was a 12-week run-in period in which the investigator optimised basal insulin dose. Insulin degludec dose was adjusted weekly by the investigator in the run-in period based on the mean of three pre-breakfast SMPG values measured on the last two days prior to and on the day of contact. If one of the SMPG values were below target (\\< 4.0 mmol/L or 71 mg/dL) then the insulin degludec dose was adjusted according to the titration guideline specified in the protocol. Faster aspart was titrated from randomisation (week 0) and onwards, twice weekly to reach the glycaemic target of pre-prandial and bedtime PG between 4.0-6.0 mmol/L (71 - 108 mg/dL) in a treat-to-target fashion."}, {"id": "OG001", "title": "NovoRapid", "description": "Participants received Insulin aspart (NovoRapid\u00ae/NovoLog\u00ae: basal-bolus regimen) along with insulin degludec (basal-bolus regimen) with or without metformin for 16 weeks. Before the treatment period was a 12-week run-in period in which the investigator optimised basal insulin dose. Insulin degludec dose was adjusted weekly by the investigator in the run-in period based on the mean of three pre-breakfast SMPG values measured on the last two days prior to and on the day of contact. If one of the SMPG values were below target (\\< 4.0 mmol/L or 71 mg/dL) then the insulin degludec dose was adjusted according to the titration guideline specified in the protocol. NovoRapid was titrated from randomisation (week 0) and onwards, twice weekly to reach the glycaemic target of pre-prandial and bedtime PG between 4.0-6.0 mmol/L (71 - 108 mg/dL) in a treat-to-target fashion."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "544"}, {"groupId": "OG001", "value": "544"}]}], "classes": [{"title": "ADA: Severe", "categories": [{"measurements": [{"groupId": "OG000", "value": "4"}, {"groupId": "OG001", "value": "8"}]}]}, {"title": "ADA: Documented symptomatic", "categories": [{"measurements": [{"groupId": "OG000", "value": "1162"}, {"groupId": "OG001", "value": "1436"}]}]}, {"title": "ADA: Asymptomatic", "categories": [{"measurements": [{"groupId": "OG000", "value": "651"}, {"groupId": "OG001", "value": "585"}]}]}, {"title": "ADA: Probable symptomatic", "categories": [{"measurements": [{"groupId": "OG000", "value": "21"}, {"groupId": "OG001", "value": "16"}]}]}, {"title": "ADA: Pseudo", "categories": [{"measurements": [{"groupId": "OG000", "value": "45"}, {"groupId": "OG001", "value": "19"}]}]}, {"title": "ADA: Unclassifiable", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "NN: BG confirmed", "categories": [{"measurements": [{"groupId": "OG000", "value": "529"}, {"groupId": "OG001", "value": "719"}]}]}, {"title": "NN: Severe or BG confirmed symptomatic", "categories": [{"measurements": [{"groupId": "OG000", "value": "376"}, {"groupId": "OG001", "value": "608"}]}]}, {"title": "NN: Severe or BG confirmed", "categories": [{"measurements": [{"groupId": "OG000", "value": "533"}, {"groupId": "OG001", "value": "727"}]}]}, {"title": "NN: Unclassifiable", "categories": [{"measurements": [{"groupId": "OG000", "value": "1350"}, {"groupId": "OG001", "value": "1337"}]}]}, {"title": "Not able to selftreat - unclassifiable", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Physical Examination", "description": "Participants with physical examination findings, normal, abnormal NCS (non- clinically significant) and abnormal CS (clinically significant) at baseline (week 0) and week 16 presented. Results are based on the data from the on-treatment observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of rescue medication and/or premature discontinuation of trial product. Results are presented for the following examinations: 1) Cardiovascular system 2) Central \\& Peripheral nervous system 3) Gastrointestinal system incl. mouth 4) Head, ears, eyes, nose, throat and neck 5) Musculoskeletal system 6) Respiratory system 7) Skin", "populationDescription": "Overall number of participants analyzed = safety analysis set (SAS) which comprised all randomised participants. Number Analyzed = number of participants with available data.", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "timeFrame": "Week 0, week 16", "groups": [{"id": "OG000", "title": "Faster Aspart", "description": "Participants received Faster aspart along with insulin degludec (basal-bolus regimen) with or without metformin for 16 weeks. Before the treatment period was a 12-week run-in period in which the investigator optimised basal insulin dose. Insulin degludec dose was adjusted weekly by the investigator in the run-in period based on the mean of three pre-breakfast SMPG values measured on the last two days prior to and on the day of contact. If one of the SMPG values were below target (\\< 4.0 mmol/L or 71 mg/dL) then the insulin degludec dose was adjusted according to the titration guideline specified in the protocol. Faster aspart was titrated from randomisation (week 0) and onwards, twice weekly to reach the glycaemic target of pre-prandial and bedtime PG between 4.0-6.0 mmol/L (71 - 108 mg/dL) in a treat-to-target fashion."}, {"id": "OG001", "title": "NovoRapid", "description": "Participants received Insulin aspart (NovoRapid\u00ae/NovoLog\u00ae: basal-bolus regimen) along with insulin degludec (basal-bolus regimen) with or without metformin for 16 weeks. Before the treatment period was a 12-week run-in period in which the investigator optimised basal insulin dose. Insulin degludec dose was adjusted weekly by the investigator in the run-in period based on the mean of three pre-breakfast SMPG values measured on the last two days prior to and on the day of contact. If one of the SMPG values were below target (\\< 4.0 mmol/L or 71 mg/dL) then the insulin degludec dose was adjusted according to the titration guideline specified in the protocol. NovoRapid was titrated from randomisation (week 0) and onwards, twice weekly to reach the glycaemic target of pre-prandial and bedtime PG between 4.0-6.0 mmol/L (71 - 108 mg/dL) in a treat-to-target fashion."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "544"}, {"groupId": "OG001", "value": "544"}]}], "classes": [{"title": "Cardiovascular system (week 0)", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "544"}, {"groupId": "OG001", "value": "544"}]}], "categories": [{"title": "Normal", "measurements": [{"groupId": "OG000", "value": "459"}, {"groupId": "OG001", "value": "460"}]}, {"title": "Abnormal NCS", "measurements": [{"groupId": "OG000", "value": "79"}, {"groupId": "OG001", "value": "79"}]}, {"title": "Abnormal CS", "measurements": [{"groupId": "OG000", "value": "6"}, {"groupId": "OG001", "value": "5"}]}]}, {"title": "Cardiovascular system (week 16)", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "525"}, {"groupId": "OG001", "value": "533"}]}], "categories": [{"title": "Normal", "measurements": [{"groupId": "OG000", "value": "448"}, {"groupId": "OG001", "value": "457"}]}, {"title": "Abnormal NCS", "measurements": [{"groupId": "OG000", "value": "71"}, {"groupId": "OG001", "value": "72"}]}, {"title": "Abnormal CS", "measurements": [{"groupId": "OG000", "value": "6"}, {"groupId": "OG001", "value": "4"}]}]}, {"title": "Central and Peripheral nervous sys. (week 0)", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "544"}, {"groupId": "OG001", "value": "544"}]}], "categories": [{"title": "Normal", "measurements": [{"groupId": "OG000", "value": "398"}, {"groupId": "OG001", "value": "404"}]}, {"title": "Abnormal NCS", "measurements": [{"groupId": "OG000", "value": "133"}, {"groupId": "OG001", "value": "127"}]}, {"title": "Abnormal CS", "measurements": [{"groupId": "OG000", "value": "13"}, {"groupId": "OG001", "value": "13"}]}]}, {"title": "Central and Peripheral nervous sys. (week 16)", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "525"}, {"groupId": "OG001", "value": "533"}]}], "categories": [{"title": "Normal", "measurements": [{"groupId": "OG000", "value": "383"}, {"groupId": "OG001", "value": "400"}]}, {"title": "Abnormal NCS", "measurements": [{"groupId": "OG000", "value": "128"}, {"groupId": "OG001", "value": "122"}]}, {"title": "Abnormal CS", "measurements": [{"groupId": "OG000", "value": "14"}, {"groupId": "OG001", "value": "11"}]}]}, {"title": "Gastrointestinal sys. including mouth (Week 0)", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "544"}, {"groupId": "OG001", "value": "544"}]}], "categories": [{"title": "Normal", "measurements": [{"groupId": "OG000", "value": "491"}, {"groupId": "OG001", "value": "485"}]}, {"title": "Abnormal NCS", "measurements": [{"groupId": "OG000", "value": "53"}, {"groupId": "OG001", "value": "59"}]}, {"title": "Abnormal CS", "measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Gastrointestinal sys. including mouth (week 16)", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "525"}, {"groupId": "OG001", "value": "533"}]}], "categories": [{"title": "Normal", "measurements": [{"groupId": "OG000", "value": "480"}, {"groupId": "OG001", "value": "476"}]}, {"title": "Abnormal NCS", "measurements": [{"groupId": "OG000", "value": "45"}, {"groupId": "OG001", "value": "57"}]}, {"title": "Abnormal CS", "measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Head, ears, eyes, nose, throat, neck (week 0)", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "544"}, {"groupId": "OG001", "value": "544"}]}], "categories": [{"title": "Normal", "measurements": [{"groupId": "OG000", "value": "498"}, {"groupId": "OG001", "value": "492"}]}, {"title": "Abnormal NCS", "measurements": [{"groupId": "OG000", "value": "43"}, {"groupId": "OG001", "value": "48"}]}, {"title": "Abnormal CS", "measurements": [{"groupId": "OG000", "value": "3"}, {"groupId": "OG001", "value": "4"}]}]}, {"title": "Head, ears, eyes, nose, throat, neck (week 16)", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "525"}, {"groupId": "OG001", "value": "533"}]}], "categories": [{"title": "Normal", "measurements": [{"groupId": "OG000", "value": "485"}, {"groupId": "OG001", "value": "483"}]}, {"title": "Abnormal NCS", "measurements": [{"groupId": "OG000", "value": "40"}, {"groupId": "OG001", "value": "49"}]}, {"title": "Abnormal CS", "measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "1"}]}]}, {"title": "Musculoskeletal system (week 0)", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "544"}, {"groupId": "OG001", "value": "544"}]}], "categories": [{"title": "Normal", "measurements": [{"groupId": "OG000", "value": "504"}, {"groupId": "OG001", "value": "496"}]}, {"title": "Abnormal NCS", "measurements": [{"groupId": "OG000", "value": "36"}, {"groupId": "OG001", "value": "42"}]}, {"title": "Abnormal CS", "measurements": [{"groupId": "OG000", "value": "4"}, {"groupId": "OG001", "value": "6"}]}]}, {"title": "Musculoskeletal system (week 16)", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "525"}, {"groupId": "OG001", "value": "533"}]}], "categories": [{"title": "Normal", "measurements": [{"groupId": "OG000", "value": "489"}, {"groupId": "OG001", "value": "494"}]}, {"title": "Abnormal NCS", "measurements": [{"groupId": "OG000", "value": "32"}, {"groupId": "OG001", "value": "33"}]}, {"title": "Abnormal CS", "measurements": [{"groupId": "OG000", "value": "4"}, {"groupId": "OG001", "value": "6"}]}]}, {"title": "Respiratory system (week 0)", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "544"}, {"groupId": "OG001", "value": "544"}]}], "categories": [{"title": "Normal", "measurements": [{"groupId": "OG000", "value": "535"}, {"groupId": "OG001", "value": "534"}]}, {"title": "Abnormal NCS", "measurements": [{"groupId": "OG000", "value": "9"}, {"groupId": "OG001", "value": "9"}]}, {"title": "Abnormal CS", "measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "1"}]}]}, {"title": "Respiratory system (week 16)", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "525"}, {"groupId": "OG001", "value": "533"}]}], "categories": [{"title": "Normal", "measurements": [{"groupId": "OG000", "value": "520"}, {"groupId": "OG001", "value": "517"}]}, {"title": "Abnormal NCS", "measurements": [{"groupId": "OG000", "value": "5"}, {"groupId": "OG001", "value": "14"}]}, {"title": "Abnormal CS", "measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "2"}]}]}, {"title": "Skin (week 0)", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "544"}, {"groupId": "OG001", "value": "544"}]}], "categories": [{"title": "Normal", "measurements": [{"groupId": "OG000", "value": "438"}, {"groupId": "OG001", "value": "429"}]}, {"title": "Abnormal NCS", "measurements": [{"groupId": "OG000", "value": "96"}, {"groupId": "OG001", "value": "108"}]}, {"title": "Abnormal CS", "measurements": [{"groupId": "OG000", "value": "10"}, {"groupId": "OG001", "value": "7"}]}]}, {"title": "Skin (week 16)", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "525"}, {"groupId": "OG001", "value": "533"}]}], "categories": [{"title": "Normal", "measurements": [{"groupId": "OG000", "value": "418"}, {"groupId": "OG001", "value": "430"}]}, {"title": "Abnormal NCS", "measurements": [{"groupId": "OG000", "value": "98"}, {"groupId": "OG001", "value": "98"}]}, {"title": "Abnormal CS", "measurements": [{"groupId": "OG000", "value": "9"}, {"groupId": "OG001", "value": "5"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Vital Signs: Systolic and Diastolic Blood Presure", "description": "Change in vital signs - systolic and diastolic blood pressure from baseline (week 0) was evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period. On-treatment period started from date of first dose of randomised NovoRapid/faster aspart and to 7 days after day of last dose or day before initiation of ancillary treatment.", "populationDescription": "Overall number of participants analyzed = number of participants with available data.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mmHg", "timeFrame": "Week 0, week 16", "groups": [{"id": "OG000", "title": "Faster Aspart", "description": "Participants received Faster aspart along with insulin degludec (basal-bolus regimen) with or without metformin for 16 weeks. Before the treatment period was a 12-week run-in period in which the investigator optimised basal insulin dose. Insulin degludec dose was adjusted weekly by the investigator in the run-in period based on the mean of three pre-breakfast SMPG values measured on the last two days prior to and on the day of contact. If one of the SMPG values were below target (\\< 4.0 mmol/L or 71 mg/dL) then the insulin degludec dose was adjusted according to the titration guideline specified in the protocol. Faster aspart was titrated from randomisation (week 0) and onwards, twice weekly to reach the glycaemic target of pre-prandial and bedtime PG between 4.0-6.0 mmol/L (71 - 108 mg/dL) in a treat-to-target fashion."}, {"id": "OG001", "title": "NovoRapid", "description": "Participants received Insulin aspart (NovoRapid\u00ae/NovoLog\u00ae: basal-bolus regimen) along with insulin degludec (basal-bolus regimen) with or without metformin for 16 weeks. Before the treatment period was a 12-week run-in period in which the investigator optimised basal insulin dose. Insulin degludec dose was adjusted weekly by the investigator in the run-in period based on the mean of three pre-breakfast SMPG values measured on the last two days prior to and on the day of contact. If one of the SMPG values were below target (\\< 4.0 mmol/L or 71 mg/dL) then the insulin degludec dose was adjusted according to the titration guideline specified in the protocol. NovoRapid was titrated from randomisation (week 0) and onwards, twice weekly to reach the glycaemic target of pre-prandial and bedtime PG between 4.0-6.0 mmol/L (71 - 108 mg/dL) in a treat-to-target fashion."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "525"}, {"groupId": "OG001", "value": "533"}]}], "classes": [{"title": "Systolic blood pressure", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.4", "spread": "14.0"}, {"groupId": "OG001", "value": "-1.2", "spread": "14.8"}]}]}, {"title": "Diastolic blood pressure", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.4", "spread": "8.9"}, {"groupId": "OG001", "value": "-0.7", "spread": "8.9"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Vital Signs: Pulse", "description": "Change in vital signs - pulse from baseline (week 0) was evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period. On-treatment period started from date of first dose of randomised NovoRapid/faster aspart and to 7 days after day of last dose or day before initiation of ancillary treatment.", "populationDescription": "Overall number of participants analyzed = number of participants with available data.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Beats per min", "timeFrame": "Week 0, week 16", "groups": [{"id": "OG000", "title": "Faster Aspart", "description": "Participants received Faster aspart along with insulin degludec (basal-bolus regimen) with or without metformin for 16 weeks. Before the treatment period was a 12-week run-in period in which the investigator optimised basal insulin dose. Insulin degludec dose was adjusted weekly by the investigator in the run-in period based on the mean of three pre-breakfast SMPG values measured on the last two days prior to and on the day of contact. If one of the SMPG values were below target (\\< 4.0 mmol/L or 71 mg/dL) then the insulin degludec dose was adjusted according to the titration guideline specified in the protocol. Faster aspart was titrated from randomisation (week 0) and onwards, twice weekly to reach the glycaemic target of pre-prandial and bedtime PG between 4.0-6.0 mmol/L (71 - 108 mg/dL) in a treat-to-target fashion."}, {"id": "OG001", "title": "NovoRapid", "description": "Participants received Insulin aspart (NovoRapid\u00ae/NovoLog\u00ae: basal-bolus regimen) along with insulin degludec (basal-bolus regimen) with or without metformin for 16 weeks. Before the treatment period was a 12-week run-in period in which the investigator optimised basal insulin dose. Insulin degludec dose was adjusted weekly by the investigator in the run-in period based on the mean of three pre-breakfast SMPG values measured on the last two days prior to and on the day of contact. If one of the SMPG values were below target (\\< 4.0 mmol/L or 71 mg/dL) then the insulin degludec dose was adjusted according to the titration guideline specified in the protocol. NovoRapid was titrated from randomisation (week 0) and onwards, twice weekly to reach the glycaemic target of pre-prandial and bedtime PG between 4.0-6.0 mmol/L (71 - 108 mg/dL) in a treat-to-target fashion."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "525"}, {"groupId": "OG001", "value": "533"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.5", "spread": "9.0"}, {"groupId": "OG001", "value": "0.03", "spread": "8.9"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Electrocardiogram (ECG)", "description": "Changes in electrocardiogram (ECG) from baseline (week 0) were evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period. On-treatment period started from date of first dose of randomised NovoRapid/faster aspart and to 7 days after day of last dose or day before initiation of ancillary treatment.", "populationDescription": "Overall number of participants analyzed = safety analysis set (SAS) which comprised all randomised participants. Number Analyzed = number of participants with available data.", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "timeFrame": "Week 0, week 16", "groups": [{"id": "OG000", "title": "Faster Aspart", "description": "Participants received Faster aspart along with insulin degludec (basal-bolus regimen) with or without metformin for 16 weeks. Before the treatment period was a 12-week run-in period in which the investigator optimised basal insulin dose. Insulin degludec dose was adjusted weekly by the investigator in the run-in period based on the mean of three pre-breakfast SMPG values measured on the last two days prior to and on the day of contact. If one of the SMPG values were below target (\\< 4.0 mmol/L or 71 mg/dL) then the insulin degludec dose was adjusted according to the titration guideline specified in the protocol. Faster aspart was titrated from randomisation (week 0) and onwards, twice weekly to reach the glycaemic target of pre-prandial and bedtime PG between 4.0-6.0 mmol/L (71 - 108 mg/dL) in a treat-to-target fashion."}, {"id": "OG001", "title": "NovoRapid", "description": "Participants received Insulin aspart (NovoRapid\u00ae/NovoLog\u00ae: basal-bolus regimen) along with insulin degludec (basal-bolus regimen) with or without metformin for 16 weeks. Before the treatment period was a 12-week run-in period in which the investigator optimised basal insulin dose. Insulin degludec dose was adjusted weekly by the investigator in the run-in period based on the mean of three pre-breakfast SMPG values measured on the last two days prior to and on the day of contact. If one of the SMPG values were below target (\\< 4.0 mmol/L or 71 mg/dL) then the insulin degludec dose was adjusted according to the titration guideline specified in the protocol. NovoRapid was titrated from randomisation (week 0) and onwards, twice weekly to reach the glycaemic target of pre-prandial and bedtime PG between 4.0-6.0 mmol/L (71 - 108 mg/dL) in a treat-to-target fashion."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "544"}, {"groupId": "OG001", "value": "544"}]}], "classes": [{"title": "Week 0", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "544"}, {"groupId": "OG001", "value": "544"}]}], "categories": [{"title": "Normal", "measurements": [{"groupId": "OG000", "value": "287"}, {"groupId": "OG001", "value": "270"}]}, {"title": "Abnormal NCS", "measurements": [{"groupId": "OG000", "value": "252"}, {"groupId": "OG001", "value": "264"}]}, {"title": "Abnormal CS", "measurements": [{"groupId": "OG000", "value": "5"}, {"groupId": "OG001", "value": "10"}]}]}, {"title": "Week 16", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "525"}, {"groupId": "OG001", "value": "533"}]}], "categories": [{"title": "Normal", "measurements": [{"groupId": "OG000", "value": "274"}, {"groupId": "OG001", "value": "272"}]}, {"title": "Abnormal NCS", "measurements": [{"groupId": "OG000", "value": "245"}, {"groupId": "OG001", "value": "253"}]}, {"title": "Abnormal CS", "measurements": [{"groupId": "OG000", "value": "6"}, {"groupId": "OG001", "value": "8"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Fundoscopy/Fundus Photography", "description": "Changes in fundoscopy/fundus photography from baseline (week 0) were evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period. On-treatment period started from date of first dose of randomised NovoRapid/faster aspart and to 7 days after day of last dose or day before initiation of ancillary treatment.", "populationDescription": "Overall number of participants analyzed = safety analysis set (SAS) which comprised all randomised participants. Number Analyzed = number of participants with available data.", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "timeFrame": "Week 0, week 16", "groups": [{"id": "OG000", "title": "Faster Aspart", "description": "Participants received Faster aspart along with insulin degludec (basal-bolus regimen) with or without metformin for 16 weeks. Before the treatment period was a 12-week run-in period in which the investigator optimised basal insulin dose. Insulin degludec dose was adjusted weekly by the investigator in the run-in period based on the mean of three pre-breakfast SMPG values measured on the last two days prior to and on the day of contact. If one of the SMPG values were below target (\\< 4.0 mmol/L or 71 mg/dL) then the insulin degludec dose was adjusted according to the titration guideline specified in the protocol. Faster aspart was titrated from randomisation (week 0) and onwards, twice weekly to reach the glycaemic target of pre-prandial and bedtime PG between 4.0-6.0 mmol/L (71 - 108 mg/dL) in a treat-to-target fashion."}, {"id": "OG001", "title": "NovoRapid", "description": "Participants received Insulin aspart (NovoRapid\u00ae/NovoLog\u00ae: basal-bolus regimen) along with insulin degludec (basal-bolus regimen) with or without metformin for 16 weeks. Before the treatment period was a 12-week run-in period in which the investigator optimised basal insulin dose. Insulin degludec dose was adjusted weekly by the investigator in the run-in period based on the mean of three pre-breakfast SMPG values measured on the last two days prior to and on the day of contact. If one of the SMPG values were below target (\\< 4.0 mmol/L or 71 mg/dL) then the insulin degludec dose was adjusted according to the titration guideline specified in the protocol. NovoRapid was titrated from randomisation (week 0) and onwards, twice weekly to reach the glycaemic target of pre-prandial and bedtime PG between 4.0-6.0 mmol/L (71 - 108 mg/dL) in a treat-to-target fashion."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "544"}, {"groupId": "OG001", "value": "544"}]}], "classes": [{"title": "Left eye (week 0)", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "544"}, {"groupId": "OG001", "value": "543"}]}], "categories": [{"title": "Normal", "measurements": [{"groupId": "OG000", "value": "225"}, {"groupId": "OG001", "value": "219"}]}, {"title": "Abnormal NCS", "measurements": [{"groupId": "OG000", "value": "287"}, {"groupId": "OG001", "value": "297"}]}, {"title": "Abnormal CS", "measurements": [{"groupId": "OG000", "value": "32"}, {"groupId": "OG001", "value": "27"}]}]}, {"title": "Left eye (week 16)", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "514"}, {"groupId": "OG001", "value": "516"}]}], "categories": [{"title": "Normal", "measurements": [{"groupId": "OG000", "value": "205"}, {"groupId": "OG001", "value": "198"}]}, {"title": "Abnormal NCS", "measurements": [{"groupId": "OG000", "value": "278"}, {"groupId": "OG001", "value": "288"}]}, {"title": "Abnormal CS", "measurements": [{"groupId": "OG000", "value": "31"}, {"groupId": "OG001", "value": "30"}]}]}, {"title": "Right eye (week 0)", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "544"}, {"groupId": "OG001", "value": "544"}]}], "categories": [{"title": "Normal", "measurements": [{"groupId": "OG000", "value": "224"}, {"groupId": "OG001", "value": "217"}]}, {"title": "Abnormal NCS", "measurements": [{"groupId": "OG000", "value": "288"}, {"groupId": "OG001", "value": "300"}]}, {"title": "Abnormal CS", "measurements": [{"groupId": "OG000", "value": "32"}, {"groupId": "OG001", "value": "27"}]}]}, {"title": "Right eye (week 16)", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "514"}, {"groupId": "OG001", "value": "517"}]}], "categories": [{"title": "Normal", "measurements": [{"groupId": "OG000", "value": "208"}, {"groupId": "OG001", "value": "194"}]}, {"title": "Abnormal NCS", "measurements": [{"groupId": "OG000", "value": "276"}, {"groupId": "OG001", "value": "297"}]}, {"title": "Abnormal CS", "measurements": [{"groupId": "OG000", "value": "30"}, {"groupId": "OG001", "value": "26"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Haematology - Haematocrit", "description": "Changes in haematology - haematocrit from baseline (week 0) were evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period. On-treatment period started from date of first dose of randomised NovoRapid/faster aspart and to 7 days after day of last dose or day before initiation of ancillary treatment.", "populationDescription": "Overall number of participants analyzed = number of participants with available data.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Percentage", "timeFrame": "Week 0, week 16", "groups": [{"id": "OG000", "title": "Faster Aspart", "description": "Participants received Faster aspart along with insulin degludec (basal-bolus regimen) with or without metformin for 16 weeks. Before the treatment period was a 12-week run-in period in which the investigator optimised basal insulin dose. Insulin degludec dose was adjusted weekly by the investigator in the run-in period based on the mean of three pre-breakfast SMPG values measured on the last two days prior to and on the day of contact. If one of the SMPG values were below target (\\< 4.0 mmol/L or 71 mg/dL) then the insulin degludec dose was adjusted according to the titration guideline specified in the protocol. Faster aspart was titrated from randomisation (week 0) and onwards, twice weekly to reach the glycaemic target of pre-prandial and bedtime PG between 4.0-6.0 mmol/L (71 - 108 mg/dL) in a treat-to-target fashion."}, {"id": "OG001", "title": "NovoRapid", "description": "Participants received Insulin aspart (NovoRapid\u00ae/NovoLog\u00ae: basal-bolus regimen) along with insulin degludec (basal-bolus regimen) with or without metformin for 16 weeks. Before the treatment period was a 12-week run-in period in which the investigator optimised basal insulin dose. Insulin degludec dose was adjusted weekly by the investigator in the run-in period based on the mean of three pre-breakfast SMPG values measured on the last two days prior to and on the day of contact. If one of the SMPG values were below target (\\< 4.0 mmol/L or 71 mg/dL) then the insulin degludec dose was adjusted according to the titration guideline specified in the protocol. NovoRapid was titrated from randomisation (week 0) and onwards, twice weekly to reach the glycaemic target of pre-prandial and bedtime PG between 4.0-6.0 mmol/L (71 - 108 mg/dL) in a treat-to-target fashion."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "532"}, {"groupId": "OG001", "value": "536"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.48", "spread": "2.47"}, {"groupId": "OG001", "value": "0.35", "spread": "2.47"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Haematology - Haemoglobin", "description": "Changes in haematology - haemoglobin from baseline (week 0) were evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period. On-treatment period started from date of first dose of randomised NovoRapid/faster aspart and to 7 days after day of last dose or day before initiation of ancillary treatment.", "populationDescription": "Overall number of participants analyzed = number of participants with available data.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mmol/L", "timeFrame": "Week 0, week 16", "groups": [{"id": "OG000", "title": "Faster Aspart", "description": "Participants received Faster aspart along with insulin degludec (basal-bolus regimen) with or without metformin for 16 weeks. Before the treatment period was a 12-week run-in period in which the investigator optimised basal insulin dose. Insulin degludec dose was adjusted weekly by the investigator in the run-in period based on the mean of three pre-breakfast SMPG values measured on the last two days prior to and on the day of contact. If one of the SMPG values were below target (\\< 4.0 mmol/L or 71 mg/dL) then the insulin degludec dose was adjusted according to the titration guideline specified in the protocol. Faster aspart was titrated from randomisation (week 0) and onwards, twice weekly to reach the glycaemic target of pre-prandial and bedtime PG between 4.0-6.0 mmol/L (71 - 108 mg/dL) in a treat-to-target fashion."}, {"id": "OG001", "title": "NovoRapid", "description": "Participants received Insulin aspart (NovoRapid\u00ae/NovoLog\u00ae: basal-bolus regimen) along with insulin degludec (basal-bolus regimen) with or without metformin for 16 weeks. Before the treatment period was a 12-week run-in period in which the investigator optimised basal insulin dose. Insulin degludec dose was adjusted weekly by the investigator in the run-in period based on the mean of three pre-breakfast SMPG values measured on the last two days prior to and on the day of contact. If one of the SMPG values were below target (\\< 4.0 mmol/L or 71 mg/dL) then the insulin degludec dose was adjusted according to the titration guideline specified in the protocol. NovoRapid was titrated from randomisation (week 0) and onwards, twice weekly to reach the glycaemic target of pre-prandial and bedtime PG between 4.0-6.0 mmol/L (71 - 108 mg/dL) in a treat-to-target fashion."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "532"}, {"groupId": "OG001", "value": "536"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.02", "spread": "0.47"}, {"groupId": "OG001", "value": "-0.04", "spread": "0.43"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Haematology - Leukocytes", "description": "Changes in haematology - leukocytes from baseline (week 0) were evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period. On-treatment period started from date of first dose of randomised NovoRapid/faster aspart and to 7 days after day of last dose or day before initiation of ancillary treatment.", "populationDescription": "Overall number of participants analyzed = number of participants with available data.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "10^9 leukocytes/L", "timeFrame": "Week 0, week 16", "groups": [{"id": "OG000", "title": "Faster Aspart", "description": "Participants received Faster aspart along with insulin degludec (basal-bolus regimen) with or without metformin for 16 weeks. Before the treatment period was a 12-week run-in period in which the investigator optimised basal insulin dose. Insulin degludec dose was adjusted weekly by the investigator in the run-in period based on the mean of three pre-breakfast SMPG values measured on the last two days prior to and on the day of contact. If one of the SMPG values were below target (\\< 4.0 mmol/L or 71 mg/dL) then the insulin degludec dose was adjusted according to the titration guideline specified in the protocol. Faster aspart was titrated from randomisation (week 0) and onwards, twice weekly to reach the glycaemic target of pre-prandial and bedtime PG between 4.0-6.0 mmol/L (71 - 108 mg/dL) in a treat-to-target fashion."}, {"id": "OG001", "title": "NovoRapid", "description": "Participants received Insulin aspart (NovoRapid\u00ae/NovoLog\u00ae: basal-bolus regimen) along with insulin degludec (basal-bolus regimen) with or without metformin for 16 weeks. Before the treatment period was a 12-week run-in period in which the investigator optimised basal insulin dose. Insulin degludec dose was adjusted weekly by the investigator in the run-in period based on the mean of three pre-breakfast SMPG values measured on the last two days prior to and on the day of contact. If one of the SMPG values were below target (\\< 4.0 mmol/L or 71 mg/dL) then the insulin degludec dose was adjusted according to the titration guideline specified in the protocol. NovoRapid was titrated from randomisation (week 0) and onwards, twice weekly to reach the glycaemic target of pre-prandial and bedtime PG between 4.0-6.0 mmol/L (71 - 108 mg/dL) in a treat-to-target fashion."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "532"}, {"groupId": "OG001", "value": "536"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.01", "spread": "1.60"}, {"groupId": "OG001", "value": "-0.01", "spread": "1.35"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Haematology - Thrombocytes", "description": "Changes in haematology - thrombocytes from baseline (week 0) were evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period. On-treatment period started from date of first dose of randomised NovoRapid/faster aspart and to 7 days after day of last dose or day before initiation of ancillary treatment.", "populationDescription": "Overall number of participants analyzed = number of participants with available data.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "10^9 thrombocytes/L", "timeFrame": "Week 0, week 16", "groups": [{"id": "OG000", "title": "Faster Aspart", "description": "Participants received Faster aspart along with insulin degludec (basal-bolus regimen) with or without metformin for 16 weeks. Before the treatment period was a 12-week run-in period in which the investigator optimised basal insulin dose. Insulin degludec dose was adjusted weekly by the investigator in the run-in period based on the mean of three pre-breakfast SMPG values measured on the last two days prior to and on the day of contact. If one of the SMPG values were below target (\\< 4.0 mmol/L or 71 mg/dL) then the insulin degludec dose was adjusted according to the titration guideline specified in the protocol. Faster aspart was titrated from randomisation (week 0) and onwards, twice weekly to reach the glycaemic target of pre-prandial and bedtime PG between 4.0-6.0 mmol/L (71 - 108 mg/dL) in a treat-to-target fashion."}, {"id": "OG001", "title": "NovoRapid", "description": "Participants received Insulin aspart (NovoRapid\u00ae/NovoLog\u00ae: basal-bolus regimen) along with insulin degludec (basal-bolus regimen) with or without metformin for 16 weeks. Before the treatment period was a 12-week run-in period in which the investigator optimised basal insulin dose. Insulin degludec dose was adjusted weekly by the investigator in the run-in period based on the mean of three pre-breakfast SMPG values measured on the last two days prior to and on the day of contact. If one of the SMPG values were below target (\\< 4.0 mmol/L or 71 mg/dL) then the insulin degludec dose was adjusted according to the titration guideline specified in the protocol. NovoRapid was titrated from randomisation (week 0) and onwards, twice weekly to reach the glycaemic target of pre-prandial and bedtime PG between 4.0-6.0 mmol/L (71 - 108 mg/dL) in a treat-to-target fashion."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "531"}, {"groupId": "OG001", "value": "533"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.9", "spread": "37.1"}, {"groupId": "OG001", "value": "-1.3", "spread": "38.7"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Haematology - Erythrocytes", "description": "Changes in haematology - erythrocytes from baseline (week 0) were evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period. On-treatment period started from date of first dose of randomised NovoRapid/faster aspart and to 7 days after day of last dose or day before initiation of ancillary treatment.", "populationDescription": "Overall number of participants analyzed = number of participants with available data.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "10^12 erythrocytes/L", "timeFrame": "Week 0, week 16", "groups": [{"id": "OG000", "title": "Faster Aspart", "description": "Participants received Faster aspart along with insulin degludec (basal-bolus regimen) with or without metformin for 16 weeks. Before the treatment period was a 12-week run-in period in which the investigator optimised basal insulin dose. Insulin degludec dose was adjusted weekly by the investigator in the run-in period based on the mean of three pre-breakfast SMPG values measured on the last two days prior to and on the day of contact. If one of the SMPG values were below target (\\< 4.0 mmol/L or 71 mg/dL) then the insulin degludec dose was adjusted according to the titration guideline specified in the protocol. Faster aspart was titrated from randomisation (week 0) and onwards, twice weekly to reach the glycaemic target of pre-prandial and bedtime PG between 4.0-6.0 mmol/L (71 - 108 mg/dL) in a treat-to-target fashion."}, {"id": "OG001", "title": "NovoRapid", "description": "Participants received Insulin aspart (NovoRapid\u00ae/NovoLog\u00ae: basal-bolus regimen) along with insulin degludec (basal-bolus regimen) with or without metformin for 16 weeks. Before the treatment period was a 12-week run-in period in which the investigator optimised basal insulin dose. Insulin degludec dose was adjusted weekly by the investigator in the run-in period based on the mean of three pre-breakfast SMPG values measured on the last two days prior to and on the day of contact. If one of the SMPG values were below target (\\< 4.0 mmol/L or 71 mg/dL) then the insulin degludec dose was adjusted according to the titration guideline specified in the protocol. NovoRapid was titrated from randomisation (week 0) and onwards, twice weekly to reach the glycaemic target of pre-prandial and bedtime PG between 4.0-6.0 mmol/L (71 - 108 mg/dL) in a treat-to-target fashion."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "532"}, {"groupId": "OG001", "value": "536"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.02", "spread": "0.28"}, {"groupId": "OG001", "value": "-0.04", "spread": "0.27"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Biochemistry - Alanine Aminotransferase (ALT)", "description": "Changes in biochemistry - alanine aminotransferase from baseline (week 0) were evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period. On-treatment period started from date of first dose of randomised NovoRapid/faster aspart and to 7 days after day of last dose or day before initiation of ancillary treatment.", "populationDescription": "Overall number of participants analyzed = number of participants with available data.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "U/L", "timeFrame": "Week 0, week 16", "groups": [{"id": "OG000", "title": "Faster Aspart", "description": "Participants received Faster aspart along with insulin degludec (basal-bolus regimen) with or without metformin for 16 weeks. Before the treatment period was a 12-week run-in period in which the investigator optimised basal insulin dose. Insulin degludec dose was adjusted weekly by the investigator in the run-in period based on the mean of three pre-breakfast SMPG values measured on the last two days prior to and on the day of contact. If one of the SMPG values were below target (\\< 4.0 mmol/L or 71 mg/dL) then the insulin degludec dose was adjusted according to the titration guideline specified in the protocol. Faster aspart was titrated from randomisation (week 0) and onwards, twice weekly to reach the glycaemic target of pre-prandial and bedtime PG between 4.0-6.0 mmol/L (71 - 108 mg/dL) in a treat-to-target fashion."}, {"id": "OG001", "title": "NovoRapid", "description": "Participants received Insulin aspart (NovoRapid\u00ae/NovoLog\u00ae: basal-bolus regimen) along with insulin degludec (basal-bolus regimen) with or without metformin for 16 weeks. Before the treatment period was a 12-week run-in period in which the investigator optimised basal insulin dose. Insulin degludec dose was adjusted weekly by the investigator in the run-in period based on the mean of three pre-breakfast SMPG values measured on the last two days prior to and on the day of contact. If one of the SMPG values were below target (\\< 4.0 mmol/L or 71 mg/dL) then the insulin degludec dose was adjusted according to the titration guideline specified in the protocol. NovoRapid was titrated from randomisation (week 0) and onwards, twice weekly to reach the glycaemic target of pre-prandial and bedtime PG between 4.0-6.0 mmol/L (71 - 108 mg/dL) in a treat-to-target fashion."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "532"}, {"groupId": "OG001", "value": "536"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.1", "spread": "9.4"}, {"groupId": "OG001", "value": "3.1", "spread": "65.4"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Biochemistry - Alkaline Phosphatase", "description": "Changes in biochemistry - alkaline phosphatase from baseline (week 0) were evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period. On-treatment period started from date of first dose of randomised NovoRapid/faster aspart and to 7 days after day of last dose or day before initiation of ancillary treatment.", "populationDescription": "Overall number of participants analyzed = number of participants with available data.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "U/L", "timeFrame": "Week 0, week 16", "groups": [{"id": "OG000", "title": "Faster Aspart", "description": "Participants received Faster aspart along with insulin degludec (basal-bolus regimen) with or without metformin for 16 weeks. Before the treatment period was a 12-week run-in period in which the investigator optimised basal insulin dose. Insulin degludec dose was adjusted weekly by the investigator in the run-in period based on the mean of three pre-breakfast SMPG values measured on the last two days prior to and on the day of contact. If one of the SMPG values were below target (\\< 4.0 mmol/L or 71 mg/dL) then the insulin degludec dose was adjusted according to the titration guideline specified in the protocol. Faster aspart was titrated from randomisation (week 0) and onwards, twice weekly to reach the glycaemic target of pre-prandial and bedtime PG between 4.0-6.0 mmol/L (71 - 108 mg/dL) in a treat-to-target fashion."}, {"id": "OG001", "title": "NovoRapid", "description": "Participants received Insulin aspart (NovoRapid\u00ae/NovoLog\u00ae: basal-bolus regimen) along with insulin degludec (basal-bolus regimen) with or without metformin for 16 weeks. Before the treatment period was a 12-week run-in period in which the investigator optimised basal insulin dose. Insulin degludec dose was adjusted weekly by the investigator in the run-in period based on the mean of three pre-breakfast SMPG values measured on the last two days prior to and on the day of contact. If one of the SMPG values were below target (\\< 4.0 mmol/L or 71 mg/dL) then the insulin degludec dose was adjusted according to the titration guideline specified in the protocol. NovoRapid was titrated from randomisation (week 0) and onwards, twice weekly to reach the glycaemic target of pre-prandial and bedtime PG between 4.0-6.0 mmol/L (71 - 108 mg/dL) in a treat-to-target fashion."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "532"}, {"groupId": "OG001", "value": "536"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "2.9", "spread": "22.6"}, {"groupId": "OG001", "value": "2.2", "spread": "18.3"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Biochemistry - Aspartate Aminotransferase (AST)", "description": "Changes in biochemistry - aspratate aminotransferase from baseline (week 0) were evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period. On-treatment period started from date of first dose of randomised NovoRapid/faster aspart and to 7 days after day of last dose or day before initiation of ancillary treatment.", "populationDescription": "Overall number of participants analyzed = number of participants with available data.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "U/L", "timeFrame": "Week 0, week 16", "groups": [{"id": "OG000", "title": "Faster Aspart", "description": "Participants received Faster aspart along with insulin degludec (basal-bolus regimen) with or without metformin for 16 weeks. Before the treatment period was a 12-week run-in period in which the investigator optimised basal insulin dose. Insulin degludec dose was adjusted weekly by the investigator in the run-in period based on the mean of three pre-breakfast SMPG values measured on the last two days prior to and on the day of contact. If one of the SMPG values were below target (\\< 4.0 mmol/L or 71 mg/dL) then the insulin degludec dose was adjusted according to the titration guideline specified in the protocol. Faster aspart was titrated from randomisation (week 0) and onwards, twice weekly to reach the glycaemic target of pre-prandial and bedtime PG between 4.0-6.0 mmol/L (71 - 108 mg/dL) in a treat-to-target fashion."}, {"id": "OG001", "title": "NovoRapid", "description": "Participants received Insulin aspart (NovoRapid\u00ae/NovoLog\u00ae: basal-bolus regimen) along with insulin degludec (basal-bolus regimen) with or without metformin for 16 weeks. Before the treatment period was a 12-week run-in period in which the investigator optimised basal insulin dose. Insulin degludec dose was adjusted weekly by the investigator in the run-in period based on the mean of three pre-breakfast SMPG values measured on the last two days prior to and on the day of contact. If one of the SMPG values were below target (\\< 4.0 mmol/L or 71 mg/dL) then the insulin degludec dose was adjusted according to the titration guideline specified in the protocol. NovoRapid was titrated from randomisation (week 0) and onwards, twice weekly to reach the glycaemic target of pre-prandial and bedtime PG between 4.0-6.0 mmol/L (71 - 108 mg/dL) in a treat-to-target fashion."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "532"}, {"groupId": "OG001", "value": "536"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.2", "spread": "7.9"}, {"groupId": "OG001", "value": "2.2", "spread": "45.7"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Biochemistry - Albumin", "description": "Changes in biochemistry - albumin from baseline (week 0) were evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period. On-treatment period started from date of first dose of randomised NovoRapid/faster aspart and to 7 days after day of last dose or day before initiation of ancillary treatment.", "populationDescription": "Overall number of participants analyzed = number of participants with available data.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "g/dL", "timeFrame": "Week 0, week 16", "groups": [{"id": "OG000", "title": "Faster Aspart", "description": "Participants received Faster aspart along with insulin degludec (basal-bolus regimen) with or without metformin for 16 weeks. Before the treatment period was a 12-week run-in period in which the investigator optimised basal insulin dose. Insulin degludec dose was adjusted weekly by the investigator in the run-in period based on the mean of three pre-breakfast SMPG values measured on the last two days prior to and on the day of contact. If one of the SMPG values were below target (\\< 4.0 mmol/L or 71 mg/dL) then the insulin degludec dose was adjusted according to the titration guideline specified in the protocol. Faster aspart was titrated from randomisation (week 0) and onwards, twice weekly to reach the glycaemic target of pre-prandial and bedtime PG between 4.0-6.0 mmol/L (71 - 108 mg/dL) in a treat-to-target fashion."}, {"id": "OG001", "title": "NovoRapid", "description": "Participants received Insulin aspart (NovoRapid\u00ae/NovoLog\u00ae: basal-bolus regimen) along with insulin degludec (basal-bolus regimen) with or without metformin for 16 weeks. Before the treatment period was a 12-week run-in period in which the investigator optimised basal insulin dose. Insulin degludec dose was adjusted weekly by the investigator in the run-in period based on the mean of three pre-breakfast SMPG values measured on the last two days prior to and on the day of contact. If one of the SMPG values were below target (\\< 4.0 mmol/L or 71 mg/dL) then the insulin degludec dose was adjusted according to the titration guideline specified in the protocol. NovoRapid was titrated from randomisation (week 0) and onwards, twice weekly to reach the glycaemic target of pre-prandial and bedtime PG between 4.0-6.0 mmol/L (71 - 108 mg/dL) in a treat-to-target fashion."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "532"}, {"groupId": "OG001", "value": "536"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.02", "spread": "0.25"}, {"groupId": "OG001", "value": "0.01", "spread": "0.26"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Biochemistry - Creatinine", "description": "Changes in biochemistry - creatinine from baseline (week 0) were evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period. On-treatment period started from date of first dose of randomised NovoRapid/faster aspart and to 7 days after day of last dose or day before initiation of ancillary treatment.", "populationDescription": "Overall number of participants analyzed = number of participants with available data.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "umol/L", "timeFrame": "Week 0, week 16", "groups": [{"id": "OG000", "title": "Faster Aspart", "description": "Participants received Faster aspart along with insulin degludec (basal-bolus regimen) with or without metformin for 16 weeks. Before the treatment period was a 12-week run-in period in which the investigator optimised basal insulin dose. Insulin degludec dose was adjusted weekly by the investigator in the run-in period based on the mean of three pre-breakfast SMPG values measured on the last two days prior to and on the day of contact. If one of the SMPG values were below target (\\< 4.0 mmol/L or 71 mg/dL) then the insulin degludec dose was adjusted according to the titration guideline specified in the protocol. Faster aspart was titrated from randomisation (week 0) and onwards, twice weekly to reach the glycaemic target of pre-prandial and bedtime PG between 4.0-6.0 mmol/L (71 - 108 mg/dL) in a treat-to-target fashion."}, {"id": "OG001", "title": "NovoRapid", "description": "Participants received Insulin aspart (NovoRapid\u00ae/NovoLog\u00ae: basal-bolus regimen) along with insulin degludec (basal-bolus regimen) with or without metformin for 16 weeks. Before the treatment period was a 12-week run-in period in which the investigator optimised basal insulin dose. Insulin degludec dose was adjusted weekly by the investigator in the run-in period based on the mean of three pre-breakfast SMPG values measured on the last two days prior to and on the day of contact. If one of the SMPG values were below target (\\< 4.0 mmol/L or 71 mg/dL) then the insulin degludec dose was adjusted according to the titration guideline specified in the protocol. NovoRapid was titrated from randomisation (week 0) and onwards, twice weekly to reach the glycaemic target of pre-prandial and bedtime PG between 4.0-6.0 mmol/L (71 - 108 mg/dL) in a treat-to-target fashion."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "532"}, {"groupId": "OG001", "value": "536"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.1", "spread": "11.1"}, {"groupId": "OG001", "value": "1.5", "spread": "13.2"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Biochemistry - Potassium", "description": "Changes in biochemistry - potassium from baseline (week 0) were evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period. On-treatment period started from date of first dose of randomised NovoRapid/faster aspart and to 7 days after day of last dose or day before initiation of ancillary treatment.", "populationDescription": "Overall number of participants analyzed = number of participants with available data.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mmol/L", "timeFrame": "Week 0, week 16", "groups": [{"id": "OG000", "title": "Faster Aspart", "description": "Participants received Faster aspart along with insulin degludec (basal-bolus regimen) with or without metformin for 16 weeks. Before the treatment period was a 12-week run-in period in which the investigator optimised basal insulin dose. Insulin degludec dose was adjusted weekly by the investigator in the run-in period based on the mean of three pre-breakfast SMPG values measured on the last two days prior to and on the day of contact. If one of the SMPG values were below target (\\< 4.0 mmol/L or 71 mg/dL) then the insulin degludec dose was adjusted according to the titration guideline specified in the protocol. Faster aspart was titrated from randomisation (week 0) and onwards, twice weekly to reach the glycaemic target of pre-prandial and bedtime PG between 4.0-6.0 mmol/L (71 - 108 mg/dL) in a treat-to-target fashion."}, {"id": "OG001", "title": "NovoRapid", "description": "Participants received Insulin aspart (NovoRapid\u00ae/NovoLog\u00ae: basal-bolus regimen) along with insulin degludec (basal-bolus regimen) with or without metformin for 16 weeks. Before the treatment period was a 12-week run-in period in which the investigator optimised basal insulin dose. Insulin degludec dose was adjusted weekly by the investigator in the run-in period based on the mean of three pre-breakfast SMPG values measured on the last two days prior to and on the day of contact. If one of the SMPG values were below target (\\< 4.0 mmol/L or 71 mg/dL) then the insulin degludec dose was adjusted according to the titration guideline specified in the protocol. NovoRapid was titrated from randomisation (week 0) and onwards, twice weekly to reach the glycaemic target of pre-prandial and bedtime PG between 4.0-6.0 mmol/L (71 - 108 mg/dL) in a treat-to-target fashion."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "532"}, {"groupId": "OG001", "value": "536"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.001", "spread": "0.50"}, {"groupId": "OG001", "value": "0.02", "spread": "0.43"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Biochemistry - Sodium", "description": "Changes in biochemistry - sodium from baseline (week 0) were evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period. On-treatment period started from date of first dose of randomised NovoRapid/faster aspart and to 7 days after day of last dose or day before initiation of ancillary treatment.", "populationDescription": "Overall number of participants analyzed = number of participants with available data.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mmol/L", "timeFrame": "Week 0, week 16", "groups": [{"id": "OG000", "title": "Faster Aspart", "description": "Participants received Faster aspart along with insulin degludec (basal-bolus regimen) with or without metformin for 16 weeks. Before the treatment period was a 12-week run-in period in which the investigator optimised basal insulin dose. Insulin degludec dose was adjusted weekly by the investigator in the run-in period based on the mean of three pre-breakfast SMPG values measured on the last two days prior to and on the day of contact. If one of the SMPG values were below target (\\< 4.0 mmol/L or 71 mg/dL) then the insulin degludec dose was adjusted according to the titration guideline specified in the protocol. Faster aspart was titrated from randomisation (week 0) and onwards, twice weekly to reach the glycaemic target of pre-prandial and bedtime PG between 4.0-6.0 mmol/L (71 - 108 mg/dL) in a treat-to-target fashion."}, {"id": "OG001", "title": "NovoRapid", "description": "Participants received Insulin aspart (NovoRapid\u00ae/NovoLog\u00ae: basal-bolus regimen) along with insulin degludec (basal-bolus regimen) with or without metformin for 16 weeks. Before the treatment period was a 12-week run-in period in which the investigator optimised basal insulin dose. Insulin degludec dose was adjusted weekly by the investigator in the run-in period based on the mean of three pre-breakfast SMPG values measured on the last two days prior to and on the day of contact. If one of the SMPG values were below target (\\< 4.0 mmol/L or 71 mg/dL) then the insulin degludec dose was adjusted according to the titration guideline specified in the protocol. NovoRapid was titrated from randomisation (week 0) and onwards, twice weekly to reach the glycaemic target of pre-prandial and bedtime PG between 4.0-6.0 mmol/L (71 - 108 mg/dL) in a treat-to-target fashion."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "532"}, {"groupId": "OG001", "value": "536"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.6", "spread": "2.6"}, {"groupId": "OG001", "value": "-0.7", "spread": "2.8"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Biochemistry - Total Bilirubin", "description": "Changes in biochemistry - total bilirubin from baseline (week 0) were evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period. On-treatment period started from date of first dose of randomised NovoRapid/faster aspart and to 7 days after day of last dose or day before initiation of ancillary treatment.", "populationDescription": "Overall number of participants analyzed = number of participants with available data.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "umol/L", "timeFrame": "Week 0, week 16", "groups": [{"id": "OG000", "title": "Faster Aspart", "description": "Participants received Faster aspart along with insulin degludec (basal-bolus regimen) with or without metformin for 16 weeks. Before the treatment period was a 12-week run-in period in which the investigator optimised basal insulin dose. Insulin degludec dose was adjusted weekly by the investigator in the run-in period based on the mean of three pre-breakfast SMPG values measured on the last two days prior to and on the day of contact. If one of the SMPG values were below target (\\< 4.0 mmol/L or 71 mg/dL) then the insulin degludec dose was adjusted according to the titration guideline specified in the protocol. Faster aspart was titrated from randomisation (week 0) and onwards, twice weekly to reach the glycaemic target of pre-prandial and bedtime PG between 4.0-6.0 mmol/L (71 - 108 mg/dL) in a treat-to-target fashion."}, {"id": "OG001", "title": "NovoRapid", "description": "Participants received Insulin aspart (NovoRapid\u00ae/NovoLog\u00ae: basal-bolus regimen) along with insulin degludec (basal-bolus regimen) with or without metformin for 16 weeks. Before the treatment period was a 12-week run-in period in which the investigator optimised basal insulin dose. Insulin degludec dose was adjusted weekly by the investigator in the run-in period based on the mean of three pre-breakfast SMPG values measured on the last two days prior to and on the day of contact. If one of the SMPG values were below target (\\< 4.0 mmol/L or 71 mg/dL) then the insulin degludec dose was adjusted according to the titration guideline specified in the protocol. NovoRapid was titrated from randomisation (week 0) and onwards, twice weekly to reach the glycaemic target of pre-prandial and bedtime PG between 4.0-6.0 mmol/L (71 - 108 mg/dL) in a treat-to-target fashion."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "531"}, {"groupId": "OG001", "value": "536"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.1", "spread": "2.7"}, {"groupId": "OG001", "value": "0.1", "spread": "3.0"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Biochemistry - Total Protein", "description": "Changes in biochemistry - total protein from baseline (week 0) were evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period. On-treatment period started from date of first dose of randomised NovoRapid/faster aspart and to 7 days after day of last dose or day before initiation of ancillary treatment.", "populationDescription": "Overall number of participants analyzed = number of participants with available data.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "g/dL", "timeFrame": "Week 0, week 16", "groups": [{"id": "OG000", "title": "Faster Aspart", "description": "Participants received Faster aspart along with insulin degludec (basal-bolus regimen) with or without metformin for 16 weeks. Before the treatment period was a 12-week run-in period in which the investigator optimised basal insulin dose. Insulin degludec dose was adjusted weekly by the investigator in the run-in period based on the mean of three pre-breakfast SMPG values measured on the last two days prior to and on the day of contact. If one of the SMPG values were below target (\\< 4.0 mmol/L or 71 mg/dL) then the insulin degludec dose was adjusted according to the titration guideline specified in the protocol. Faster aspart was titrated from randomisation (week 0) and onwards, twice weekly to reach the glycaemic target of pre-prandial and bedtime PG between 4.0-6.0 mmol/L (71 - 108 mg/dL) in a treat-to-target fashion."}, {"id": "OG001", "title": "NovoRapid", "description": "Participants received Insulin aspart (NovoRapid\u00ae/NovoLog\u00ae: basal-bolus regimen) along with insulin degludec (basal-bolus regimen) with or without metformin for 16 weeks. Before the treatment period was a 12-week run-in period in which the investigator optimised basal insulin dose. Insulin degludec dose was adjusted weekly by the investigator in the run-in period based on the mean of three pre-breakfast SMPG values measured on the last two days prior to and on the day of contact. If one of the SMPG values were below target (\\< 4.0 mmol/L or 71 mg/dL) then the insulin degludec dose was adjusted according to the titration guideline specified in the protocol. NovoRapid was titrated from randomisation (week 0) and onwards, twice weekly to reach the glycaemic target of pre-prandial and bedtime PG between 4.0-6.0 mmol/L (71 - 108 mg/dL) in a treat-to-target fashion."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "532"}, {"groupId": "OG001", "value": "536"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.01", "spread": "0.35"}, {"groupId": "OG001", "value": "-0.02", "spread": "0.36"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Body Weight", "description": "Changes in body weight from baseline (week 0) were evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period. On-treatment period started from date of first dose of randomised NovoRapid/faster aspart and to 7 days after day of last dose or day before initiation of ancillary treatment.", "populationDescription": "Overall number of participants analyzed = number of participants with available data.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "kg", "timeFrame": "Week 0, week 16", "groups": [{"id": "OG000", "title": "Faster Aspart", "description": "Participants received Faster aspart along with insulin degludec (basal-bolus regimen) with or without metformin for 16 weeks. Before the treatment period was a 12-week run-in period in which the investigator optimised basal insulin dose. Insulin degludec dose was adjusted weekly by the investigator in the run-in period based on the mean of three pre-breakfast SMPG values measured on the last two days prior to and on the day of contact. If one of the SMPG values were below target (\\< 4.0 mmol/L or 71 mg/dL) then the insulin degludec dose was adjusted according to the titration guideline specified in the protocol. Faster aspart was titrated from randomisation (week 0) and onwards, twice weekly to reach the glycaemic target of pre-prandial and bedtime PG between 4.0-6.0 mmol/L (71 - 108 mg/dL) in a treat-to-target fashion."}, {"id": "OG001", "title": "NovoRapid", "description": "Participants received Insulin aspart (NovoRapid\u00ae/NovoLog\u00ae: basal-bolus regimen) along with insulin degludec (basal-bolus regimen) with or without metformin for 16 weeks. Before the treatment period was a 12-week run-in period in which the investigator optimised basal insulin dose. Insulin degludec dose was adjusted weekly by the investigator in the run-in period based on the mean of three pre-breakfast SMPG values measured on the last two days prior to and on the day of contact. If one of the SMPG values were below target (\\< 4.0 mmol/L or 71 mg/dL) then the insulin degludec dose was adjusted according to the titration guideline specified in the protocol. NovoRapid was titrated from randomisation (week 0) and onwards, twice weekly to reach the glycaemic target of pre-prandial and bedtime PG between 4.0-6.0 mmol/L (71 - 108 mg/dL) in a treat-to-target fashion."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "522"}, {"groupId": "OG001", "value": "530"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "1.19", "spread": "2.95"}, {"groupId": "OG001", "value": "1.12", "spread": "4.01"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Body Mass Index (BMI)", "description": "Change in the body mass index (BMI) from baseline (week 0) were evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period. On-treatment period started from date of first dose of randomised NovoRapid/faster aspart and to 7 days after day of last dose or day before initiation of ancillary treatment.", "populationDescription": "Overall number of participants analyzed = number of participants with available data.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "kg/m^2", "timeFrame": "Week 0, week 16", "groups": [{"id": "OG000", "title": "Faster Aspart", "description": "Participants received Faster aspart along with insulin degludec (basal-bolus regimen) with or without metformin for 16 weeks. Before the treatment period was a 12-week run-in period in which the investigator optimised basal insulin dose. Insulin degludec dose was adjusted weekly by the investigator in the run-in period based on the mean of three pre-breakfast SMPG values measured on the last two days prior to and on the day of contact. If one of the SMPG values were below target (\\< 4.0 mmol/L or 71 mg/dL) then the insulin degludec dose was adjusted according to the titration guideline specified in the protocol. Faster aspart was titrated from randomisation (week 0) and onwards, twice weekly to reach the glycaemic target of pre-prandial and bedtime PG between 4.0-6.0 mmol/L (71 - 108 mg/dL) in a treat-to-target fashion."}, {"id": "OG001", "title": "NovoRapid", "description": "Participants received Insulin aspart (NovoRapid\u00ae/NovoLog\u00ae: basal-bolus regimen) along with insulin degludec (basal-bolus regimen) with or without metformin for 16 weeks. Before the treatment period was a 12-week run-in period in which the investigator optimised basal insulin dose. Insulin degludec dose was adjusted weekly by the investigator in the run-in period based on the mean of three pre-breakfast SMPG values measured on the last two days prior to and on the day of contact. If one of the SMPG values were below target (\\< 4.0 mmol/L or 71 mg/dL) then the insulin degludec dose was adjusted according to the titration guideline specified in the protocol. NovoRapid was titrated from randomisation (week 0) and onwards, twice weekly to reach the glycaemic target of pre-prandial and bedtime PG between 4.0-6.0 mmol/L (71 - 108 mg/dL) in a treat-to-target fashion."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "522"}, {"groupId": "OG001", "value": "530"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.43", "spread": "1.04"}, {"groupId": "OG001", "value": "0.40", "spread": "1.40"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "timeFrame": "Week 0 to Week 16 + 7 days. All reported adverse events (AEs) are treatment emergent (i.e., TEAE).", "description": "All presented AEs are TEAEs. A TEAE was defined as an event that had onset date on or after the first day of exposure to trial product and no later than 7 days after the last day of trial product administration. Results are based on the SAS which included all participants receiving at least one dose of randomised treatment.", "eventGroups": [{"id": "EG000", "title": "Faster Aspart", "description": "Participants received Faster aspart along with insulin degludec (basal-bolus regimen) with or without metformin for 16 weeks. Before the treatment period was a 12-week run-in period in which the investigator optimised basal insulin dose. Insulin degludec dose was adjusted weekly by the investigator in the run-in period based on the mean of three pre-breakfast SMPG values measured on the last two days prior to and on the day of contact. If one of the SMPG values were below target (\\< 4.0 mmol/L or 71 mg/dL) then the insulin degludec dose was adjusted according to the titration guideline specified in the protocol. Faster aspart was titrated from randomisation (week 0) and onwards, twice weekly to reach the glycaemic target of pre-prandial and bedtime PG between 4.0-6.0 mmol/L (71 - 108 mg/dL) in a treat-to-target fashion.", "deathsNumAffected": 2, "deathsNumAtRisk": 544, "seriousNumAffected": 38, "seriousNumAtRisk": 544, "otherNumAffected": 32, "otherNumAtRisk": 544}, {"id": "EG001", "title": "NovoRapid", "description": "Participants received Insulin aspart (NovoRapid\u00ae/NovoLog\u00ae: basal-bolus regimen) along with insulin degludec (basal-bolus regimen) with or without metformin for 16 weeks. Before the treatment period was a 12-week run-in period in which the investigator optimised basal insulin dose. Insulin degludec dose was adjusted weekly by the investigator in the run-in period based on the mean of three pre-breakfast SMPG values measured on the last two days prior to and on the day of contact. If one of the SMPG values were below target (\\< 4.0 mmol/L or 71 mg/dL) then the insulin degludec dose was adjusted according to the titration guideline specified in the protocol. NovoRapid was titrated from randomisation (week 0) and onwards, twice weekly to reach the glycaemic target of pre-prandial and bedtime PG between 4.0-6.0 mmol/L (71 - 108 mg/dL) in a treat-to-target fashion.", "deathsNumAffected": 1, "deathsNumAtRisk": 544, "seriousNumAffected": 40, "seriousNumAtRisk": 544, "otherNumAffected": 33, "otherNumAtRisk": 544}], "seriousEvents": [{"term": "Accidental overdose", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 21", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 544}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 544}]}, {"term": "Acute coronary syndrome", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 21", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 544}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 544}]}, {"term": "Acute kidney injury", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA 21", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 544}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 544}]}, {"term": "Acute myocardial infarction", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 21", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 544}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 544}]}, {"term": "Adenocarcinoma of colon", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 21", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 544}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 544}]}, {"term": "Angina pectoris", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 21", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 544}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 544}]}, {"term": "Angina unstable", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 21", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 544}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 544}]}, {"term": "Aortic aneurysm", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA 21", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 544}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 544}]}, {"term": "Aortic valve replacement", "organSystem": "Surgical and medical procedures", "sourceVocabulary": "MedDRA 21", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 544}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 544}]}, {"term": "Arteriosclerosis coronary artery", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 21", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 544}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 544}]}, {"term": "Arthritis", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 21", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 544}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 544}]}, {"term": "Atrial fibrillation", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 21", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 544}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 544}]}, {"term": "Bile duct obstruction", "organSystem": "Hepatobiliary disorders", "sourceVocabulary": "MedDRA 21", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 544}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 544}]}, {"term": "Bradycardia", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 21", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 544}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 544}]}, {"term": "Bronchitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 21", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 544}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 544}]}, {"term": "Cardiac failure", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 21", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 544}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 544}]}, {"term": "Cardiac failure congestive", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 21", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 544}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 544}]}, {"term": "Cardiac stress test abnormal", "organSystem": "Investigations", "sourceVocabulary": "MedDRA 21", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 544}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 544}]}, {"term": "Carpal tunnel decompression", "organSystem": "Surgical and medical procedures", "sourceVocabulary": "MedDRA 21", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 544}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 544}]}, {"term": "Cerebellar infarction", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 21", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 544}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 544}]}, {"term": "Chest pain", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 21", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 544}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 544}]}, {"term": "Chronic obstructive pulmonary disease", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 21", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 544}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 544}]}, {"term": "Colitis", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 21", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 544}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 544}]}, {"term": "Contusion", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 21", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 544}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 544}]}, {"term": "Coronary artery disease", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 21", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 544}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 544}]}, {"term": "Cyclic vomiting syndrome", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 21", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 544}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 544}]}, {"term": "Deep vein thrombosis", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA 21", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 544}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 544}]}, {"term": "Dehydration", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA 21", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 544}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 544}]}, {"term": "Delusion", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA 21", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 544}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 544}]}, {"term": "Device malfunction", "organSystem": "Product Issues", "sourceVocabulary": "MedDRA 21", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 544}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 544}]}, {"term": "Device related sepsis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 21", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 544}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 544}]}, {"term": "Diabetic neuropathy", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 21", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 544}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 544}]}, {"term": "Diarrhoea", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 21", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 544}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 544}]}, {"term": "Dizziness", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 21", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 544}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 544}]}, {"term": "Duodenal ulcer", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 21", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 544}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 544}]}, {"term": "Encephalopathy", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 21", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 544}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 544}]}, {"term": "Fall", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 21", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 544}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 544}]}, {"term": "Fibula fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 21", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 544}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 544}]}, {"term": "Gangrene", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 21", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 544}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 544}]}, {"term": "Gastritis erosive", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 21", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 544}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 544}]}, {"term": "Gastroenteritis viral", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 21", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 544}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 544}]}, {"term": "Haemorrhagic anaemia", "organSystem": "Blood and lymphatic system disorders", "sourceVocabulary": "MedDRA 21", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 544}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 544}]}, {"term": "Haemorrhagic stroke", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 21", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 544}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 544}]}, {"term": "Headache", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 21", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 544}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 544}]}, {"term": "Hepatocellular carcinoma", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 21", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 544}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 544}]}, {"term": "Humerus fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 21", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 544}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 544}]}, {"term": "Hyperglycaemia", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA 21", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 544}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 544}]}, {"term": "Hypoglycaemia", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA 21", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 4, "numAffected": 4, "numAtRisk": 544}, {"groupId": "EG001", "numEvents": 3, "numAffected": 3, "numAtRisk": 544}]}, {"term": "Hypoglycaemic unconsciousness", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 21", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 3, "numAffected": 3, "numAtRisk": 544}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 544}]}, {"term": "Hypotension", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA 21", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 544}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 544}]}, {"term": "Infective exacerbation of chronic obstructive airways disease", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 21", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 544}, {"groupId": "EG001", "numEvents": 2, "numAffected": 1, "numAtRisk": 544}]}, {"term": "Invasive ductal breast carcinoma", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 21", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 544}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 544}]}, {"term": "Iron deficiency anaemia", "organSystem": "Blood and lymphatic system disorders", "sourceVocabulary": "MedDRA 21", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 544}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 544}]}, {"term": "Left ventricular failure", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 21", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 544}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 544}]}, {"term": "Lower respiratory tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 21", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 544}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 544}]}, {"term": "Lumbar spinal stenosis", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 21", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 544}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 544}]}, {"term": "Lung neoplasm malignant", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 21", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 544}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 544}]}, {"term": "Mitral valve incompetence", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 21", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 544}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 544}]}, {"term": "Myocardial ischaemia", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 21", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 544}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 544}]}, {"term": "Obstructive pancreatitis", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 21", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 544}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 544}]}, {"term": "Orchitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 21", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 544}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 544}]}, {"term": "Osteomyelitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 21", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 544}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 544}]}, {"term": "Pain", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 21", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 544}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 544}]}, {"term": "Pancreatic carcinoma metastatic", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 21", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 544}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 544}]}, {"term": "Peripheral vascular disorder", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA 21", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 544}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 544}]}, {"term": "Pneumonia", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 21", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 544}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 544}]}, {"term": "Pulmonary oedema", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 21", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 544}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 544}]}, {"term": "Rapid eye movements sleep abnormal", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA 21", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 544}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 544}]}, {"term": "Rehabilitation therapy", "organSystem": "Surgical and medical procedures", "sourceVocabulary": "MedDRA 21", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 544}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 544}]}, {"term": "Renal failure", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA 21", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 544}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 544}]}, {"term": "Respiratory failure", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 21", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 544}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 544}]}, {"term": "Respiratory tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 21", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 544}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 544}]}, {"term": "Road traffic accident", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 21", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 544}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 544}]}, {"term": "Small intestinal obstruction", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 21", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 544}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 544}]}, {"term": "Spinal pain", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 21", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 544}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 544}]}, {"term": "Subclavian vein occlusion", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA 21", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 544}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 544}]}, {"term": "Transient ischaemic attack", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 21", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 544}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 544}]}, {"term": "Trigger finger", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 21", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 544}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 544}]}, {"term": "Upper respiratory tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 21", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 544}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 544}]}, {"term": "Varicose ulceration", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA 21", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 544}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 544}]}, {"term": "Vascular parkinsonism", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 21", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 544}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 544}]}, {"term": "Vitrectomy", "organSystem": "Surgical and medical procedures", "sourceVocabulary": "MedDRA 21", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 544}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 544}]}, {"term": "Vitreous haemorrhage", "organSystem": "Eye disorders", "sourceVocabulary": "MedDRA 21", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 544}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 544}]}, {"term": "Wrong product administered", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 21", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 544}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 544}]}], "otherEvents": [{"term": "Nasopharyngitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 21", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 35, "numAffected": 32, "numAtRisk": 544}, {"groupId": "EG001", "numEvents": 36, "numAffected": 33, "numAtRisk": 544}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "At the end of the trial, one or more scientific publications may be prepared collaboratively by the investigator(s) and Novo Nordisk. Novo Nordisk reserves the right to postpone publication and/or communication for up to 60 days to protect intellectual property."}, "pointOfContact": {"title": "Clinical Reporting Anchor and Disclosure (1452)", "organization": "Novo Nordisk A/S", "email": "clinicaltrials@novonordisk.com", "phone": "(+1) 866-867-7178"}}}, "documentSection": {"largeDocumentModule": {"largeDocs": [{"typeAbbrev": "Prot", "hasProtocol": true, "hasSap": false, "hasIcf": false, "label": "Study Protocol", "date": "2019-06-20", "uploadDate": "2020-01-07T00:31", "filename": "Prot_000.pdf", "size": 1881358}, {"typeAbbrev": "SAP", "hasProtocol": false, "hasSap": true, "hasIcf": false, "label": "Statistical Analysis Plan", "date": "2019-06-20", "uploadDate": "2020-01-07T00:31", "filename": "SAP_001.pdf", "size": 573825}]}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24", "submissionTracking": {"firstMcpInfo": {"postDateStruct": {"date": "2020-02-05", "type": "ACTUAL"}}}}, "conditionBrowseModule": {"meshes": [{"id": "D000003920", "term": "Diabetes Mellitus"}, {"id": "D000003924", "term": "Diabetes Mellitus, Type 2"}], "ancestors": [{"id": "D000044882", "term": "Glucose Metabolism Disorders"}, {"id": "D000008659", "term": "Metabolic Diseases"}, {"id": "D000004700", "term": "Endocrine System Diseases"}], "browseLeaves": [{"id": "M7115", "name": "Diabetes Mellitus", "asFound": "Diabetes", "relevance": "HIGH"}, {"id": "M7119", "name": "Diabetes Mellitus, Type 2", "asFound": "Diabetes Mellitus, Type 2", "relevance": "HIGH"}, {"id": "M11639", "name": "Metabolic Diseases", "relevance": "LOW"}, {"id": "M25403", "name": "Glucose Metabolism Disorders", "relevance": "LOW"}, {"id": "M7862", "name": "Endocrine System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC18", "name": "Nutritional and Metabolic Diseases"}, {"abbrev": "BC19", "name": "Gland and Hormone Related Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000007328", "term": "Insulin"}, {"id": "C000557859", "term": "Insulin, Globin Zinc"}, {"id": "D000008687", "term": "Metformin"}, {"id": "D000061267", "term": "Insulin Aspart"}, {"id": "D000049528", "term": "Insulin, Long-Acting"}, {"id": "C000578220", "term": "Insulin degludec, insulin aspart drug combination"}], "ancestors": [{"id": "D000007004", "term": "Hypoglycemic Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}], "browseLeaves": [{"id": "M10365", "name": "Insulin", "asFound": "Blood", "relevance": "HIGH"}, {"id": "M11667", "name": "Metformin", "asFound": "Assessment", "relevance": "HIGH"}, {"id": "M173166", "name": "Insulin, Globin Zinc", "asFound": "Blood", "relevance": "HIGH"}, {"id": "M29801", "name": "Insulin Aspart", "asFound": "Obtained", "relevance": "HIGH"}, {"id": "M17768", "name": "Zinc", "relevance": "LOW"}, {"id": "M26073", "name": "Insulin, Long-Acting", "asFound": "Obtained", "relevance": "HIGH"}, {"id": "M117006", "name": "Insulin degludec, insulin aspart drug combination", "asFound": "Obtained", "relevance": "HIGH"}, {"id": "M10054", "name": "Hypoglycemic Agents", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Hypo", "name": "Hypoglycemic Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "Micro", "name": "Micronutrients"}]}}, "hasResults": true}